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Résumé  
 
L’aire tegmentaire ventrale (VTA) contient une forte densité de terminaisons 
neurotensinergiques ainsi que des récepteurs à la surface des neurones dopaminergiques et non-
dopaminergiques. Le VTA a été impliqué dans des maladies comme la schizophrénie, les 
psychoses et l’abus de substance. Les drogues d’abus sont connues pour induire le phénomène 
de sensibilisation - un processus de facilitation par lequel l’exposition à un stimulus produit une 
réponse augmentée lors de l’exposition subséquente au même stimulus. La sensibilisation se 
développe dans le VTA et implique mécanismes dopaminergiques et glutamatergiques. Il a été 
montré que les antagonistes neurotensinergiques bloquaient le développement de la 
sensibilisation et certains mécanismes de récompense et ces effets pourraient être médiés 
indirectement par une modulation de la neurotransmission glutamatergique. Cependant, on 
connaît peu les mécanismes de modulation de la transmission glutamatergique par la 
neurotensine (NT) dans le VTA. 
Le but de la présente thèse était d’étudier la modulation neurotensinergique de la 
neurotransmission glutamatergique dans les neurones dopaminergiques et non-dopaminergiques 
du VTA. Pour ce faire, nous avons utilisé la technique du patch clamp dans la cellule entière 
dans des tranches horizontales du VTA pour étudier les effets de différents agonistes et 
antagonistes neurotensinergiques. Les neurones ont été identifié comme Ih+ (présumés 
dopaminergiques) ou  Ih- (présumés non-dopaminergiques) selon qu’ils exprimaient ou non un 
courant cationique activé par l’hyperpolarisation (Ih). Des techniques d’immunocytochimie ont 
été utilisées pour marquer les neurones et vérifier leur localisation dans le VTA. 
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Dans une première étude nous avons trouvé que la neurotensine indigène (NT1-13) ou son 
fragment C-terminal, NT8-13, induisait une augmentation comparable des courants    
postsynaptiques excitateurs glutamatergiques (CPSEs) dans les neurones  Ih+ ou Ih- du VTA.  
L'augmentation induite dans les neurones  Ih+ par la NT8-13 a été bloquée par le SR48692, un 
antagoniste des récepteurs NTS1, et par le SR142948A, un antagoniste des récepteurs NTS1 et 
NTS2, suggérant que l'augmentation était médiée par l’activation des récepteurs NTS1. Dans 
les neurones Ih- l'augmentation n’a été bloquée que par le SR142948A indiquant une implication 
des récepteurs NTS2. 
Dans une deuxième étude, nous avons testé les effets de la D-Tyr[11]NT (un analogue 
neurotensinergique ayant différentes affinités de liaison pour les sous-types de récepteurs 
neurotensinergiques) sur les CPSEs glutamatergiques dans les neurones Ih+ et Ih- en parallèle 
avec une série d’expériences comportementales utilisant un paradigme de préférence de place 
conditionnée (PPC) menée dans le laboratoire de Pierre-Paul Rompré. Nous avons constaté que 
la D-Tyr[11]NT induisaient une inhibition dépendante de la dose dans les neurones Ih+ médiée 
par l'activation de récepteurs NTS2. En revanche, la D-Tyr[11]NT a produit une augmentation 
des CPSEs glutamatergiques médiée par des récepteurs NTS1 dans les neurones Ih-. Les résultats 
des expériences comportementales ont montré que des microinjections bilatérales  de D-
Tyr[11]NT dans le VTA induisait une PPC bloquée uniquement par la co-injection de 
SR142948A et SR48692, indiquant un rôle pour les deux types de récepteurs, NTS1 et NTS2. 
Cette étude nous a permis de conclure que i) la D-Tyr[11]NT agit dans le VTA via des récepteurs 
NTS1 et NTS2 pour induire un effet de récompense et ii) que cet effet est dû, au moins en partie, 
à une augmentation de la neurotransmission glutamatergique dans les neurones non-
dopaminergiques (Ih-). 
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Dans une troisième étude nous nous sommes intéressés aux effets de la D-Tyr[11]NT sur les 
réponses isolées médiées par les récepteurs N-méthyl-D-aspartate (NMDA) et acide α-amino-
3-  hydroxy-5-méthyl-4-isoxazolepropionique (AMPA) dans les neurones du VTA. Nous avons 
constaté que dans les neurones Ih+ l’amplitude des CPSEs NMDA et AMPA étaient atténuées  
de la même manière par la D-Tyr[11] NT. Cette modulation des réponses était médiée par les 
récepteurs NTS1 et NTS2. Au contraire, dans les neurones Ih-, l’amplitude des réponses NMDA 
et AMPA étaient augmentées en présence de D-Tyr[11]NT et ces effets dépendaient de 
l’activation des récepteurs NTS1 localisés sur les terminaisons glutamatergiques. Ces résultats 
fournissent une preuve supplémentaire que le NT exerce une modulation bidirectionnelle sur la 
neurotransmission glutamatergique dans les neurones du VTA et met en évidence un nouveau 
type de modulation peptidergique des neurones non-dopaminergiques qui pourrait être impliqué 
dans la sensibilisation. 
En conclusion, la modulation neurotensinergique de la neurotransmission glutamatergique dans 
les neurones dopaminergiques et non-dopaminergiques du VTA se fait en sens opposé soit, 
respectivement, par une inhibition ou par une excitation. De plus, ces effets sont médiés par 
différents types de récepteurs neurotensinergiques. En outre, nos études mettent en évidence une 
modulation peptidergique de la neurotransmission glutamatergique dans le VTA qui pourrait 
jouer un rôle important dans les mécanismes de lutte contre la toxicomanie. 
Mots-clés : dopamine, aire tegmentaire ventrale, glutamate, neurotensine, courant 
postsynaptique excitateur, patch-clamp. 
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Abstract 
 
The ventral tegmental area (VTA) contains a high density of neurotensin (NT) terminals and 
receptors that are expressed on dopaminergic (DA) and non-DA neurons. This area of the 
brain is strongly implicated in disorders like schizophrenia, psychosis and drug abuse. Drugs 
of abuse induce behavioural sensitization- a facilitatory process whereby exposure to a 
stimulus results in an enhanced response to a subsequent exposure of the same stimulus. 
Sensitization develops in the VTA and involves glutamatergic neuroadaptations in VTA DA 
neurons. NT antagonists prevent the development of sensitization and reward mechanisms 
and this could be mediated through a modulation of glutamatergic neurotransmission in the 
VTA. However, how NT modulates glutamatergic neurotransmission in VTA neurons 
remains unclear.  
The present thesis was aimed at investigating the NTergic modulation of glutamatergic 
neurotransmission in VTA DA and non-DA neurons. Whole cell patch clamp 
electrophysiology in acute VTA horizontal slices was used to study the effects of different 
NTergic agonists on VTA neurons.  Neurons were classified as either Ih+ (putative 
dopaminergic neurons) or Ih- (putative non-dopaminergic neurons) based on the presence or 
absence of a hyperpolarisation activated cationic current (Ih) respectively. 
Immunohistochemical techniques were routinely used to label neurons and confirm their 
location in the medial VTA.  
In the first study we report that native neurotensin (NT1-13) or its C-terminal fragment, NT8-
13 induced comparable increases in the amplitude of glutamatergic excitatory post-synaptic 
currents (EPSCs) in VTA neurons. The NT8-13 induced augmentation in Ih+ neurons was 
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blocked by SR48692 (NTS1 antagonist) and SR142948A (NTS1/NTS2 antagonist), 
suggesting that the augmentation effect was mediated by NTS1 receptors. In Ih- neurons, 
however, only  SR142948A blocked the increase in the EPSC amplitude, indicating the 
involvement of NTS2.   
 In the second study we tested the effects of D-Tyr[11]NT (an active NT analog with differential 
binding affinities for NT receptor subtypes) on glutamatergic EPSCs in Ih+ and Ih- neurons and 
conducted (by Romrpe’s Lab) a parallel series of behavioral experiments using a conditioned 
place preference (CPP) paradigm. We found that D-Tyr[11]NT induced a dose dependent 
inhibition of EPSCs in Ih+ neurons that was mediated by the activation of NTS2 receptor. In 
contrast, D-Tyr[11]NT dose dependently enhanced glutamatergic EPSCs through an NTS1 
receptor involvement in Ih- neurons. Results from behavioural experiments show that bilateral 
VTA microinjections of D-Tyr[11]NT induced a CPP that was blocked only by co-injection of 
SR142948A and SR48692, indicating a role for NTS1. This study allowed us to conclude that 
i) NT acts on VTA NTS1 receptors to induce a rewarding effect and ii) that this effect is due, at 
least in part, to an enhancement of glutamatergic inputs to non-dopamine (Ih-) neurons. 
 The third study entailed investigating the effects of D-Tyr[11]NT on isolated n-methyl-D-
aspartate (NMDA) and  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor mediated EPSCs in VTA neurons. We found that in Ih+  neurons both NMDA and 
AMPA EPSC amplitudes were attenuated by D-Tyr[11]NT. This attenuation appeared to be 
mediated by both NTS1 and NTS2 receptors. In Contrast, in Ih- neurons both NMDA and 
AMPA EPSC amplitudes were enhanced by an NTS1 dependent mechanism. Additionally, the 
enhancement effect resulted from a presynaptic potentiation of glutamatergic inputs. These 
results provide additional evidence that NT exerts a bidirectional modulation on glutamatergic 
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neurotransmission in VTA neurons and highlights a novel peptidergic modulation of non-DA 
neurons that might be implicated in sensitization mechanisms.  Altogether, our studies allowed 
us to conclude that the NTergic modulation of glutamatergic neurotransmission in VTA DA 
and non-DA neurons is oppositely regulated by NTS2 and NTS1 receptors respectively. 
Additionally it highlights a peptidergic modulation of glutamatergic inputs to VTA non-DA 
neurons that might be crucial for addiction mechanisms.  
Keywords: dopamine, VTA, glutamate, NT, EPSCs, patch-clamp. 
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Introduction 
 
This thesis focuses on the modulation of glutamatergic neurotransmission by neurotensin (NT) 
in the ventral tegmental area (VTA). NT is a thirteen amino acid endogenous neuropeptide that 
modulates neurotransmission in several brain regions like the VTA, the prefrontal cortex 
(PFC) and the nucleus accumbens (nAcb)(Binder et al. 2001a). The VTA is a midbrain 
dopamine (DA) rich region and plays a role in sensitization, reward, motivation cognition and 
processes information about emotion(Nestler 2013). The neurotensinergic projections from 
surrounding brain areas (eg. PFC, lateral hypothalamus(LH),) densely innervate the VTA  and 
80-90%percent of the VTA neurons express NT receptors, the activation of which is known to 
modulate DA cell activity and consequently DA dependent behaviors(Rompre et al. 1998). 
The VTA DA neurons also receive glutamatergic inputs containing NT terminals and 
receptors from limbic brain regions such as the PFC(Vezina and Queen 2000a). 
Drugs of abuse elicit motor stimulant effects that enhance with repeated drug administration, 
and this sensitized behavioral response can endure for months after the last repeated drug 
administration(Robinson and Berridge 1993). The sensitized behavioural response is a 
bipartite phenomenon, consisting of initiation and expression phases. The VTA serves as the 
key anatomical substrate for the initiation of sensitization. Furthermore, the glutamatergic 
inputs to the VTA are essential for the development of drug induced synaptic plasticity on DA 
neurons (Bellone and Luscher 2006;Ungless et al. 2001). It was found that blockade of 
ionotropic glutamate receptors disrupted the development of psychostimulant induced 
behavioural sensitization. Interestingly, it was also found that blockade of NT receptors 
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disrupted the development of sensitization. Since the VTA is heavily innervated by NT 
receptors and terminals and often these terminals are found on glutamatergic efferents from 
limbic regions such as the PFC, it is possible that NT modulates these inputs to the DA 
neurons of the VTA and thereby play a role in the development of sensitization. However, 
how glutamatergic neurotransmission is modulated by NT in the VTA at the cellular level 
remains elusive. This study was aimed at characterising the effects of NT on glutamatergic 
neurotransmission in VTA DA and non-DA neurons using electrophysiological and 
immunohistochemical techniques. 
In my attempt to create a background for my readers, in the subsequent sections, I will draw an 
overview of the VTA and its projections that are relevant to this study ; its neuronal 
composition Following this, I will focus on the properties of NT as a neuropeptide 
neurotransmitter, the distribution of NT neurons and terminals in the midbrain, the mechanism 
of action of NT ,effects of NT administration in the VTA, effects of NT on glutamatergic 
neurotransmission and the relevance of a role for NT in reward mechanisms and 
schizophrenia.   
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 Chapter 1: VTA anatomy, neuronal composition and 
projections. 
 
 The VTA serves as a key anatomical substrate of neuroadaptive changes that result in reward 
and addiction mechanisms and is also crucial for the development of sensitization. Drugs of 
abuse induce synaptic plasticity on VTA DA neurons by modulating glutamatergic inputs to 
the VTA. The present study involves characterizing the neurotensinergic modulation of 
glutamatergic inputs to VTA neurons. This section therefore focusses on the anatomical 
organisation of the VTA, its neuronal composition, projections and the functions.  
1.1 VTA Anatomy:  
 
In 1984, Lindvall and Bjorklund (Lindvall et al., 1984) grouped the DA containing nuclei of 
the midbrain and named them A1-A17. The VTA or the A10 group of cells was further 
divided into four subzones that were called the paranigral nucleus (PN), the parabrachial 
pigmented area (PBP), the parafasciculus retroflexus area (PFR), and the ventral tegmental tail 
(VTT). The cell density in these sub-regions is estimated by TH (tyrosine hydroxylase- rate 
limiting enzyme for DA synthesis) immunocytochemistry (Kohler et al. 1983). The PFR and 
VTT, border the VTA rostrally and caudally respectively and contain a low density of 
dopaminergic cell bodies that are small in size. Laterally the VTA is marked by the PN. Both 
PN and PBP are rich in dopaminergic cells,  and comprise mainly of medium to large sized 
TH-positive cell bodies (Binder et al. 2001a).   
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1.2 Neuronal composition of the VTA  
 
The VTA is majorly comprised of dopaminergic, glutamatergic and GABAergic neurons. 
Among other peptidergic neurons that are found in the VTA, the neurotensinergic neurons are 
particularly relevant in the present study. While there is a controversy over the exact number 
of each neuronal sub-population in the VTA, there seems to be a general agreement in most 
studies that in the VTA DA neurons constitute about 60-65%, the ɣ-aminobutyirc acid 
(GABA) neurons account for 30-35% and the glutamatergic neurons constitute about 5 % of 
the total cell population (Margolis et al. 2006a;Nair-Roberts et al. 2008;Yamaguchi et al. 
2011). About 1-2% of the VTA neurons are neurotensinergic (Binder et al. 2001a). The 
following section describes the characteristics of each of these subpopulations of VTA 
neurons.  
1.2.1 DA neurons: 
 
Using TH immunohistochemistry Margolis and group, morphologically classified VTA TH-
positive DA neurons as fusiform, round, multipolar or elliptical. The fusiform and elliptical 
dopaminergic neurons, are approximately equal in number and each population constitute 
about 32% of the VTA DA neurons. Both fusiform and elliptical DA neurons have an 
elliptical cell body with the exception that fusiform neurons have two dendrites at opposite 
ends of the major axis whereas elliptical dopaminergic neurons lack a readily identifiable 
number of dendrites. DA cells with round or multipolar soma constitute 20% and 17% of the 
VTA dopaminergic neurons. The size of TH positive dopaminergic neurons varied between 
200-600µm2 in horizontal tissue sections of the rat VTA (Margolis et al. 2006a). The dendrites 
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of VTA DA neurons branch out in forks or tufts and these have 2-3 fine processes which 
sometimes wrap around another terminal. The VTA dendrites are also possessed with irregular 
spinule like projections which can possibly serve as dendritic DA release sites. In vivo 
recordings of VTA DA neurons display two modes of spike firing: tonic single spike activity 
and burst spike firing (Goto et al. 2007;Grace and Bunney 1983a;Grace and Bunney 
1983b;Grace and Onn 1989;Koyama and Appel 2006). However, when recorded in vitro, in 
slices, VTA DA neurons display only the tonic pacemaker activity of 0-5Hz (as shown in 
figure 1B) while the bursts are absent due to the transection of afferent synaptic inputs 
required to promote a DA neuron to the burst firing mode (Mao et al. 2011;Ungless and Grace 
2012). 
The resting membrane potential in DA neurons recorded in vitro in  VTA slices from the rat 
vary between -44mV and -47mV and the action potential (AP) threshold lies between -24 to-
28mV (Margolis et al. 2006a). Recent studies nominate the AP width as a criteria to identify 
DA neurons. In vitro recordings of VTA DA neurons display a broader AP width (than non-
DA neurons) of >2 ms as shown in Figure 1C (Mao et al. 2011;Ungless and Grace 2012). 
 VTA DA neurons are characterized by the presence of a hyperpolarisation activated cationic 
current (Ih) (Ferrario et al. 2005;Kempadoo et al. 2013a;Margolis et al. 2006a). The Ih current 
results from an activation of non-specific cationic conductance at hyperpolarised potentials, 
when the voltage of the neuron is stepped from -40mV to -120 mV and the inward current 
reflects as a long sag at the most hyperpolarised potential. Figure 1D shows an example of an 
Ih current in a DA neuron recorded in-vitro from a rat VTA slice preparation. 
Based on the presence or absence of Ih and TH immunohistochemistry, VTA dopaminergic 
neurons are classified as Ih+TH+, Ih+TH- and Ih-TH- cells. Figure 1 A shows a double labelled 
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recorded neuron with TH immunohistochemistry (left panel shows: recorded neuron; middle 
panel: TH positive neuron; right panel: merged). The Ih+TH+ cell group defines the 
dopaminergic cell type whereas the Ih +TH- represent either the glutamate or GABA neurons 
(Lammel et al. 2014;Li et al. 2013;Margolis et al. 2006a;Margolis et al. 2012a;Ungless and 
Grace 2012). However there is no ambiguity about Ih- cells representing the non-DA cell type, 
the exact neurotransmitter identity of which is still elusive (Lammel et al. 2014;Margolis et al. 
2006a).  
 
In addition to the firing pattern of DA neurons, Johnson and North (Johnson and North 1992a) 
included hyperpolarisation of DA neurons by dopamine D2 receptor (dopamine receptor 
subtype 2 which mediates inhibitory actions by inhibiting adenylyl cyclase activity) agonist, 
quinpirole as a property typical to DA neurons. However recent studies suggest that only 55% 
of TH+ DA neurons are hyperpolarised by quinpirole (Margolis et al. 2006a). Additionally, 
about 20% of TH+ DA neurons in the VTA are insensitive to quinpirole application. DA 
neurons are also characterised by the presence of DA transporter (DAT), D2 autoreceptors  and 
G protein regulated inward rectifier potassium channel  subtype 2 (GIRK2) however none of 
the characteristics unequivocally characterize DA neurons (Bellone and Luscher 2006;Saal et 
al. 2003;Wanat et al. 2008a).  
The use of different parameters for characterizing a DA neuron in different studies, has led to 
the understanding that the VTA DA neurons are a heterogeneous group of neurons and there 
exist controversies in the identification and classification of this neuronal population (Ungless 
and Grace 2012).This issue is addressed in detail in the discussion section of the thesis. 
Figure 1 shows the properties of in vitro recorded DA neurons in the VTA. 
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Figure 1: Properties of in vitro recorded VTA DA neurons. A, Immunohistochemistry of a 
VTA neuron filled with biocytin via the recording electrode. Left, Biocytin staining; middle, 
TH staining; right, co-labelling of biocytin and TH. B, Representative whole-cell recording of 
regular spontaneous action potentials (tonic pacemaker activity). C, Representative trace of an 
action potential from a DA neuron. DA neurons were associated with action potential duration 
of >2 ms. D, A representative trace of Ih induced by hyperpolarizing steps from −40 to −55 
mV through −115 mV in 10 mV increments. Scale bar: A, 10 μm. Calibration: B, 350 ms, 6.25 
mV; C, 1.0 ms, 10 mV; D, 80 ms, 80 pA. Adapted from Mao D et al., 2011. 
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 1.2.2 GABA neurons:  
 
 GABAergic neurons constitute 30-35% of the total neuronal population in the VTA, and their 
main function in the VTA was assigned as providing inhibitory input to dopaminergic cells by 
Johnson and group(Johnson and North 1992a). GABA neurons have been studied using 
glutamic acid decarboxylase (GAD67) immunohistochemistry and like DA neurons, GABA 
neurons exist in fusiform (44%), round (11%), multipolar (38%) and elliptical shapes (7%). 
GABA neurons possess fewer dendritic processes and are usually larger than DA neurons with 
a diameter greater than 30µm. DA neurons were reported to have an approximate diameter of 
24-26µm(Grace and Onn 1989;Margolis et al. 2006a).  
GABA neurons are grouped into two sub populations based on their firing rates; one neuronal 
population is characterized by a relatively high frequency firing (≈ 8 Hz), while the second 
cluster consists of slow-firing cells (≈ 0.7 Hz) (Korotkova et al. 2002;Korotkova et al. 2004). 
However, a later study reported a spontaneous firing rate of around 5 Hz for GAD67 identified 
GABA neurons in the VTA (Margolis et al. 2006a). It is important to note that in the former 
study, the GABA neurons were identified by the lack of TH, smaller AP width and a smaller 
amplitude of Ih. Recent studies suggest that a small or no Ih and the lack of TH signal also 
qualify as characteristics for glutamatergic neurons (Hnasko et al. 2012). Therefore it is 
possible that the two population of GABA neurons also contain a subset of glutamatergic 
neurons.  
The resting membrane potential of GABA neurons recorded in vitro is similar to that of DA 
neurons and range between -44 and -46mV. The AP threshold for GABA neurons is more 
hyperpolarised than DA neurons, and vary between -30 and -32 mV. However when compared 
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between the two groups of GABA neurons (as identified by difference in firing rates) the spike 
threshold is more negative for the fast firing cells (Korotkova et al. 2004). The AP duration for 
in vitro recorded GABAergic neurons of the VTA is smaller than DA neurons and the narrow 
AP width of <3 ms is often used to identify a GABAergic neuron (Margolis et al. 
2012a;Ungless and Grace 2012). Both subpopulations of GABA neurons have little or no Ih 
current. The amplitude of Ih GABA neurons is smaller than that of DA neurons and range 
between 5-100pA(Margolis et al. 2012a).  
Although initially GABA neurons were differentiated from DA neurons by their sensitivity to 
opioid peptides and insensitivity to quinpirole (Johnson and North 1992a), recent evidences 
suggest that GAD67 positive GABA neurons do not unequivocally adhere to these 
characteristics(Margolis et al. 2012a). In this latter study the authors report that a significant 
proportion of GABA neurons (7 out of 13) were not hyperpolarised by opioid peptides. Most 
of these neurons confirmed by GAD67 immunohistochemistry, were found to be Ih+ and only a 
small proportion to be Ih-(4 out of 31 cells). Furthermore, about 30% of GABA neurons are 
inhibited by quinpirole. However, Korotkova et al.,(Korotkova et al. 2004) report that GABA 
neurons (as identified by a difference in their firing rates) have little or no Ih, therefore a subset 
of neurons n the two populations is truly GABAergic as Margolis et al.,(Margolis et al. 2012a) 
reports that a small proportion of GABA neurons were also Ih-. Therefore it appears that at 
least some GABA neurons and some glutamatergic neurons are Ih- and it is reliable to 
designate a non-dopaminergic identity to these neurons. In summary, although some Ih- 
neurons are GABA, whether GABA neurons are exclusively Ih- is still debatable as there are 
reports of contradiction as explained above. However, it is important to note that within the 
scope of our studies the neurotranmistter content of Ih+ and Ih- neuron can only be speculated. 
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Nonetheless categorizing neurons as Ih+ or Ih- does enable us in characterizing effects induced 
by NT (discussed in Section 4.4). 
 
1.2.3 Glutamatergic neurons: 
 
  The identification of glutamatergic neurons in the VTA is comparatively recent and 
glutamateric neurons are located primarily to the medial aspects of the VTA (Kawano et al. 
2006;Lammel et al. 2014). The glutamatergic neurons represent 2-4% of the total VTA 
neuronal population and share resemblance in terms of electrophysiological and 
morphological properties to DA neurons of the same area. The glutamatergic neurons of 
medial VTA are said to have little or no Ih current and have reduced D2 receptor sensitivity 
(Root et al. 2014). Since in the present study the location of cell recordings was restricted to 
the medial VTA, it is possible that a subset of our neurons are glutamatergic. Glutamatergic 
neurons are characterized by the presence of vesicular glutamate transporters (VGluT- that 
pack glutamate into synaptic vesicles). All glutamatergic neurons in the VTA contain VGluT2. 
VGluT2 neurons sometimes colocalise TH and these neurons may co-release dopamine and 
glutamate from their projection terminals (Hnasko et al. 2012) and are mostly found in the 
medial VTA (Sanchez-Catalan et al. 2014).  
VgluT2 neurons form local synapses on VTA DA  and non-DA neurons (Dobi et al. 2010). 
Furthermore, VGluT2 neurons project to the mPFC (Yamaguchi et al. 2011), which indicates 
that this population of cells possibly modulate dopaminergic activity not only through direct 
synaptic contacts but also affect dopaminergic activity indirectly by  modulating PFC neurons 
                                                           
 
11 
 
that project back to the VTA and provide feedback to dopaminergic neurons  (Dobi et al. 
2010). 
1.2.4 Neurotensinergic neurons:  
 
NT positive cell bodies are located in the dorsolateral aspect of the VTA and there are few NT 
only neurons in the VTA. Most VTA neurotensinergic neurons co-localise TH and 
cholecystokinin (CCK) and are significant in number when compared to the substantia nigra 
pars compacta(SNc) (where NT positive cell bodies do not co-localise TH) (Jennes et al. 
1982a;Uhl et al. 1979). The VTA is densely innervated by NT terminals from surrounding 
brain regions and  NT receptors are abundantly found on the cell bodies, dendrites of VTA 
neurons (Binder et al. 2001a). However NT terminals rarely form direct synaptic contacts on 
VTA neurons and less than 10 % of these synaptic contacts are with DA neurons. 
Nevertheless, about 60% of the NTergic terminals are in close vicinity of DA cells 
(within5µm) thus enabling NT to act on DA cells by volume or paracrine transmission 
(Woulfe and Beaudet 1989;Woulfe and Beaudet 1992).  
1.3 VTA projections and functions: 
1.3.1 VTA Projections 
 
  The dopaminergic projections from the VTA innervate the PFC, ventral pallidum (VP), 
nAcb, amygdala, thalamus and the hippocampus and activation of dopaminergic neurons in 
the VTA lead to DA release in these terminal fields (Oades and Halliday 1987;Sotty et al. 
2000a). The dopaminergic projections are implicated in reward, reinforcement, memory 
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formation, processing information about emotion and drug seeking behaviour (Britt and Bonci 
2013;Russo and Nestler 2013). The dopaminergic projections of the VTA are shown in green 
in Figure 2.  
 
 The dopaminergic neurons of the VTA send out projections to different brain regions and 
often these regions send back projections, thus connecting reciprocally and forming loops 
(Watabe-Uchida et al. 2012). The concerted activity of such projections provide a positive 
feedback mechanism that make the VTA a control centre for certain behaviours. For example, 
psychostimulant induced DA release from VTA DA neurons cause an increase of NT 
expression in the nAcb shell on neurons that selectively project back to the VTA (Geisler and 
Zahm 2006). Since NT increase the excitability of DA neurons (Binder et al. 2001a)(discussed 
in chapter 2), the enhanced release of NT in the VTA, causes DA release in the nAcb which 
results in enhanced NT release in the VTA. This leads to a positive feedback mechanism, 
which may contribute to facilitate or lock in neuroadaptive changes associated with 
psychostimulant drug addiction (Geisler and Wise 2008).  
 
The glutamatergic projections to the VTA come from the PFC, thalamus, amygdala, lateral 
habenula, hypothalamus, pedunculopontine and laterodorsal tegmentum (PPTG/LDT) and the 
dorsal raphe (DR). The glutamatergic projections to the VTA from these anatomical substrates 
are shown in blue in Figure 2. The glutamatergic afferents modulate DA cell firing and 
activation of glutamatergic neurons in the efferent areas increase the rate of DA cell firing and 
eventually takes the DA neurons to a burst firing mode that leads to DA release and DA 
dependent behaviour (Geisler and Wise 2008). For example, PFC glutamatergic neurons 
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project to DA neurons, that send back efferents to the PFC. Also the PFC projections possess 
NT receptors at its terminals which may modulate glutamatergic neurotransmission in the 
VTA and this is particularly crucial to the development of sensitization induced by the 
psychostimulant –amphetamine (Cador et al. 1999a;Kim and Vezina 1998).  
 
 There is also evidence for peptidergic innervation of the VTA. For example, the lateral 
hypothalamus in addition to sending glutamatergic inputs to the VTA also send orexinergic, 
and neurotensinergic projections to the VTA (Aston-Jones et al. 2010). The lateral 
hypothalamus send an abundant source of peptidergic input to the VTA and is particularly 
relevant for its implication in reward (Tyhon et al. 2008). Recent studies show that lateral 
hypothalamic  NTergic projections to VTA promote reward by modulating glutamatergic 
neurotransmission in VTA DA neurons (Kempadoo et al. 2013a) (discussed in detail in 
Chapter 2). 
 
 Local interneurons provide the major inhibitory inputs to DA neurons (Tan et al. 2012). The 
other inhibitory afferents to the VTA arise from the nAcb and the VP (Britt and Bonci 
2013;Xia et al. 2011). However, recent studies suggest that the tail of the VTA or the 
rostromedial tegmental nucleus  (RMTg) sends GABAergic projections to the VTA DA 
neurons and  this inhibitory input serves as the “ master brake” for VTA dopaminergic 
pathways (Barrot et al. 2012).The inhibitory inputs to the VTA are shown in red in Figure 2.  
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Figure 2: Schematic of the principal brain regions that innervate the VTA. Green: 
Dopaminergic projections; Blue: excitatory projections; Red: inhibitory projections (Modified 
from Britt and Bonci 2013). Abbreviations: Amyg, amygdala; vHipp, ventral hippocampus; 
LH, lateral hypothalamus; PAG, periaqueductal gray; DR, dorsal raphe; PPTG/LDT, 
pedunculopontine and 
Laterodorsal tegmentum; RMTG, rostromedial tegmental nucleus. 
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1.3.2 Functions of the VTA: 
Being one of the major substrates of the limbic system, the VTA is implicated in reward, 
working memory formation, cognition, motivation and drug addiction. The functional role of 
VTA depends on its afferent inputs and efferent outputs. Since majority of the VTA neuronal 
population is accounted for by DA neurons, most of its functions also involve these neurons.  
 
The dopaminergic  projection from the VTA to the nucleus accumbens  is vital for the 
development of drug addiction ,sensitization and reward mechanisms (Britt and Bonci 2013) 
(Grueter et al., 2012; Britt  et al., 2013). In an elegant study by Deisseroth and colleagues 
(insert citation) it was shown that  optogenentic stimulation of VTA DA neurons induced 
intracranial self-stimulation in rats, promoted conditioned place preference to 
psychostimulants whereas stimulation of GABAergic interneurons in the VTA disrupted 
reward and promoted conditioned place aversion(Tan et al. 2012;van et al. 2012;Witten et al. 
2011). Enhanced DA cell firing in the VTA, leads to release of DA in the terminal fields and 
this release augments with repeated activation of DA neurons induced by the action of 
psychostimulants. 
The dopaminergic projection to the PFC is critical for working memory formation and 
learning (D'Ardenne et al. 2012). Normal cognitive functions, motivated behaviour, emotions 
as well as pathological manifestations for e.g. schizophrenia and ADHD (attention deficit 
hyperactivity disorder) have also been implicated in abnormal functioning of these projections 
(Lammel et al. 2008;Volkow et al. 2011). Prefrontal cortical dopamine tone is characterized 
by an inverted U shaped dose response curve, suggesting that too much or too little DA 
perturbs working memory formation and other PFC functions (Arnsten 2009;Arnsten and Li 
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2005). This suggests that functionally distinct sets of DA neurons projecting to different 
cortical layers are activated at either ends of the inverted U curve, thereby mediating the dual 
roles. It is possible for example, that DA neurons that have a role in working memory project 
selectively to cortical layers associated with  primary sensory cortices, thereby keeping the 
continuum of representation  of a stimulus even in its absence(Chandler et al. 2014).  
 On the other hand, afferents from the LHb to the VTA synapse on DA neurons that project to 
the medial PFC and induce aversion (Lammel et al. 2012).Thus it is possible that these DA 
neurons selectively project to PFC regions associated with limbic structures and not sensory 
structures.  
Lateral hypothalamic projections to the VTA and NAcc have been associated with pain 
modulation. Stimulation of LH efferents (orexinergic) to the VTA can induce antinociception, 
thus suggesting the involvement of VTA DA neurons. Recent studies highlight a preferential 
role for D2 receptors in the NAcc over VTA D2 receptors in antinociception. However, a role 
for D1 receptors in the VTA has been attributed to antinociception suggesting the involvement 
of a concerted D1-D2 mechanism in antinociception (Moradi et al. 2015a;Moradi et al. 
2015b).  
LH VTA projections are also implicated in reward. Activation of NT neurons in the LH that 
project to the VTA were found to augment locomotor activity , induce prolonged dopamine 
efflux in the ventral striatum and transient increase in VTA NT levels. Intra VTA injections of 
NT antagonist, attenuated DA efflux in the NAcc, suggesting that lateral hypothalamic 
afferent induced transient NT release in the VTA links LH signalling to prolonged DA release 
in the NAccc, thereby affecting reward and mesolimbic functions (Patterson et al. 2015).    
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 Recent studies report that selective activation of VTA DA neurons rescue depression like 
symptoms in mice subjected to chronic mild stress (Chaudhury et al. 2013). Owing to the 
heterogeneity of DA neurons in the VTA, VTA functions emerges as a direct readout of 
functioning of distinct neuronal populations within the VTA.  
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Chapter 2: Neurotensin synthesis, receptors and effects.    
  
An action of NT in modulating glutamatergic neurotransmission in the ventral midbrain is 
required for the development of amphetamine sensitization. Since NTergic innervation is 
dense in the VTA and VTA neurons possess NT receptors, NT may modulate DA neural 
activity either directly or by modulating inputs to VTA neurons. This section aims to discuss 
NT as a neuropeptide neurotransmitter, the distribution of NT in the midbrain, the mechanism 
of action of NT, effects of NT administration in the VTA, effects of NT on glutamatergic 
neurotransmission and the relevance of a role for NT in reward mechanisms and 
schizophrenia. 
2.1.1 Discovery and synthesis: 
 
NT is a tridecapeptide that was originally isolated and sequenced from the bovine 
hypothalamus in 1973(Carraway and Leeman 1973). The NT gene encodes a 170-amino acid 
precursor protein that contain both the tridecapeptide NT and a closely related hexapeptide, 
neuromedin N (NN). In the brain, NT and NN are produced by the action of the prohormone 
convertase PC2(Kitabgi 2010).  
In neurons, NT is stored in dense core vesicles and is released in a traditional calcium 
dependent manner. NT transmission is arrested by the cleavage of NT by endopeptidases.  
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2.1.2 NT as a neuropeptide neurotransmitter: 
NT is an endogenous neuropeptide that serves as a neuromodulator and neurotransmitter in the 
central nervous system(CNS) (Vincent et al. 1999). In the CNS, NT is known for its role in 
reward mechanisms, pain modulation  and regulation of body temperature (Kleczkowska and 
Lipkowski 2013) . The neuromodulating role of NT in dopaminergic and glutamatergic 
systems is implicated in diseases like Parkinson’s disease and schizophrenia (Binder et al. 
2001a;Tanganelli et al. 2012). NT is believed to act both as a psychostimulant and a 
neuroleptic in the CNS as NT administration produced similar dopamine dependent 
behaviours in animals that receive exposure to psychostimulants (Dobner et al. 2003;Fadel et 
al. 2006). On the other hand NT also increases glutamate levels in the thalamocortical system 
(projections from the thalamic nucleus to the prefrontal cortex) that is hypothesized to 
ameliorate negative symptoms such as cognitive deficits associated with schizophrenia 
(Borroto-Escuela et al. 2013). 
2.1.3 NT receptors:  
NT has three well characterised receptors, NT receptor subtype (NTS) 1 to 3. NTS1 and 2 
belong to the G protein coupled receptor family, with 7 transmembrane domain. NTS 3 belong 
to the single transmembrane domain receptor type 1 and is mainly located intracellularly 
(Mazella et al. 1998;St-Gelais et al. 2006a) 
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The possibility of the existence of a fourth NT receptor , SorLA/LR11, has been proposed, 
which like NTS 3 receptors belong to the single transmembrane domain receptor type 1(St-
Gelais et al. 2006a). 
NTS1 receptors:  
 
NTS1 receptor was first cloned in rat and is the high affinity receptor for NT (Kd = 0.1-
0.3nM). NTS1 receptor is expressed in dendrites, cell bodies and terminals in the VTA. NTS1 
is the predominant receptor subtype in DA cells of the VTA and exist at presynaptic as well as 
postsynaptic sites to VTA neurons (Binder et al. 2001a). Functionally, NTS1 is coupled to 
phospholipase C (PLC), inositol triphosphate (IP3), mitogen activated protein kinases 
(MAPKs) and the production of diacylglycerol (DAG). These signalling cascades are linked to 
an elevated level of intracellular calcium and suggest induction of excitatory effects to 
depolarise the neuron (St-Gelais et al. 2006a;Trudeau 2000). NTS1 receptor activation is also 
linked with an enhanced formation of cyclic guanosine monophosphate (cGMP) and 
production of arachidonic acid (Binder et al. 2001a;Binder et al. 2001c). The properties of 
NTS1 receptors in terms of its size, location, receptor type, agonists and antagonists have been 
summarized in Table 1. 
  Once NT binds to NTS1, the receptor ligand complex is internalized into neurons that 
express NTS1 and the NTS1 receptors reach the lyzosomes for degradation (Beaudet et al. 
1994;Vandenbulcke et al. 2000). Recent studies suggest that prolonged exposure to NT 
agonists might result in a second gene activation process, resulting in recycling of some NTS1 
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receptors to the cell surface and this process is  mediated by NTS2 receptors(Perron et al. 
2006). 
NTS2 receptors: 
 
 NTS2 receptor is a low affinity NT receptors (Kd =3-10nM)(Binder et al. 2001a). Table 1 
summarizes the properties of NTS2 receptors in terms of its location, size, receptor 
classification, agonists and antagonists. While the NTS2 receptor share sequence homology 
with NTS1 receptor, these receptors functionally coupled to different downstream signalling 
cascades. NTS2 receptor does not stimulate cytosolic calcium mobilization or IP3 
accumulation but is linked to mitogen activated protein kinases (MAPK) and are suggested to 
elicit inhibitory effects when cloned human NTS2 receptors are expressed on  Chinese 
Hamster Ovary cell lines(CHO) cell lines (Sarret et al. 2002). However, when the human 
NTS2 receptors were transfected in COS cells, IP3 production was reported to be constitutive. 
This constitutive activity was enhanced by almost 50% by an NTS1 antagonist (SR48692), not 
affected by NT concentrations of up to 10µM and decreased below constitutive levels by 
levocabastine (a histaminergic antagonist which is known to bind to NTS2 receptors, thus 
suggesting a weak partial inverse agonist activity. Additionally, NT, concentration 
dependently reversed the effect of SR48692 back to constitutive levels, suggesting that it acts 
like a neutral antagonist. Therefore, whether NT acts as an agonist, inverse agonist or neutral 
antagonist for NTS2 receptors is undetermined (Richard et al. 2001).  
In contrast to NTS1, NTS2 receptors once sequestered into the cell as NT-NTS2 complex, 
preferentially reaches the recycling complex and efficiently recycles back to the cell surface 
(Botto et al. 1998).  
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NTS3 receptors: 
 
NTS3 receptors are also called gp95/ sortilin owing to its 100% homology with the previously 
cloned gp95 protein that is involved in receptor sorting (Mazella et al. 1998;Vincent et al. 
1999). NTS3 receptors are located in glia, neurons and adipocytes and only 5-10% of these 
receptors are found on the cell surface (Mazella et al. 1998). Table 1 summarizes the 
characteristics of NTS3 receptors in terms of its size, receptor classification, location, agonists 
and antagonists. These receptors recognize NT only after it is translocate to the plasma 
membrane and acts like a scavenger protein to sequester extracellular NT. This receptor is 
predominantly associated with the Golgi apparatus and the endoplasmic reticulum (Mazella 
and Vincent 2006b) but is known to heteromize with NTS1 after translocation to the cell 
surface and modulate NTS1 activity in terms of activating MAPK (Sarret et al. 2003b). 
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Table 1 summarizes the characteristics of the different NT receptor subtypes, their locations, 
agonist and antagonists. 
 
NT 
receptor 
subtype 
Size Receptor 
classification 
Location Agonist Antagonists 
NTS1 50-60 
kDa 
G protein 
coupled- 7 
transmembrane 
spanning regions 
Neurons   
Glia (astrocytes) 
• NT (Kd=0.1-
0.3nM) 
• NN 
• Xenopsin 
• SR48692 
• SR142948A 
NTS2 45 kDa G protein 
coupled- 7 
transmembrane 
spanning regions 
Neurons  
Glia (astrocytes) 
• NT(Kd=3-
10nM) 
• NN 
• Xenopsin 
• SR48692 
(expressed in 
oocytes) 
• SR142948A 
(expressed in 
oocytes or CHO 
cells) 
• Levocabastine 
(expressed in 
oocytes or CHO 
cells) 
• NT(express
ed in 
oocytes or 
CHO cells) 
• SR142948A 
• Levocabasti
ne 
NTS3 100 kDa Type I amino acid 
receptor single 
transmembrane 
spanning region 
Neurons  
Glia (astrocytes)  
Intracellular 
vesicles 
containing GluT4 
glucose 
transporter 
NT triggers 
insertion of the 
receptor into the 
membrane. 
• NT 
(Kd=0.10.3nM) 
• Receptor 
associated 
protein(40kDa 
endoplasmic 
reticulum 
associated 
protein) 
• Cleaved sortilin 
propeptide 
Uncleaved   
sortilin 
propeptide 
functional 
antagonist 
blocks 
agonist 
binding 
until 
cleaved 
from 
receptor. 
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2.1.4 NT analogs: 
 
Neurotensin analogs are derived from cleavage of the native NT peptide and since 1975 when 
Carraway and Leeman(Carraway and Leeman 1973) confirmed the importance of the carboxy 
terminal domain in conferring the biological activity and binding of NT, the first few analogs 
that were synthesized were variants of the C-terminal domain. Interestingly, NT analogs 
respond differently in the same anatomical substrates or the same analog behaves differently in 
various regions of the brain (Sotty et al. 2000a). Since, the binding affinity of these analogs to 
NT receptors have different orders of potency  as does it depend on the dose of the analog 
used, the physiological effects that translate from these binding events also vary. In the present 
study, three NT analogs have been used to evaluate their effects on glutamatergic transmission 
in DA and non-DA neurons of the VTA. NT1-13(the native peptide), NT8-13 (the C terminal 
hexapeptide) and D-Tyr [11] NT1-13 (the native peptide substituted at the 11 th residue by a 
D-tyrosine which renders the peptide more resistant to cleavage by endopeptidases). The 
following section aims to describe the properties of each of these analogs, and the similarity 
and differences in the effects mediated by them.  
NT 1-13 and NT8-13: NT1-13 is the 13 amino acid, native neurotensin peptide which is 
endogenous in the brain, mostly found in the dopamine rich regions (for example the VTA) 
and most effects mediated by this peptide are through its C terminal region. When applied 
exogenously, NT1-13 fails to cross the blood brain barrier and is not resistant to peptide 
degradation. AT the rat NTS 1 receptor, NT1-13 has a Kd of 1.97nM while NT 8-13 has a Kd 
of 1.60E-01. NT1-13 is less potent than NT8-13 but more than D-Tyr [11] NT1-13 at NTS 1 
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receptors. However, at the NTS 2 receptors, NT1-13 has a similar potency as that of NT8-
13(Kitabgi et al. 1980a;Labbe-Jullie et al. 1994). 
  NT1-13 when locally applied increases dopamine cell firing in the VTA (Seutin et al. 
1989;Shi and Bunney 1991b), stimulates dopamine metabolism and consequentially dopamine 
release in the terminal fields of DAergic projections (Cador et al. 1995;Kalivas and Taylor 
1985a)  and that these effects are similarly mimicked by NT8-13. 
NT8-13 or the hexapeptide C terminal fragment produces most of the known effects of NT and 
therefore most peptide agonists for NT receptors are analogs of this hexapeptide. There are 
discrepancies on the similarity in effectiveness of NT1-13 and NT 8-13. For example, a study 
by Rompre et al., (Rompre and Boye 1993) suggests, both these peptides are equally effective 
in operant responding for brain stimulation reward paradigms. This observation is further 
supported by the similarity of both these peptides in terms of binding affinities and receptor 
activation(Kitabgi et al. 1980a). Interestingly, there are reports of differential actions of these 
two peptides too. For example, ventromesencephalic tegmental microinjections of NT1-13 but 
not NT81-13 induce conditioned place preference (an experimental paradigm that reflects 
sensitization)(Glimcher et al. 1984a). Another, evidence comes from the evaluation of 
dopamine efflux using electrochemical methods in different brain regions upon different NT 
analog administration. In the rostral nucleus accumbens, the effect of NT and D-Tyr [11] NT 
1-13 (another NT analog, described in detail in the following paragraphs) were found to be 
similar, whereas NT8-13 was less potent (Sotty et al. 2000a). In glial cells, NT 8-13 was 
reported to cause an increase in  both internal and external Ca2+ levels that implicated both 
external and internal, and that the initiation of this release is mediated from calcium sources 
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dependent on inositol triphosphate (IP3)(Trudeau 2000). Another study in the VTA of guinea 
pigs, revealed two types of responses, a fast and short duration and a long and slow duration 
inward current that were induced on application of NT. While both the responses could be 
induced, by NT 1-13 only the fast/ short inward current could be induced by NT8-13. 
Additionally, NT was found to be more potent in reducing the DA induced inhibition in the 
VTA (Nalivaiko et al. 1998a). Therefore, although a general consideration might be made that 
NT8-13 is more or equally potent compared to NT in exerting its effects, there are studies that 
report otherwise, which suggests, that there are multiple receptor types that are activated by 
each of these peptides and that this activation is concentration sensitive. In the present studies, 
NT1-13 and NT8-13 have been used to test their effectiveness in modulating glutamatergic 
responses in VTA neurons and NT antagonists have been used in identifying the receptors 
involved in mediating these responses. 
 D-Tyr [11]NT1-13 is a neurotensin analog that has the 13 amino acids of the peptide intact 
but the 11th position is substituted by a D-tyrosine residue that makes it more resistant to 
cleavage by endopeptidases(Checler et al. 1983a). In fact, after an intracerebroventricular 
injection of NT, 98% of the NT was cleared and degraded in brain tissues during a 30 min 
period after the injection. Under the same conditions,33% of  D-Tyr [11]NT1-13 was retained, 
thereby suggesting a half-life  1.5 times greater than that of  NT(Checler et al. 1983a). D-Tyr 
[11]NT1-13  is known to stimulate DA release in vitro and in vivo , because of the close 
interplay between interacting DA and NTergic systems majorly in the limbic system(Steinberg 
et al. 1995). This peptide is known to sensitize to the locomotor effects of amphetamine 
sensitization, when injected in the VTA and has similarity in effectiveness when compared to 
NT but has a greater potency, thus  possibly explaining its property of being resistance to 
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peptidase degradation(Rompre 1997a). A similar sensitization effect to cocaine, possibly 
mediated  by NMDA receptors in the VTA has also been reported(Rompre and Bauco 2006a). 
In a more recent study, a role for D-Tyr [11]NT1-13  in induction of both context dependent 
and independent , amphetamine sensitization has been elucidated(Rouibi and Rompre 2014).In 
comparison to  NT and NT8-13, D-Tyr [11]NT1-13   has a more stable metabolic profile and 
that in the presence of thiorphan, a peptidase inhibitor D-Tyr [11]NT1-13 induces larger 
locomotor effects caused by elevated levels of extracellular dopamine concentrations,  than 
NT alone(Steinberg et al. 1995) . However, it is important to note that thiorphan by itself 
increases extracellular dopamine concentration, and therefore the evaluation of effects 
metabolically unstable NT analogs, in terms of increasing dopamine concentration is not 
possible (Labbe-Jullie et al. 1994). However, the failure of D-Tyr [11] NT1-13 in stimulating 
dopamine release in the PFC when injected in the VTA cannot be explained by the 
metabolically stable profile whereas both NT8-13 and NT in similar range of concentrations 
have been effective in causing dopamine release. Interestingly, in the same study, differential 
effects of D-Tyr [11] NT1-13 are reported in the rostral and caudal aspects of the nucleus 
accumbens. For example, in the caudal aspects, NT8-13 and NT were more potent than D-Tyr 
[11] NT1-13, whereas, in the rostral aspects NT8-13 was less potent than D-Tyr [11] NT1-13 
and NT. Therefore the effects of these three peptides in limbic regions specially seem to be 
varied and dependent on (i) the concentration in which it is applied, (ii) the binding affinity of 
NT analogues at multiple NT receptors and their consequent activation (Sotty et al. 2000a). 
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2.2 NT in the Midbrain:  
 
In the VTA NT colocalizes with TH and these mixed NT/DA neurons project to the PFC, 
Entorhinal cortex(EC), nAcb, BLA and lateral septum (LS) (Fallon 1988). The incoming NT 
afferents to the VTA do not colocalize TH suggesting their non-dopaminergic origin. In rats, 
these fibers were reported to originate from the bed nucleus of the stria terminalis (BNST), 
lateral hypothalamus (LH), LS and the preoptic area (Zahm et al. 2001). Neurotensinergic 
efferents from the VTA project to the EC, amygdala, nAcb, piriform cortices, LS and pre-optic 
area. Figure 3 shows the neurotensinergic projections and NT rich regions of the rat brain. 
Evidence for  local direct synaptic connections between NT axon terminals from adjacent 
brain regions and TH positive cells and dendrites within  the VTA, indicate a possible 
presynaptic mode of action of NT owing to the vast majority of NT positive terminals as 
evidenced by electron microscopic autoradiography (Woulfe and Beaudet 1992).   
Eighty to ninety percent of midbrain NT receptors are located on DA neurons of the VTA and 
these are predominantly NTS1 receptors. The remaining NT receptors are found on projection 
neurons (glutamatergic or GABAergic), non-Dopaminergic axon terminals and glial cells 
(Fassio et al. 2000;Nicot et al. 1994;Szigethy and Beaudet 1989). There are also reports of 
NTS2 mRNA in the midbrain, however their exact cellular location has not been verified 
(Lepee-Lorgeoux et al. 1999;Walker et al. 1998).  
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Figure 3: NT distribution and NTergic projections of the rat brain. Acc, accumbens nucleus; 
Amy, amygdala; BasF, basal forebrain; BG, basal ganglia; BNST, bed nucleus of the stria 
terminalis; CA1, hippocampal field CA1; CPu, caudate putamen; DG, dentate gyrus; EntCx, 
entorhinal cortex; Hab, medial habenula; Hyp, hypothalamic nucleus; LS, lateral septum; 
MPA, medial proptic area; NX, dorsal motor nucleus of the vagus; PAG, periaqueductal grey; 
PBN, parabrachial nucleus; PIR, piriform area; POA, preoptic area; Sub, subiculum; SN, 
substantia nigra; STN, solitary tract nucleus; ThN, thalamic nucleus; VP, ventral pallidum; 
VTA, ventral tegmental area. Adapted from (Griebel and Holsboer 2012). 
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   2.3 Modulation of DA neurotransmission by NT:  
 
The localization of NT receptors on DA neurons in the VTA raises the possibility of a 
functional interaction between these two neurotransmitter systems (Binder et al. 2001a). Once 
NT binds to NT receptors on DA cells, an NT –NTS complex is formed and NT receptors are 
activated. The section below describes these events and their consequent effect on DA cells.  
1. Effects of NT-NTS complex formation 
 
Once NT binds to NT receptors, the NT-NTS complex is internalized and depending on the 
receptor type that was activated, the receptor is either recycled to the cell surface or degraded 
in the lysosome (Mazella et al. 1998;Mazella and Vincent 2006b). The internalized NT ligand, 
eventually moves to surround the nucleus and has been reported to increase TH gene 
expression in DA neurons (Burgevin et al. 1992). Step1 of Figure 4 shows the formation of the 
NT-NTS complex. 
The NT-NTS complex decreases the agonist binding affinity of D2 dopamine receptors for DA 
and DA agonists as shown in Step2 of Figure 4. This leads to a decrease in DA autoinhibition 
(binding of DA to D2 receptors increase K+ conductance and hyperpolarise the neuron) and 
shifts the activity of post synaptic cells to D1(dopamine receptor subtype 1 , that depolarises 
the neuron and increase firing) mediated transmission. The mechanism of this decrease is a 
concerted effect of direct receptor interactions between NTS1 and D2; and activation of 
second messenger pathways. At the receptor level, NT via allosteric receptor/receptor 
interactions and second messenger dependent pathways decreases the dissociation constant 
(Kd) of  D2 receptors without affecting the total density of receptors ( Bmax), which indicates 
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that the dynamics of the receptors are altered, leaving the density of functional receptors 
unaltered (Fuxe et al. 1992;Tanganelli et al. 1993). Although, NTS1, has been the only well 
characterised receptor known to modulate D2 function, the potency of NT analogs in 
decreasing D2 receptor agonist binding affinity is incongruent with their binding affinities for 
NTS1. NT is more potent than NT8-13 in decreasing agonist binding affinity at D2 receptors, 
however the binding affinity at NTS1 is higher for NT8-13 than NT. This indicates the 
possible involvement of another NTR, in addition to NTS1 in mediating this effect (Kitabgi et 
al. 1980a;Li et al. 1993a;Li et al. 1993b). 
2. Effects of NT receptor activation 
 
Activation of NTS1 by intracerebroventricular (i.c.v) injections of NT depolarised and 
increased the firing rate of midbrain DA neurons as evidenced from extracellular singe unit 
field recordings. This depolarisation and increase in firing rate culminate in an increase in the 
number of active DA neurons (Kobayashi et al. 1977;Pinnock 1985;Shi and Bunney 1991a;Shi 
and Bunney 1991c). 
NT-NTS1 binding decreases the binding affinity of DA agonists for D2 receptors (Figure 4 
step1), thus removing the inhibitory effect of D2 receptors that consequentially led to DA cell 
firing. Using patch clamp recordings of rat midbrain DA neurons that were identified with TH 
immunohistochemistry it was reported that NT and D2 receptors oppositely regulate the same 
K+ conductance. While NT decrease the K+ conductance resulting in depolarisation and 
enhance the firing rate of the neuron, D2 receptors enhance it to hyperpolarize the neuron 
(Farkas et al. 1997). However, another study argues against the involvement of the same K+ 
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channel conductance, as in extracellular recordings of firing of DA neurons, NT attenuated the 
inhibitory effect of the D2R agonist, at concentrations that were insufficient to promote 
augmentation in firing rates (Werkman et al. 2000a). NT induced attenuation of D2 inhibition 
is not a result of antagonizing general excitation as glutamate (neurotransmitter that increases 
DA cell firing) failed to mimic this effect (Shi and Bunney 1990). 
The cell depolarisation induced in step 2 leads to a two component inward current. While the 
first component is a fast excitation, the second component is a slow excitation. The fast 
component comprised an increase in the non-selective cationic conductance mediated by the 
activation of Gαq and Gα11 (G protein subtypes) and IP3 and involved NTS2 as shown in Step4 
of Figure 4. The slow component is comprised of a decrease in an inwardly rectifying K+ 
channel conductance (Ih) and involves PKC activation and activation of NTS1 (Cathala and 
Paupardin-Tritsch 1997;Chien et al. 1996;Farkas et al. 1996;Nalivaiko et al. 1998a). This 
reflects as a decrease in Ih current. Step 3 of figure 4 shows the decrease of Ih. Additionally, 
only NT8-13 was able to induce the fast response, however NT8-13 has a higher affinity for 
NTS1 than NTS2 (Kitabgi et al. 1980a). The NT initiated inward current was blocked by the 
NTS1 antagonist SR48692, was equally permeable to Na+ and  K+ ions and  blocked externally  
by Ca2+ and Mg2+ ions. (Farkas et al. 1996;Nalivaiko et al. 1998a) 
 As described earlier, it is important to note that most of the work on the mechanism of NT 
action on DA cells have focussed on NTS1, however in the VTA NTS2 exist on the cell body, 
dendrites of DA neurons and terminals from afferent areas, and therefore NTS2 receptor 
activation will also have consequences on DA cell activity (Jennes et al. 1982a;Woulfe et al. 
1992;Woulfe and Beaudet 1992). However little is known about the effects of NTS2 receptor 
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activation in neurons. In other expression systems activation of NTS2 have resulted in 
inhibitory effects (Sarret et al. 2002).For details see section on NTS2. 
 
 
Figure 4   is a schematic that shows the effects of NT on DA cells as described in the section 
above. 
 
Figure 4: Mechanism of action of NT on DA cells. 2: once NT binds to the NT1receptor, the 
NT-NT1 complex is rapidly internalized. 1: the NT-NT1complex decreases the agonist binding 
affinity of the DA D2receptor. 3: binding of NT to NT1 decreases Ih. 4: NT binding to the 
NTR increases the conductance of a nonselective cation channel, transduced by activation of 
Gαq and/or Gα-11 G-protein subtypes and IP3. 5: NT interacts with the extracellular portion of 
2 
1 
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the D2 receptor via hydrophobic mode matches. This interaction leads to a change in the K d of 
D2 receptor antagonist binding. Adapted from(Binder et al. 2001a). 
 
2.4 Effects of NT administration in the VTA  
 
 As described in the section above, the effects of NT are concentration dependent.  Bath 
application of NT to VTA slices in guinea pigs at a concentration of 0.5µM or lower induced 
reduction of Ih in DA neurons in culture, resulting in a slow depolarisation (Chien et al. 
1996;Nalivaiko et al. 1998a). Bath application of NT induced increase in DA cell firing in 
VTA cultured neurons at a potentially non-physiologic dose (1µM) when the conductance of 
the non-selective cation channel is increased (Farkas et al. 1997). At even higher 
concentrations, DA cell firing as recorded in vitro in extracellular field recordings is arrested 
due to the overexcitation resulting from depolarisation inactivation (Pozza et al. 1988;Seutin et 
al. 1989).  
The excitatory effects of NT on DA neurons of the VTA, lead to increased DA cell firing and 
eventually translate to increased DA release in the terminal areas of projection of the DA 
neurons. For example NT administration in the VTA leads to increased levels of DA efflux in 
the nAcb and the PFC. At the cellular level, the DA release is measured as a function of increase 
in homovanillic acid (HVA-a catecholamine metabolite associated with dopamine levels)  and 
3,4-dihydroxyphenylacetic acid (DOPAC- a metabolite obtained from the degradation of 
dopamine). A schematic representative of this effect is shown in Figure 5 A and B. 
Behaviourally this relates to potentiation of DA dependent behaviours such as increased 
                                                           
 
35 
 
locomotor activity, circling that finally culminate in sensitization and rewarding effects (Sotty et 
al. 2000a).  
 
 
 
 Figure 5 shows the summary of the electrophysiological effects of NT injection in the VTA. 
 
Figure 5: Summary of the electrophysiological and neurochemical effects of NT 
administered in the VTA. Effects are shown at the sight of injection (VTA) and in the 
prefrontal cortex (A) and nucleus accumbens (B). Low dose (0.5µM or less) of NT 
depolarize DA neurons without increasing cell firing (1). Moderate dose (1µM) of NT 
increases the number and rate of spontaneously firing DA neurons (2) which leads to 
increased DA turnover in the terminal regions. At high doses (>1µM) NT decreases the 
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firing rate of DA neurons in the VTA that project to the nucleus accumbens (3). Adapted 
from (Binder et al. 2001a).  
2.5 Effect of NT on glutamatergic neurotransmission 
 
Glutamatergic neurotransmission in the VTA play an important role in modulating VTA 
neuronal activity and is vital for the functioning of the VTA. Release of glutamate from 
glutamatergic terminals, depolarise VTA DA neurons and increase their excitability (Nestler 
2013).  Activation of glutamatergic inputs to DA neurons (for e.g. from the PFC, LdTg) 
induce burst firing and consequentially increases DA release in terminal areas of projection 
(for e.g. in the nAcb) (Seutin et al. 1989). Glutamatergic inputs to the VTA are also crucial to 
the development of sensitization and blockade of glutamatergic receptors in the VTA impair 
this process (Rompre and Bauco 2006b). Furthermore, synaptic plasticity at excitatory 
synapses on DA neurons is a key neural adaptation that contributes to addiction (Geisler and 
Wise 2008). Therefore the modulation of such inputs are pivotal to the understanding of 
neuroadaptations involved in sensitization, reward and addiction related processes. 
The VTA is an NT rich region in that it receives a dense innervation of NT fibers from cortical 
and subcortical structures and possesses NT receptors on VTA neurons. Amphetamine 
induced sensitization requires a role for NT and blockade of NMDA receptors in the VTA 
disrupted this process. This suggests a possible role for NT in modulating glutamatergic 
neurotransmission in the VTA (Vezina and Queen 2000b).  
 Early studies that focussed on the effect of NT on glutamatergic neurotransmission at the 
cellular level, were performed in the striatum or the cortex (Ferraro et al. 1995;Ferraro et al. 
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2000). Although, the anatomical substrate in our study is different, it would give us a general 
idea about the possible modes of interaction between these two interacting systems. 
A functional interaction between NTS1 and D2 receptors at the cortico-striatal glutamatergic 
terminal comes from an in-vivo microdialysis study in awake rats. In the presence of a high 
concentration of K+ in the Ringer’s solution, extracellular glutamate levels increased, which 
was blocked by the D2 receptor agonist quinpirole. This inhibitory effect was counteracted by 
the addition of NT8-13 or NT thus indicating NTS1 receptor modulation at the cortico-striatal 
glutamate terminal(Ferraro et al. 1995). Another study in rat cortical slices, reported that NT 
enhanced glutamate release in the cortex and that this effect was further enhanced in the 
presence of NMDA, leading to excitotoxicity induced cell death. The pattern of enhancement 
followed a bell shaped curve and that the maximal effect was observed at a concentration of 
10nM and thereafter at even higher concentrations (100nM and 1000nM) the enhancement 
effect progressively declined. Since this effect was blocked by the NTS1 antagonist -SR48692 
, an involvement of NTS1 receptors was suggested (Ferraro et al. 2000). However, in contrast 
to the observation in these studies, another electrophysiological study in the nAcb of rats, 
suggests that NT at higher concentrations (0.5-1µM) reduced glutamate release from terminals 
and that this action required the activation of D2 and group I metabotropic glutamate 
receptors. Since, SR142948A (the non-selective antagonist for NT receptors) blocked the 
inhibitory effect, the authors suggest a role for NTS1. However, it is important to note that 
SR142948A is an antagonist for both NTS1 and 2 receptor subtypes. Additionally, the 
depression also recruited CB1 receptors (Yin et al. 2008).A similar in vitro 
electrophysiological study in VTA slices from TH EGFP (green fluorescent protein) 
transgenic mice, reported a reduction of glutamatergic EPSCs in VTA DA neurons produced 
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by NT8-13 that involved NTS1 receptors. Moreover, AM251, a CB1 antagonist, blocked this 
synaptic depression and the NTergic effect was independent of intracellular calcium dynamics 
but dependent on PLC and G protein activation. The endocannabinoid responsible for this 
effect was identified as 2AG, the same molecule known to gate long term potentiation in the 
VTA (Kortleven et al. 2011;Kortleven et al. 2012a). In a more recent study in rats (Kempadoo 
et al. 2013a) optogenetic techniques was used to selectively activate hypothalamic NTergic 
afferents to the VTA. This study suggested that NT 8-13 potentiates composite glutamatergic 
EPSCs and isolated NMDA at low concentrations (10nM) and inhibited pharmacologically 
isolated AMPA EPSCs at equimolar concentrations of NT in DA neurons that were identified 
using TH immunohistochemistry and the presence of Ih. However, at higher concentrations 
(100nM and 500nM), NT 8-13 inhibited both AMPA and NMDA EPSCs. While the 
potentiation of the NMDA currents was mediated by NTS1 receptor activation, the reduction 
of NMDA EPSCs at higher concentrations was attenuated but not eliminated by SR48692, 
suggesting the involvement of another receptor (possibly NTS2) in addition to NTS1. The 
reduction in AMPA mediated EPSC was not NTS1 dependent as SR48692 failed to block or 
attenuate the depression (Kempadoo et al. 2013a). 
Not much is known about the effect of NTergic modulation of glutamatergic inputs to non-DA 
neurons of the VTA. A behavioural study reported that blockade of NMDA receptor1 (NR1) 
on non-DA neurons in the VTA, by using NR1DATCre transgenic mice (NR1DATCre - Cre-
loxp mice lacking functional NMDARs in DA neurons expressing Cre recombinase under the 
control of the endogenous dopamine transporter gene) impair the development of sensitization 
to cocaine (Luo et al. 2010a) . Since non-DA neurons of the VTA receive efferent 
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glutamatergic inputs and express NT receptors, the possibility of NTergic modulation of these 
neurons and its inputs are likely to play a role in sensitization mechanisms. 
  2.6 Relevance of a role for NT in behavioural disorders 
 
 The close anatomical and functional interaction of NT with the mesolimbic system prompts 
NT to be studied in relation to the adverse effects implicated by this system, including reward, 
addiction and schizophrenia. In fact, NT produces behavioral effects (for example enhanced 
locomotor activity) similar to that produced by psychostimulants when directly injected in the 
VTA (Kalivas et al. 1981;Kalivas 1993;Kalivas and Taylor 1985a). It induced conditioned 
preference for a place that was previously paired with the use of NT, indicating a reinforcing 
effect (Glimcher et al. 1984a) and the rats subsequently self-administer NT. In rats, NT also 
sensitizes to the locomotor effect of amphetamine (Cador et al. 1999a) and NT antagonists 
disrupt the development of NT induced sensitization to amphetamine (Panayi et al. 
2002;Rompre and Perron 2000a). The behavioural manifestation of sensitization effects relates 
to the rewarding properties of drugs of abuse or psychostimulants which finally translate to 
long lasting effects reflecting a compulsive pattern of drug intake.   
One of the corner stones of the DA hypothesis of schizophrenia is that schizophrenia is a 
disorder of overactivity of DA systems and all clinically effective APDs (antipsychotic drugs) 
that are used to treat schizophrenia have high affinity for DA D2 receptors (Dobner et al. 
2003). Interestingly, NT administration in the nACb have antipsychotic like effects or D2 
antagonistic effects. For example, NT injected into the nAcb reduced hyperlocomotion 
induced by DA agonists and SR48692 blocked this effect (Boules et al. 2014;Dobner et al. 
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2003;Feifel et al. 1999;Jolicoeur et al. 1984;Robledo et al. 1993). Furthermore, amphetamine 
induced locomotor activity is also attenuated by NT administration in the nAcb (Ervin et al. 
1981;Feifel et al. 1997a;Feifel et al. 1997b). In addition to reducing the DAergic tone, the 
antipsychotic like effect of NT has also been evaluated in its potential to increase inhibitory 
(GABA) transmission in the striato-pallidal pathway (part of the indirect pathway of the basal 
ganglia that controls movement; projects from the striatum to the VP and then the sub thalamic 
nucleus (STN)) (Chen et al. 2006;Ferraro et al. 2011;Matsuyama et al. 2003). This restores the 
glutamate tone of the thalamo-cortical pathway (the other part of the indirect pathway of the 
basal ganglia; projections from the sub thalamic nucleus to the cortex) that is reduced in 
schizophrenic patients (Antonelli et al. 2007;Ferraro et al. 2001). Since NT produces a bell 
shaped and concentration dependent enhancement in cortical glutamate levels (Ferraro et al. 
2000), it is suggested that the antipsychotic-like effects of NT may be mediated in part by its 
modulatory effect on glutamate (Boules et al. 2013). Recent studies reveal that NT peptide 
analogs hold a great promise in treating disorders like psychosis, schizophrenia, drug abuse 
and autism (Boules et al. 2014). 
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Chapter 3. Questions and Hypothesis 
 
Psychostimulants or drugs of abuse induce motor stimulant effects that endure with repeated 
drug administration and lead to long lasting effects that culminate in behavioural sensitization 
and subsequently addiction. The VTA is involved in the initiation of drug induced sensitized 
behavioural response and glutamatergic neuroadaptations of VTA DA neurons contribute to 
this phenomenon. Disruption of the development of sensitization by blockade of NMDA 
receptors in the VTA, support a role for glutamatergic neurotransmission. Additionally, 
blockade of NT receptors in the VTA also leads to the disruption of the development of 
sensitization to drugs. These led us to think that the role of NT in behavioural sensitization 
mechanisms possibly resides in its ability to modulate glutamatergic neurotransmission in 
VTA neurons. However, how NT modulates glutamatergic neurotransmission of VTA neurons 
remain largely unknown.  
Hypothesis 
Since the VTA is heavily innervated with NT terminals and NT receptors colocalize in most 
DA neurons, most actions of NT in the VTA involve the activity of DA neurons. This led 
us to hypothesize that 1) activation of ventral midbrain NT receptors (sub-type 1 (NTS1) 
and/or 2 (NTS2)) by endogenous NT increases DA neuronal activity; 2) that results in 
activation DA receptors; 3) which in turn increases local glutamate which activates NMDA 
and/or non-NMDA receptors; 4) activation of these receptors leads to activation of 
intracellular signaling pathway(s) that lead to long lasting functional changes that sub-serve 
sensitization. The model focuses on the possibility that NT acts directly or indirectly on 
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ventral midbrain non-DA neurons and/or nerve terminals from glutamatergic efferents. A 
schematic of the hypothesis is outlined in Figure 6. 
 Specific hypotheses:  
Specific hypothesis 1: 
 
 The effect of NT on DA neurons reflects as a biphasic inward current comprising of a fast 
excitation followed by a slower longer excitation involving the increase in non-selective 
cationic conductance and the reduction of K+ conductance respectively (Farkas et al. 1996). 
However, o n l y  the slower component is generated by the C terminal fragment NT8-13 
whereas the fast excitation is elicited by both NT1-13 and NT8-13 suggesting that different 
NT analogs generate varied responses. D-Tyr[11]NT1-13 , another NT analog with a d-
tyrosine substitution in the  11th position is more resistant to cleavage by endopeptidases. D-
Tyr[11]NT also has a higher affinity for NTS2 than NTS1, thus enabling characterisation of 
effects that are attributed to these two different receptor subtypes.  
Since NT analogs generate varied responses, we first sought to characterize the effects of 
different NT analogs (NT1-13, NT8-13 and D-Tyr[11]NT1-13) on glutamatergic EPSCs 
from VTA DA and non-DA neurons and identify the receptors mediating the effects. To test 
this hypothesis, in the first study we used three different NT analogs; NT1-13, NT8-13 and D-
Tyr[11]NT1-13   and tested their effects on glutamatergic EPSCs from DA and non-DA 
neurons of the VTA. To identify the receptor associated in mediating the effects produced by 
these analogs, we used SR142948A (the non-selective NTs antagonist) and SR48692 (NTS1 
antagonist) to test their effectiveness in blocking the effects. 
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Specific Hypothesis 2:  
Since NT receptors within the VTA are located not only on neuron somata and on dendrites, 
but also on axon terminals, activation of these receptors could possibly modulate 
neurotransmitter release as well as induce postsynaptic effects. Our model proposes two 
pathways through which NT can modulate glutamatergic neurotransmission: 1- Directly by 
modulating glutamate release via the activation of NT receptors located on glutamatergic 
terminals (see Figure 7A) and 2- indirectly through the activation of DA neurons, which will 
release DA that can act on D1or D2 receptors on glutamatergic terminals (see Figure 7B). 
The second study is aimed at testing these hypotheses and identify the locus of glutamatergic 
neurotransmission modulation. Bath application of NT agonists will activate both 
mechanisms, and therefore, we proposed, in a first series of experiments, to study the 
modulatory actions of D-Tyr[11]NT1-13 on evoked NMDA and non- NMDA EPSCs  from 
DA and non-DA neurons and estimate the contribution of NMDA vs non- NMDA 
modulatory effects. NT antagonists would be tested in a separate set of experiments to 
identify the NT receptor subtype mediating the modulatory effect. Paired pulse protocols 
would be administered in all experiments to isolate presynaptic effects if any. 
The studies entailed above would enable a better understanding of the neurotensinergic 
modulation of glutamatergic neurotransmission of VTA neurons and highlight a role for non-
DA neurons in sensitization and addiction mechanisms. 
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The studies entailed above would enable a better understanding of the neurotensinergic 
modulation of glutamatergic neurotransmission of VTA neurons and highlight a role for non-
DA neurons in sensitization and addiction mechanisms. 
 
 
Figure 6- schematic of the proposed model. 
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Figure 7A: Direct pathway  
  
 
  
 
   
  
 
 
 
 
  
   
              Figure 7B: Indirect pathway 
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implies that I realized most of the experiments presented in the 3 articles that I have written.  
This work was majorly supervised by Dr. Richard A Warren. A special mention to Dr. Pierre 
Paul Rompre for helping me write the manuscripts of the 1st and 2nd articles. 
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Abstract 
Neurotensin (NT) is an endogenous neuropeptide that modulates dopamine and glutamate 
neurotransmission in several limbic regions innervated by neurons located in the ventral 
tegmental area (VTA). While several studies showed that NT also exerts a direct modulation 
on VTA dopamine neurons less is known about its role in the modulation of glutamatergic 
neurotransmission in this region. The present study was aimed at characterising the effects 
of NT on glutamate-mediated responses in different populations of VTA neurons. Using 
whole cell patch clamp recording technique in horizontal rat brain slices, we measured the 
amplitude of glutamatergic excitatory post-synaptic currents (EPSCs) evoked by electrical 
stimulation of VTA afferents before and after application of different concentrations of NT1-
13 or its C-terminal fragment, NT8-13. Neurons were classified as either Ih+ or Ih- based on 
the presence or absence of a hyperpolarisation activated cationic current (Ih). We found that 
NT1-13 and NT8-13 produced comparable concentration dependent increase in the 
amplitude of EPSCs in both Ih+ and Ih- neurons. In Ih+ neurons, the enhancement effect of 
NT8-13 was blocked by both antagonists, while in Ih- neurons it was blocked by the 
NTS1/NTS2 antagonist, SR142948A, but not the preferred NTS1 antagonist, SR48692. In 
as much as Ih-  neurons are non-dopaminergic neurons and Ih+ neurons represent both 
dopamine and non-dopamine neurons, we can conclude that NT enhances glutamatergic 
mediated responses in dopamine, and in a subset of non-dopamine, neurons by acting 
respectively on NTS1 and an NT receptor other than NTS1.  
Keywords: Neurotensin, Ventral Tegmental Area, Glutamatergic EPSCs, SR142948A, 
SR48692. 
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Introduction  
Neurotensin (NT) is an endogenous tridecapeptide that modulates neurotransmission in 
several limbic nuclei known to play a role in substance use disorder(Binder et al. 2001b).  
These limbic nuclei are densely innervated by terminals from the ventral tegmental area 
(VTA), a midbrain region that also contains a dense network of NT fibers(Beaudet and 
Woulfe 1992). The majority of VTA neurons that constitute the mesocorticolimbic pathway 
contain dopamine (DA) and nearly 80-90% of them express NT receptors(Szigethy et al. 
1990) . Activation of VTA NT receptors stimulate DA cell firing, an effect that is mediated, 
at least in part, by an increase in non-selective cationic conductance and by inactivation of 
the somatodendritic auto-receptors(St-Gelais et al. 2006b).Consistent with these findings are 
neurochemical and behavioral results showing that VTA microinjections of the native NT 
peptide, NT1-13, or its active C-terminal fragment, NT8-13, stimulate ventral striatal DA 
release, increase forward locomotion and enhance brain stimulation reward(Kalivas and 
Duffy 1990;Sotty et al. 2000b) . In addition to playing a role in DA modulation and DA-
dependent behaviors, NT also contributes to the induction of neural plastic changes that sub-
serve sensitization to the behavioral effects of psychostimulant drugs. For instance, repeated 
central injections of NT, and its active analog, D-Tyr [11] NT1-13, lead to an enhancement 
of cocaine- and amphetamine-induced locomotor activity (Rompre 1997b;Rompre and 
Bauco 2006b) . Moreover, the development of amphetamine sensitization is prevented by 
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blockade of VTA NT receptors(Panayi et al. 2005a) . The role of NT in sensitization is 
consistent with the fact that NT, by stimulating VTA DA neurons, increases VTA DA release 
a phenomenon that is critical for the development of amphetamine sensitization(Vezina et 
al. 2007) . Other studies have also revealed that VTA glutamate plays a key role in the 
development of amphetamine sensitization. When sensitization is initiated by either repeated 
systemic or VTA injections of amphetamine, it is prevented by blockade of VTA N-Methyl-
D-Aspartate (NMDA) receptors(Cador et al. 1999b;Vezina and Queen 2000a) . This raises 
the hypothesis that NT may initiate sensitization by modulating glutamatergic inputs to VTA 
DA neurons. In support of this hypothesis are recent findings by Kempadoo et al., 
(Kempadoo et al. 2013b) showing that activation of the efferent hypothalamic NT pathway 
to the VTA induces a NMDA-dependent rewarding effect, and that NT8-13 enhances 
NMDA excitatory postsynaptic currents (EPSCs) in putative VTA DA neurons. Using a 
higher concentration of NT8-13, Kortleven et al., (Kortleven et al. 2012b) reported a 
suppression of glutamatergic EPSCs in VTA DA neurons. It is possible that these opposite 
effects are related to the action of the NT8-13 fragment on different NT receptors. Activation 
of NT receptors with NT1-13 induces two types of excitatory response in DA neurons, a fast 
and short lasting response mediated by NTS2 receptors that is followed by a slow and longer 
lasting response mediated by NTS1 receptors (Nalivaiko et al. 1998b). Interestingly, NT8-
13 only elicits the fast response suggesting that it preferentially activates NTS2 
receptors(Nalivaiko et al. 1998b;Werkman et al. 2000b); this is inconsistent, however, with 
the high affinity and the high efficacy of NT8-13 for the NTS1 receptor(Tanaka et al. 1990a). 
To further characterize the modulating action of NT on VTA glutamatergic 
neurotransmission, we used whole cell patch clamp recordings to measure the effects of 
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different concentrations of NT1-13 and NT8-13 on glutamatergic EPSCs measured in 
putative VTA DA and non-DA neurons. Putative VTA DA and non-DA neurons were 
distinguished by the presence, or the absence, of a hyperpolarization-activated potassium 
current (Ih) respectively(Margolis et al. 2006b). The interest in studying VTA non-DA 
neurons resides in the evidence that activation of NMDA receptors expressed by these 
neurons is required for the development of VTA neural plasticity that sub-serves drug reward 
and drug sensitization, two phenomena that are modulated by NT. 
Methods 
Animals and slice preparation   
All experimental procedures were approved by the Institutional Animal Committee in 
accordance with guidelines of the Canadian Council on Animal Care. All efforts were made 
to minimize the suffering and number of animals used. 
 Fourteen to 21-day-old (P14-P21) Long Evans pups of either sex obtained from Charles 
River (St-Constant, QC) were used. Pups were anaesthetized by inhalation of methoxyfluran 
vapor in a closed chamber, decapitated and their brain quickly removed and transferred to 
chilled, oxygenated artificial cerebrospinal fluid (ACSF) in which NaCl had been replaced 
by equivalent osmolarity of sucrose and containing (in mM) sucrose 252 (NaCl 126 in 
standard ACSF); KCl, 3; NaH2PO4, 1.25; MgSO4 7 H2O, 1.3; CaCl2, 2.5; NaHCO3, 26; and 
glucose, 10, and saturated with a gas mixture of 95% O2 and 5% CO2. Two hundred and fifty 
micrometer thick horizontal slices preserving the VTA afferents (Margolis et al. 2006b) were 
cut using a vibrating microtome(DSK Microslicer). Slices were transferred to a submerged 
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recording chamber maintained between 32 to 34°C and superfused with standard ACSF at a 
rate of 2 ml/min; slices were incubated for at least one hour before recording began.   
Drugs and peptides 
The following pharmacological agents were applied through the superfusing ACSF:  (-) 
bicuculline methiodide, 6 cyano-7-nitroquinoxaline-2,3-dione (CNQX) (in some 
experiments) , (+)-2-amino-5-phosphonopentanoic acid (APV)  (in some 
experiments)obtained from Sigma Aldrich(Oakville, Ontario, Canada) ; neurotensin- (1-13), 
neurotensin-(8-13) were obtained from Bachem (Sunnyvale, CA,USA); SR-48692 [2-(1-[7-
chloro-4-quinolinyl]-5-[2, 6-dimethoxyphenyl]-1H-pyrazol-3-)carbonylamino-adamantane-
2-carboxylacid]and SR142948A2-[[[5-(2,6-Dimethoxyphenyl)-1-[4-[[[3-
(dimethylamino)propyl]methylamino]carbonyl]-2-(1-methylethyl)phenyl]-1H-pyrazol-3-
yl]carbonyl]amino]-tricyclo[3.3.1.13,7]decane-2-carboxylic acid were obtained from Tocris 
Biosciences. All drugs were made up as 10 mM stock solutions in distilled water and diluted 
with ACSF solution to final concentration just before addition to the perfusion medium with 
the exception of SR48692 and CNQX which was dissolved in DMSO (final concentration 
0.1%) and distilled water.  
Electrophysiological recordings  
Whole-cell configuration was achieved using the ‘blind’ patch-clamp technique(Blanton et 
al. 1989a). Pipettes were pulled from thin wall borosilicate capillary glass on a P-87 
micropipette puller (Sutter Instrument, Novato, CA, USA. Recording pipettes had a 
resistance of 3-5MΩ when filled with a solution containing (in mM) potassium gluconate, 
140; MgCl2, 2; CaCl2, 0.1; EGTA, 1.1; HEPES, 10; K2-adenosine trisphosphate (ATP), 2; 
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guanosine trisphosphate (GTP), 0.5 and biocytin (5%). The pH was adjusted to 7.3 with 
KOH solution, and final osmolarity was 280 ±5 mosmol/kg. All recorded neurons were 
labelled to confirm their location in the medial VTA. 
Whole-cell recordings were made with an Axoclamp-2B amplifier (Molecular Devices, 
Sunnyvale, CA, USA) in continuous single-electrode voltage-clamp mode. The output of the 
amplifier was fed into a LPF 200A DC amplifier/filter (Warner Instruments Corp., Hamden, 
CT, USA) and digitized at 5 to 10 kHz with a real-time acquisition system (CED 1401 
Power). Data acquisition was achieved using the Signal 4.0 software (Cambridge Electronic 
Design, Cambridge, England). Recording pipette’s capacitance was optimally adjusted 
before whole-cell configuration was achieved. The resting membrane potential was 
measured just after rupturing the cell membrane and the offset potential, measured upon 
withdrawal of the electrode from the cell, was accounted for assuming that it drifted in a 
linear fashion with time from the start of the recording session. We did not correct for liquid 
junction potential, which for a pipette containing 140 mM potassium gluconate amounts for 
an additional potential shift of around -10mV(Spigelman et al. 1992). 
Synaptic activation and drug application 
The presence of Ih was first determined by voltage clamping cells at -60mV and stepping  to 
−40, −50, −70, −80, −90, −100, −110 and −120 mV. Input resistance was monitored with 
hyperpolarizing pulses in current clamp mode. A monopolar tungsten stimulating 
microelectrode was placed rostral to the recording site in the medial VTA, on the slice 
superficial layer, 0.5-1.0 mm from the recording electrode. Excitatory postsynaptic currents 
were evoked by 0.1ms, 3 to 6V cathodal pulses delivered at 15 sec intervals. In order to 
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isolate glutamate receptor-mediated EPSCs, all experiments were performed in the presence 
of (-) bicuculline methiodide (BMI, 10µM) in bath solution to block GABAA receptor-
mediated synaptic currents. BMI was applied 30 min before obtaining whole-cell 
configuration to ensure a complete diffusion in the slice tissue.   
 In all experiments the EPSCs were recorded from an online voltage-clamped potential of -
70mV. The effects of NT1-13 and NT8-13 on glutamatergic EPSCs were assessed at a 
holding membrane potential of -70mV.Three concentrations of each peptide (0.01µM, 0.1 
µM and 0.5 µM) were tested and only one concentration was tested per cell. Upon agonist 
application, the change in amplitude of the glutamatergic EPSC was measured.  Five minutes 
of baseline EPSC activity was recorded before superfusion with the peptide. The EPSC 
amplitudes were recorded during 7 min after the onset of the peptide application and 
averaged over the last 5 min.  A washout period of 15 min was allowed before the amplitude 
of the recovered EPSC was measured. In some experiments, the control EPSC amplitude 
was measured for 4 min before a NT antagonist was added to the superfusion medium. 
However, SR142948A or SR48692 produced no effect on the control EPSC amplitude (n=9; 
data not shown). Therefore in further experiments where NTS receptor antagonists were 
used, SR142948 or SR48692 was added to the superfusing medium for 7 min and control 
response was measured in the presence of the antagonist. Additionally, only one antagonist 
was tested per cell and each type of antagonist was tested on different cells and their results 
were pooled together for each neuronal population. 
Data analysis   
Data analysis was performed using Signal software (Cambridge Electronic Design, 
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Cambridge, England). Statistical analysis was performed using Sigmaplot 12 software 
(Systat, San Jose, CA, USA). The magnitude of EPSC recorded after application of the 
peptide was expressed as percent of baseline and group means were calculated for drug 
condition. A one-way ANOVA was performed and Bonferroni post-hoc test used to 
determine significant differences between concentration or drug and peptide condition (P < 
0.05) when justified. 
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RESULTS 
Whole-cell voltage-clamp recording was obtained from 91 physiologically identified VTA 
neurons from rat pups aged between P14 and P21 (Margolis et al. 2006b;Margolis et al. 
2010a). Neurons were categorized as Ih+ (n=44) or Ih-(n=39) based on the presence or absence 
of the hyperpolarization activated cationic current (Ih). The amplitude of Ih in Ih+ positive 
neurons ranged between 81 pA and 407 pA with an average of 151.64pA (data not shown). 
The action potential and membrane characteristics of all Ih+ and Ih- neurons were measured 
and found to be similar to those reported in previous studies.  
 
NT1-13 and NT8-13 enhance glutamatergic EPSCs. 
Application of NT1-13 or NT8-13 produced a dose dependent increase in the amplitude of 
the glutamatergic EPSCs in both Ih+ and Ih- cells. Representative examples of the 
enhancement effect of NT1-13 (0.5µM) and NT 8-13 (0.5µM) on the glutamatergic EPSC 
in Ih+ cell and Ih- cells are shown in Figure 1 (Panel A and B). The amplitude of the EPSC 
increased significantly following application of each peptide and returned to baseline level 
following a washout. 
The mean change in EPSC produced by NT8-13 in Ih+ and Ih- neurons is shown in panel C 
of Figure 1. The C-terminal fragment increased the EPSC amplitude by 20 % (0.01µM) to 
66% (0.5 µM) while in Ih- cells the mean percent increase ranges from 17% (0.01µM) to 
75% (0.5 µM). As seen with NT1-13, the increase in EPSC was larger in Ih- than in Ih+ 
neurons at the highest dose but the difference did not reach statistical significance. A two-
way ANOVA yielded a significant effect of dose (F2, 27 = 29.6, p < 0.001) but no effect of 
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cell type (F1, 2 = 3.6, p > 0.05) and no cell type by dose interaction (F2, 27 = 0.17 p > 0.05). 
Post-hoc test confirmed that the EPSC amplitude increased orderly with the dose (medium 
> low; high > medium). 
 To determine whether the effects of NT8-13 differ from that of NT1-13, we ran a three-way 
ANOVA comparing peptide, dose and cell type. Results yielded a significant dose effect as 
expected (F2,51 = 154.9, p < 0.001) and a significant cell type by dose interaction (F2,51 = 
6.35, p < 0.01), but no effect of peptide (F1,51 = 0.76, p > 0.05), no peptide by dose interaction 
(F1,51 = 0.15, p > 0.05) and no peptide by dose by cell type interaction (F1,51 = 0.37 , p > 
0.05). This analysis confirmed that NT1-13 and NT8-13 produced a similar enhancement of 
the EPSC in both cell types. But it also reveals that when we combined the results obtained 
with each peptide, we observed a significant difference between Ih+   and Ih- neurons as a 
function of the dose. The post-hoc test reveals that this difference is due to a significantly 
larger increase in EPSC at the highest dose in Ih- neurons (Figure 1 panel D). 
Effects of neurotensinergic antagonists 
To determine which subtype of NT receptors mediate the increase in glutamatergic EPSCs 
in each cell type, we tested the effectiveness of the NTS1 and NTS2 antagonist, SR142948a, 
and the preferred NTS1 antagonist, SR48692, at blocking the enhancing effect of NT8-13 . 
Since, Nt1-13 and NT8-13 produced similar effects we tested the antagonists with the more 
active C terminal fragment, NT8-13. Representative examples for Ih- neurons are shown in 
Figure 2 (Panel A and B). The non-selective antagonist, SR1412948a, completely prevented 
the enhancement effect of NT8-13 (Panel A) while the preferred NTS1 antagonist had no 
effect. Mean percent change in EPSCs following application of NT8-13 in the presence or 
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not of each antagonist is shown in panel C of Figure 2. In Ih+ neurons, application of each 
antagonist produced a near complete suppression of the enhancing effect of NT8-13. The 
ANOVA yielded a significant effect of treatment (F2, 16 = 24.1, p < 0.001) and post-hoc test 
showed that the increase following application of NT8-13 was significantly different than 
that measured in the presence of SR142948a and SR48692; there was no difference between 
SR142948a and SR48692 in Ih+ neurons. In Ih- neurons, application of SR142948a, but not 
SR48692, prevented the increase in EPSCs by NT8-13. The ANOVA yielded a significant 
effect of treatment (F2, 16 = 25.2, p < 0.001) and post-hoc test showed that the increase 
following application of NT8-13 was significantly different than that measured in the 
presence of SR142948a but not in the presence of SR48692. There was also a significant 
difference between SR142948a and SR48692. When applied alone, the antagonists had no 
effect on the amplitude of the glutamatergic EPSCs neither in Ih+ nor in Ih- neurons (F3, 13 = 
0.05, p > 0.05; data not shown).  
Discussion  
The important findings of the present study are that NT1-13 and NT8-13 produced a 
dose-dependent increase in the amplitude of the EPSCs in rat VTA neurons and that this 
enhancement is mediated by different NTS1 and NTS2 receptor subtypes in Ih+ and Ih- 
neurons respectively. Initial studies on the interaction of NT with its receptors (now 
known as NTS1 and NTS2) have shown that the C-terminal segment, NT8-13, is required 
for binding and for activation of the receptors (Binder et al. 2001b;Schotte et al. 1986). 
Consistently, VTA microinjections of equimolar concentrations of NT1-13 and NT8-13 
produce similar enhancement of locomotor activity, dopamine metabolism and brain 
stimulation reward (Kalivas and Taylor 1985b;Rompre and Gratton 1993a). One 
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behavioral study, however, reported that repeated VTA microinjections of NT1-13, but 
not NT8-13, induce a conditioned place-preference(Glimcher et al. 1984b). A 
discrepancy between the effects of the two peptides was also found for NT-induced 
excitation of VTA DA neurons. For instance, NT receptor  activation was found to 
induce two excitatory responses in DA neurons: a fast and short duration excitation, 
and a late and prolong excitation. The fast component involves non-selective cationic 
conductance, Gαq and Gα11 (G protein subtypes) and inositol-3-phosphate (IP3). The 
slow component is comprised of a decrease in an inwardly rectifying K+ channel 
conductance (Ih) and involves PKC activation.  Both components were induced by NT1-
13 but only the fast one could be induced by NT8-13. Moreover, the fast component 
was blocked by SR142948A, the non-selective NT antagonist, while the slow one was 
blocked by SR48692 (NTS1 antagonist). This shows that different NT receptors, with 
differential sensitivity to NT peptides, mediate excitatory responses in DA neurons that 
differ by latency and coupling to downstream intracellular cascades (Chien et al. 
1996;Farkas et al. 1996;Nalivaiko et al. 1998a). 
The present results show that NT8-13, over a wide range of concentrations, was as effective 
as NT1-13 at enhancing glutamatergic EPSCs, and this, independently of the VTA cell type 
recorded.  The isolation of glutamatergic EPSCs in our preparation was achieved by the 
superfusion of BMI in the bathing solution. BMI is known to block SK channels and 
modulate the cell conductance and afterhyperpolarisation (AHP) by interfering with the 
calcium activated K+ channel(Khawaled et al. 1999). However, in the present studies we did 
not find any change in the cell conductance upon addition of BMI to the superfusing medium 
(data not shown).  The effect of BMI on AHP is not particularly relevant to our experiments. 
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Additionally, in the presence of BMI, we did observe no residual current in the presence of 
both CNQX and AP5, glutamatergic antagonists for iontotropic AMPA and NMDA 
receptors as shown in our previous studies (Yang et al. 2008;Zhang et al. 2014;Zhang and 
Warren 2002) suggesting that a role for BMI in modulating cell conductance or producing 
any other relevant effect apart from enabling isolation of glutamatergic EPSCs can be 
negated. 
   The excitatory effects induced by NT in our studies, is consistent with microdialysis 
studies showing that NT can increase glutamatergic transmission in the striatum (Ferraro et 
al. 1995;Ferraro et al. 1998;Ferraro et al. 2000) (Ferraro et al., 1995; Ferraro et al., 1998) 
and cortex (Ferraro et al. 2000). . In several other brain regions for instance the cortex, 
striatum , globus pallidus and the hippocampus, NT  has been reported to augment glutamate 
release via activation of NTS1 receptor subtype(Antonelli et al. 2007;St-Gelais et al. 
2006a;Zhang et al. 2015). Electrophysiological evidence suggest that NT augments the 
excitability and the firing rate of DA neurons suggesting a post synaptic effect. This is 
attributed to a reduction in K+ conductance which consequentially reduce D2 receptor 
mediated inhibition (Farkas et al. 1997). At the cortico striatal glutamatergic terminal, a 
functional interaction between NTS1 and D2 receptors mediated increase in extracellular 
glutamate levels was reported in a microdialysis study in awake rats(Ferraro et al. 1995). 
High concentrations of K+ in the Ringer’s solution resulted in an increase in extracellular 
glutamate levels and that this effect was blocked by the D2 receptor agonist quinpirole. This 
inhibitory effect of quinpirole was counteracted by the addition of NT8-13 or NT1-13 thus 
indicating an NTS1 receptor modulation. It is thus possible that NT enhances glutamatergic 
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neurotransmission in VTA neurons by a similar mode of action. However, further 
investigations are required to delineate a modulatory role for D2 receptors in this effect.  
Although, NTS1, has been the only well characterised receptor known to modulate D2 
function, the potency of NT analogs in decreasing D2 receptor agonist binding affinity is 
incongruent with their binding affinities for NTS1. NT1-13 has a greater potency in 
decreasing the agonist binding affinity at D2 receptors than NT8-13, however the binding 
affinity of NT8-13 is higher than NT-13 at NTS1 receptors. This indicates the possible 
involvement of another NT receptor subtype, in addition to NTS1 in mediating this effect 
(Kitabgi et al. 1980a;Li et al. 1993a;Li et al. 1993b). At this point we can only speculate 
about the possibility of an involvement of NTS2 receptors on Ih-neurons that mediate this 
action as we observe that there is a significant cell type by dose interaction in Ih- neurons at 
the highest concentration. This is congruent with the fact that NTS2 receptors require a 
higher concentration of NT agonist (Kd=3-10nM) to be activated (Binder et al. 2001a;Gully 
et al. 1997a;Kempadoo et al. 2013a).   
Nearly all dopaminergic neurons, and the great majority of GABA neurons, express an Ih 
current (Johnson and North 1992b;Lacey et al. 1989;Margolis et al. 2012b;Wanat et al. 
2008b). According to Margolis et al.,(Margolis et al. 2006b) Ih- neurons represent another 
subset of non-dopaminergic neurons. While both peptides equally enhanced glutamatergic 
EPSCs in Ih- and Ih+ at low and moderate concentrations, the enhancement was larger in Ih- 
than in Ih+ neurons at the highest concentration in our studies. Previous studies have reported 
inhibition a reduction of glutamatergic EPSC amplitude in DA neurons (Kempadoo et al. 
2013a;Kortleven et al. 2012a). However, these studies suggest activation of different NT 
receptor subtypes in mediating the inhibition. While one, suggests an NTS1 mediated 
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reduction in glutamatergic EPSCs which also involves a role of endocannabinoid signaling 
(Kortleven et al. 2012a), the other, suggests a reduction in glutamatergic EPSCs which is 
NTS1 receptor independent. This latter study suggests, that NT8-13 induced an NTS1 
dependent excitatory effect at lower concentrations on NMDA EPSCs, while it depressed 
AMPA EPSCs at equimolar concentrations via activation of another NT receptor subtype but 
not NTS1. Furthermore, they also found a consistent NTS1 independent depression of 
isolated AMPA EPSCs at all concentrations. This suggests that the actions of NT8-13 on 
VTA DA neurons are complex and controversial. The reason why we did not observe an 
inhibition when the concentration was increased is not clear. One possible explanation is that 
most of the cells that we recorded from were located below the surface of the slice. Peptides 
are highly sensitive to enzymatic degradation (Checler et al. 1983b;Kitabgi et al. 1980b) and 
it could be that in our study, the concentration of intact peptide that reached the cell or its 
afferent was smaller than the concentration in the superfusing medium. Whether the site of 
electrical stimulation has a role to play in the effect produced by NT is still open to 
investigation, in our studies the stimulation electrode was placed 0.5-1mm rostral to the 
recording site in the medial VTA whereas the stimulation site in the study by Kortleven is 
unclear (Kortleven et al. 2012a). Therefore it is possible that in our studies the afferents are 
stimulated although within the scope of our experiments, identification of the origins of these 
afferents were not possible. An evidence in support of our observation is that stimulation of 
hypothalamic afferents lead to potentiation of the NMDA component of glutamatergic 
EPSCs, when NT is applied at a concentration of 0.01µM suggesting that NT does induce 
NTS1 dependent excitatory effects (Kempadoo et al. 2013a). Several other factors for 
instance, the age of the animal, the slicing procedure that might differentially influence the 
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survival of different cell types of neurons and interspecies difference should also be taken 
into account in evaluating the variedness of the effects produced. It is particularly interesting 
to note that  non-dopamine neurons with Ih (possibly glutamatergic neurons) are more 
commonly found in brain slices from guinea pigs (Cameron et al. 1997) and rats (Margolis 
et al. 2006a) in comparison to brain slices from mice (Margolis et al. 2010b;Ungless 
2004;Zhang et al. 2010). Additionally, the ontogeny of NT receptor expression is dependent 
on the age of the animal and thus might be another contributing factor to the differences in 
the observed effects induced by NT agonists (Lepee-Lorgeoux et al. 1999;Nicot et al. 
1992;Nicot et al. 1994;Walker et al. 1998). 
Both NTS1 and NTS2 receptors are found in the VTA, and therefore we used the non-
selective NTS1 and NTS2 antagonist, SR142948A, and the preferred NTS1 antagonist, 
SR48692 to determine which receptor subtype(s) is or are involved in the enhancement effect 
of NT8-13(Gully et al. 1993;Gully et al. 1997b). In Ih+ neurons, the increase in glutamatergic 
EPSCs amplitude was prevented by the application of a low concentration of SR48692 and 
SR142948A, hence suggesting that it is mediated by NTS1 receptors. This result is consistent 
with Kempadoo et al.,(Kempadoo et al. 2013b) result showing that the SR48692 blocks the 
enhancement of glutamatergic EPSCs induced by a low concentration of NT8-13 in Ih+  
dopaminergic neurons, and that this enhancement is absent in NTS1 knockout mice. 
Kortleven et al., (Kortleven et al. 2012b) however, reported that the reduction in 
glutamatergic EPSCs they recorded in VTA dopaminergic neurons following application of 
NT8-13 was also blocked by SR48692 and SR142948A suggesting that the NTS1 receptor 
also mediates the inhibition. In this study, however, the authors used a concentration of 
SR48692 that was five times higher (0.5 µM) than that used in our study and that most likely 
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blocks both NTS1 and NTS2 receptors (Chalon et al. 1996;Gully et al. 1993). Moreover, a 
reduction of both AMPA and NMDA EPSCs following application of high concentrations 
of NT8-13 is still observed in NTS1 knockout mice suggesting that the inhibition possibly 
involves NTS2 receptor subtype (Kempadoo et al. 2013b).   
 Although it would be highly relevant to identify the locus of NT receptor modulation, the 
present studies do not allow us to do so. Since, NT augments the firing rate in DA neurons 
by reducing D2 receptor mediated autoinhibition it is likely that the effects of NT are a result 
of direct activation of post synaptic receptors (Farkas et al. 1996;Farkas et al. 1997;Johnson 
and North 1992a). A presynaptic locus of receptor modulation in either Ih+ or Ih- neurons 
cannot be ruled out, however it is unlikely as paired pulse experiments using NT8-13 by 
Kempadoo et al did not yield significant results (Kempadoo et al. 2013a). Additionally there 
is little information about the precise location of NT receptors in the VTA and therefore 
whether NT agonists have a preferential locus of action for one population of cells or the 
other remain undetermined. Nonetheless, it is important to note that in our studies we find 
NT8-13 has a preferential mode of activation of NTS1 receptors over NTS2 receptors in Ih+ 
and Ih- cells respectively. This raises the possibility of a preferential distribution of NTS2 
receptors on Ih- cells or terminals that innervate them. However further studies are required 
to support this hypothesis and at this point we can only speculate about such a possibility. 
In the present studies ,the potentiation effect of NT8-13 on Ih+ neurons likely stems from a 
NTS1 receptor mediated mobilization and accumulation of intracellular calcium in addition 
to glutamatergic excitation(Kempadoo et al. 2013b;St-Gelais et al. 2006b); the NTS1 
receptor mediates several effects of NT that is dependent upon activation of phospholipase 
C, activation of protein kinase C and  increase of intracellular Ca2+ release(Rostene et al. 
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1997). In Ih- neurons, the increase in glutamatergic EPSCs amplitude was prevented by 
SR142948A but not SR48692. To our knowledge this provides the first evidence of a 
modulation of glutamatergic input to VTA non-dopamine neurons by NT. The 
ineffectiveness of SR48692 at blocking the enhancement of EPSCs by NT8-13 in Ih- neurons, 
suggest that it is likely mediated by NTS2 receptors. The implication of a non-NTS2 
receptor, sensitive to SR142948 but insensitive to SR48692 cannot be excluded. Previous 
studies have shown, for instance, that the enhancement of DA cell firing and ventral striatal 
DA release initiated by VTA NT is sensitive to SR142948A but insensitive to SR48692 and 
to the selective NTS2 partial agonist, levocabastine; it could be that the enhancement of 
glutamatergic EPSCs by NT8-13 in Ih- neurons is mediated by a receptor that display a 
similar pharmacological profile. It is unlikely that this receptor is the NTS3. Although 
present in the VTA, this SR48692- and levocabastine-insensitive receptor is not coupled to 
a G-protein and there is no evidence to date supporting a direct modulatory role of the NTS3 
in neurotransmission (Mazella and Vincent 2006a;Sarret et al. 2003a). Studies rather suggest 
that the NTS3 interacts with other receptors being involved in intracellular trafficking and 
in translocation of receptors to the plasma membrane(Mazella and Vincent 2006a). 
The present findings shed additional light on the role of NT in the development of neural 
plastic changes that sub-serve sensitization to the behavioral effects of psychostimulant 
drugs. Indeed, previous studies have shown that VTA glutamate is necessary for the 
initiation of amphetamine sensitization (Cador et al. 1999b;Vezina and Queen 2000a). 
Moreover, repeated central NT injections sensitize to amphetamine, and sensitization is 
blocked by either a VTA microinjection of SR142948 or a systemic injection of SR48692 
(Panayi et al. 2005a;Rompre and Perron 2000b;Rompre 1997b). These findings suggest that 
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NT may act upstream and initiate the development of sensitization by enhancing 
glutamatergic neurotransmission in VTA Ih+ neurons through activation of NTS1 receptors. 
A role for the NTS2, or for the SR48692-insensitive, receptor in psychostimulant 
sensitization cannot be ruled out. The development of cocaine sensitization is also dependent 
upon VTA glutamate neurotransmission(Vanderschuren and Kalivas 2000) and Luo et 
al.,(Luo et al. 2010b) have shown that sensitization to cocaine is abolished by selective 
deletion of NMDA receptors on VTA non-dopamine neurons. Moreover, cocaine 
sensitization is initiated by repeated central NT injections but is not blocked by SR48692 
(Horger et al. 1994;Rompre and Bauco 2006b). This suggests that the enhancement of 
glutamatergic EPSCs in VTA non-dopamine Ih- neurons by NT may play a role in the 
initiation of sensitization to cocaine. 
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 Figure 1. Effect of NT1-13 and NT8-13 on glutamatergic EPSCs. Evoked 
glutamatergic EPSCs recorded from Ih- neurons before (left traces), during (middle traces) 
and after (right traces) application of 0.5 µM of NT1-13 (A) or NT8-13 (B). The bargraph 
in panel C represents the mean percent change in EPSC amplitude produced by different 
concentrations of NT1-13 and NT8-13 in Ih+ and Ih- neurons. NT 1-13 at 0.01µM (Ih+ n=5, 
Ih- n=4); 0.1 µM (Ih+ n=6, Ih– n=4) and 0.5µM (Ih+ n=6, Ih– n= 6). For NT 8-13 at 0.01µM 
(Ih+ n=4, Ih- n=4); 0.1 µM (Ih+ n=5, Ih– n=5) and 0.5µM (Ih+ n=8, Ih– n= 5). Panel D shows 
the mean percent change in EPSC amplitude produced by NT1-13 and NT8-13 (pooled 
together) as a function of the peptide concentration in Ih+ and Ih- neurons. The star indicates 
a significant different between Ih+ and Ih- neurons (p < 0.05). See text for details. 
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 Figure 2: Effect of NT receptor antagonists on glutamatergic EPSCs. Evoked 
glutamatergic EPSCs recorded from Ih- neurons during application of 0.1 µM of SR142948A 
(A) or 0.1 µM of SR48692 (B) alone (left traces), in combination with 0.01 µM of NT8-13 
(middle traces) and after the washout of NT8-13 (right traces). The bargraph in panel C 
represents the mean percent change in EPSC amplitude produced by NT8-13 in the absence, 
or in the presence, of SR142498A or SR48692 in Ih+ (n=5) and Ih- (n=6) neurons. Stars and 
crosses indicate a significant difference with NT8-13 alone and NT8-13+SR142948A 
respectively (p < 0.001). See text for details.   
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Abstract  
 
The present study was aimed at characterizing the mechanisms by which neurotensin (NT) 
is acting within the ventral midbrain to induce a psychostimulant-like effect. In a first 
experiment, we determine which subtype(s) of NT receptors is involved in the reward-
inducing effect of ventral midbrain microinjection of NT using the conditioned place-
preference (CPP) paradigm. In a second study, we used in vitro patch clamp recording 
technique to characterize the NT receptor subtype(s) involved in the modulation of 
glutamatergic neurotransmission (excitatory post-synaptic current, EPSC) in ventral 
tegmental neurons that expressed (Ih+), or do not express (Ih-), a hyperpolarization-activated 
cationic current. Behavioral studies were performed with adult male Long-Evans rats while 
electrophysiological recordings were obtained from brain slices of rat pups aged between 
14 and 21 days. Results show that bilateral ventral midbrain microinjections of 1.5 and 3 
nmol of D-Tyr[11]NT induced a CPP that was respectively attenuated or blocked by co-
injection with 1.2 nmol of the NTS1/NTS2 antagonist, SR142948, and the preferred NTS1 
antagonist, SR48692. In electrophysiological experiments, D-Tyr[11]NT (0.01-0.5 M) 
attenuated glutamatergic EPSC in Ih+  but enhanced it in Ih- neurons. The attenuation effect 
(Ih+ neurons) was blocked by SR142948 (0.1 M) while the enhancement effect (Ih- 
neurons) was blocked by both antagonists (0.1 M). These findings suggest that i) NT is 
acting on ventral midbrain NTS1 receptors to induce a rewarding effect and ii) that this 
psychostimulant-like effect could be due to a direct action of NT on dopamine neurons 
and/or an enhancement of glutamatergic inputs to non-dopamine (Ih-) neurons. 
Keywords: Conditioned reward, Glutamate, Neurotensin, Ventral midbrain. 
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Introduction 
 
Neurotensin (NT), a tridecapeptide (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-
Tyr-Ile-Leu-OH) isolated from the hypothalamus more than four decades ago (Carraway and 
Leeman 1973), acts as a potent modulator of limbic neurotransmission. Cell bodies and 
terminals that express NT-like immunoreactivity are found in several limbic brain regions 
including the amygdala, the nucleus accumbens, the prefrontal cortex, the septum, and the 
ventral midbrain (Delle Donne et al. 1996;Hokfelt et al. 1984;Jennes et al. 1982a;Woulfe 
and Beaudet 1989). When released from nerve terminals, NT can activate three receptor sub-
types, NTS1, NTS2 and NTS3 (see Vincent et al. 1999). The NTS1 and NTS2 are 
metabotropic receptors that are coupled to G-proteins linked to different signaling pathways 
such as cyclic guanosine-monophosphate, phospholipase C and mitogen-activated protein 
kinase. The NTS3 is a non G- protein coupled receptor that possesses a single transmembrane 
domain; this receptor appears to be non-selective for NT as its binds several other 
endogenous ligands (see Mazella and Vincent, 2006). The great majority of the central 
effects of NT have been attributed to its action on either NTS1 or NTS2 receptors. When 
administered into the lateral ventricle, for instance, NT produces a dose-dependent 
hypothermia and analgesia that are prevented by the NTS1/NTS2 antagonist, SR142948, but 
not the preferred NTS1 antagonist, SR48692, suggesting that they are mediated by the NTS2 
receptor (Gully et al. 1997a). Central NT injections also attenuate spontaneous and 
methamphetamine-induced locomotor activity, effects that are prevented by SR48692 
suggesting that they are mediated by the NTS1 receptor (Gully et al. 1995;Wagstaff et al. 
1994). The behavioral effects of NT are not only dependent upon the receptor sub-type that 
is activated but also upon the site of action of the peptide within the limbic system. In the 
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ventral midbrain, for instance, NT stimulates dopamine impulse flow and dopamine-
dependent behaviors (Holmes and Wise 1985;Kalivas et al. 1981;Rompre et al. 1992) while 
in the ventral striatum and the prefrontal cortex, it reduces the post-synaptic effect of 
dopamine and attenuates dopamine-dependent behaviors (Beauregard et al. 1992;Ervin et al. 
1981;Jennes et al. 1982b;Kalivas and Miller 1984;Stowe et al. 2005). These findings led to 
the hypothesis that NT may act as either an endogenous antipsychotic- or psychostimulant-
like neuromodulator (Berod and Rostene 2002;Kinkead and Nemeroff 2002). 
 The mechanisms by which NT produces psychostimulant-like effects remain 
imprecise. The main hypothesis is that NT enhances dopamine release and dopamine-
dependent behaviors by stimulating dopamine impulse flow through activation of NTS1 
receptors expressed on dopamine cell bodies and dendrites (see Berode and Rostene, 2002). 
Consistently, NT induces an increase in dopamine inward current and firing rate that is 
prevented by SR48692 (St-Gelais et al. 2006a). Activation of NTS1 receptors expressed on 
dopamine neurons also inactivates the dopamine auto-receptor which contributes to enhance 
dopamine impulse flow (Thibault et al. 2011). We, and others, also reported that NT and its 
C-terminal fragment, NT-(8-13), enhance excitatory post-synaptic currents (EPSCs) in 
presumed dopamine neurons, an effect that is blocked by SR48692 (Bose et al. 2015; 
Kempadoo et al. 2013). Unexpectedly, the increase in ventral striatal dopamine release 
induced by ventral midbrain application of NT is blocked by SR142948 but not by SR48692 
(Leonetti et al. 2002;Steinberg et al. 1995) suggesting that NT is rather stimulating dopamine 
impulse flow through activation of NTS2 receptors. This latter finding, however, was not 
supported by another study showing that application of ventral midbrain NT enhances 
                                                           
 
89 
 
ventral striatal dopamine release in NTS2 but not NTS1 knock-out mice (Leonetti et al. 
2004). 
 Neurotensin structure-activity studies have also generated conflicting results 
regarding the role of NTS1 receptors in the psychostimulant-like effect of NT. For example, 
the enhancement effect of NT on locomotor activity and on brain stimulation reward is 
mimicked by NT-(8-13) and neuromedin N (Kalivas et al. 1986;Kalivas and Taylor 
1985a;Rompre et al. 1992;Rompre and Gratton 1993b), two peptides that bind and activate 
the NTS1 receptor (Kitabgi et al. 1980a;Tanaka et al. 1990b). But the induction of a 
conditioned place-preference (CPP) by repeated ventral midbrain NT microinjections is not 
mimicked by an equimolar concentration of NT-(8-13); in fact it is mimicked by a NT 
fragment, NT-(1-11), that failed to interact with the NTS1 receptor (Glimcher et al. 
1984a;Kitabgi et al. 1980a); these results suggest that the conditioned rewarding effect of 
NT may be mediated by a NT receptor other than NTS1 receptor. In order to clarifying this 
issue, we attempted to determine which ventral midbrain NT receptor is involved in the 
induction of a CPP using the NT analog, [D-Tyr11]NT. Contrary to NT and NT-(8-13) which 
stimulate mesoaccumbens and mesoprefrontal dopamine projections, two pathways 
respectively involved in reward and aversion (Lammel et al. 2014), [D-Tyr11]NT can 
selectively enhance the activity of the mesoaccumbens projection (Sotty et al. 2000a). 
Because NT and NT-(8-13) also enhance ventral midbrain glutamatergic neurotransmission, 
we characterized the effect of [D-Tyr11]NT on glutamatergic EPSCs in putative ventral 
midbrain dopamine and non-dopamine neurons; the two populations were distinguished by 
the presence, or the absence, of a hyperpolarization-activated cationic current (Margolis et 
al. 2006a) using the patch clamp recording technique. Results of the behavioral experiments 
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show that [D-Tyr11]NT induced a dose-dependent CPP that was blocked by SR48692 and 
attenuated by SR142948, suggesting that it is mediated by NTS1 receptors. 
Electrophysiological results show that [D-Tyr11]NT dose-dependently attenuates 
glutamatergic EPSCs in putative dopamine neurons while it enhances the EPSCs amplitude 
in non-dopamine neurons; these effects are likely mediated by a respective activation of 
NTS2 and NTS1 receptors. 
 
 
Materials and methods 
 
Behavioral experiments 
Animals 
Male Long-Evans rats (Charles River, St-Constant, Qc, Canada) weighing 280-320g at 
the time of surgery were used. They were housed 1 (after surgery) or 2 per cage in a 
temperature (22±1 °C) and humidity (40-50%) controlled room with a 12h light/dark cycle 
(lights on 06:00); standard rat chow and water were available ad libitum. All testing was 
performed during the light phase of the light–dark cycle. All animal experimental procedures 
were approved by the Institutional Animal Ethics Committee (Comité de déontologie de 
l’expérimentation sur les animaux de l’Université de Montréal), in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes 
of Health (n°: 85-23, revised 1996). All efforts were made to minimize the suffering and 
number of animals used. 
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Surgery 
Following one week habituation period to the colony room, each rat was anesthetized 
with isoflurane (2.5-3.5%, 0.75 L/min O2); solutions of 0.1 ml of Anafen (5 mg/kg, s.c.) and 
0.05 ml (i.m.) of duplocillin LA containing 15,000 I.U. of penicillin were administered to 
prevent inflammation and infection. The animals was then mounted on a stereotaxic 
apparatus, the surface of the skull was exposed and a guide cannula (Model C315G, Plastic 
One, VA, USA,) was implanted in each hemisphere, above the ventral tegmental area (VTA), 
using the following stereotaxic coordinates: 5.5 mm posterior to bregma, 1.7 mm lateral and 
6.3 mm below the surface of the cranium (Paxinos and Watson, 1986); cannulae were 
inserted into the brain with a mediolateral angle of 8° and were closed with an obturator of 
the same length. Four stainless-steel screws were threaded into the bone and the cannulae 
were anchored to the skull with dental acrylic. Behavioral tests started one week after the 
surgery. 
 
Conditioned place preference (CPP) paradigm 
The CPP apparatus (Med Associates, St. Albans, VT, USA) consisted of a rectangular 
Plexiglas box divided into two large compartments (26x21x21 cm) separated by a smaller 
central compartment (21x12x21 cm). Two sliding doors separated the central grey 
compartment from the two others which have distinct wall colors (white or black) and floors 
(grid or bar). Locomotor activity and times spent in each chamber were measured by 
computer-interfaced infrared photobeams (Med Associates, St. Albans, VT, USA). The CPP 
experiment lasted 10 days and consisted of a habituation phase, a conditioning phase and a 
test phase. On the first day of the habituation phase, rats were allowed to explore the entire 
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CPP apparatus for 20-min to reduce neophobia. On day 2, all animals received a first intra-
VTA injection of 0.5 µl/side of saline and were allowed to explore freely the entire CPP 
apparatus for 20-min. On the third day, animals were allowed to explore the entire CPP 
apparatus for 20-min and time spent in each of the two large compartments was measured; 
rats exhibiting higher or lower time interval than 20-80% of time in a compartment were 
excluded (unbiased procedure). Conditioning began the next day. Conditioning trials lasted 
30-min and were conducted daily for 6 days. Control and drug treatment groups were 
conditioned in either the black or the white compartment of the apparatus. On the first day 
of the conditioning phase, the drug-conditioned animals were injected in the VTA with 
vehicle and were immediately placed into one compartment of the apparatus for 30 min. The 
next day, animals were injected with [D-Tyr11]NT (1.5 or 3 nmol/0.5l/side), SR142948 (1.2 
nmol/0.5l/side), SR48692 (1.2 nmol/0.5l/side), [D-Tyr11]NT (3 nmol/0.5l/side) + 
SR142948 (1.2 nmol/0.5l/side) or [D-Tyr11]NT (3 nmol/0.5l/side) + SR48692 (1.2 
nmol/0.5l/side) and were immediately placed into the other compartment of the apparatus 
for 30 min. This procedure was repeated three times so that rats received three vehicle (Day 
4, 6 and 8) and three drug (Day 5, 7, 9) injections. Animals in the control group were injected 
with the vehicle on each day and were similarly conditioned for 6 days. Twenty four hours 
after the last day of the conditioning phase, on day 10, animals were allowed to explore the 
apparatus for 20 min and the time spent in each compartment was measured. Animals were 
tested between 11:00 and 17:00 under an ambient light intensity of 5 lux and were habituated 
to the experimental room for 1-hr prior to the behavioral testing. 
 
Microinjection procedure  
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Bilateral microinjections were made by inserting into each guide cannula an injection 
cannula (model C315I) that extended 2 mm beyond the tip of the guide. Each cannula was 
connected with polyethylene tubing to a 2-μl microsyringe and a volume of 0.5 μl of solution 
was injected into each hemisphere simultaneously with a micro-infusion pump over a period 
of 60 sec; cannulae were left in place for an additional 60 sec to allow diffusion into the 
surrounding brain tissue. 
 
 
Histology 
At the end of the experiment, animals were deeply anesthetized with urethane (2 g/kg, 
i.p.) and transcardially perfused with 0.9% saline followed by 10% formalin. Brains were 
removed, stored in 10% formalin and subsequently sliced in serial 40-m sections that were 
stained with formal-thionin solution. Locations of the injection sites were determined under 
light microscopic examination. Only animals that had both injection sites within the VTA, 
including the rostral and caudal linear nuclei, the paranigral, parabrachial and the 
interfascicular nuclei between 5.0 and 6.0 mm behind bregma (Paxinos and Watson, 1986) 
were included in the analyses. 
 
Drugs 
[D-Tyr11]neurotensin-(1-13) was purchased from Bachem (Sunnydale, CA, USA) 
and  dissolved in sterile 0.9% saline at a concentration of 3 or 6 nmol/µl. The neurotensin 
antagonist, SR-142948 and SR-48692 were purchased from Tocris Bioscience (Burlington, 
ON, Canada) and were dissolved at a concentration of 2.4 nmol/µl in a sterile 0.9% sodium 
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chloride solution that contained 20% dimethylsufoxyde (DMSO). All solutions were stored 
at -20°C in 50 µl aliquots in silicone-coated tubes; they were thawed just before testing and 
were used only once. 
 
Statistical analysis 
Preference score was determined by subtracting the time spent in the drug-paired 
compartment measured before the conditioning phase (Pre) to the time spent in the same 
compartment measured on the conditioning test day (Post). Preference score and locomotor 
activity (horizontal and stereotypic-like movements) measured during the conditioning test 
day were analyzed with a one-way analysis of variance (ANOVA). The Duncan’s multiple 
range post-hoc tests was used for individual group comparisons. The accepted value for 
significance was set at 0.05 (Statistica V5.0, StatSoft). 
 
Electrophysiological experiments 
 
Animals and slice preparation   
Fourteen to 21-day-old (P14-P21) Long Evans pups of either sex obtained from 
Charles River (St-Constant, QC) were used. Pups were anaesthetized by methoxyflurane 
vapor inhalation in a closed chamber, decapitated and their brain quickly removed and 
transferred to chilled, oxygenated artificial cerebrospinal fluid (ACSF) in which NaCl had 
been replaced by equivalent osmolarity of sucrose and containing (in mM) sucrose 252 
(NaCl 126 in standard ACSF); KCl, 3; NaH2PO4, 1.25; MgSO4 7 H2O, 1.3; CaCl2, 2.5; 
NaHCO3, 26; and glucose, 10, and saturated with a gas mixture of 95% O2 and 5% CO2. 
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Two hundred and fifty micrometer thick horizontal slices preserving the VTA afferents 
(Margolis et al. 2006) were cut using a vibrating microtome (DSK Microslicer). Slices 
were transferred to a submerged recording chamber maintained between 32 to 34°C and 
superfused with standard ACSF at a rate of 2 ml/min; slices were incubated for at least one 
hour before recording began.   
 
 
 
Electrophysiological recordings  
Whole-cell configuration was achieved using the ‘blind’ patch-clamp technique 
(Blanton et al. 1989). Pipettes were pulled from thin wall borosilicate capillary glass on a 
P-87 micropipette puller (Sutter Instrument, Novato, CA, USA). Recording pipettes had a 
resistance of 3-5MΩ when filled with a solution containing (in mM) potassium gluconate, 
140; MgCl2, 2; CaCl2, 0.1; EGTA, 1.1; HEPES, 10; K2-adenosine trisphosphate (ATP), 2; 
guanosine trisphosphate (GTP), 0.5 and biocytin (5%). The pH was adjusted to 7.3 with 
KOH solution, and final osmolarity was 280 ±5 mosmol/kg. Biocytin (5%) was added in 
the recording pipette and all recorded cells were processed after recording to confirm their 
location in the medial VTA. 
 
Whole-cell recordings were made with an Axoclamp 2B amplifier (Molecular 
Devices, Sunnyvale, CA, USA) in continuous single-electrode voltage-clamp mode. The 
output of the amplifier was fed into a LPF 200A DC amplifier/filter (Warner Instruments 
Corp., Hamden, CT, USA) and digitized at 5 to 10 kHz with a real-time acquisition system 
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(CED 1401 Power). Data acquisition was achieved using the Signal 4.0 software 
(Cambridge Electronic Design, Cambridge, England). Recording pipette’s capacitance was 
optimally adjusted before whole-cell configuration was achieved. The resting membrane 
potential was measured just after rupturing the cell membrane and the offset potential, 
measured upon withdrawal of the electrode from the cell, was accounted for assuming that 
it drifted in a linear fashion with time from the start of the recording session. We did not 
correct for liquid junction potential which for a pipette containing 140 mM potassium 
gluconate amounts for an additional potential shift of around -10mV (Spigelman et al. 
1992). 
 
 
Synaptic activation and drug application 
The presence of Ih current was determined by voltage clamping cells at -60mV and 
stepping  to −40, −50, −70, −80, −90, −100, −110 and −120 mV. Input resistance was 
monitored with hyperpolarizing pulses in current clamp mode. A monopolar tungsten 
stimulating microelectrode was placed rostral to the recording site in the medial VTA, on 
the slice superficial layer, 0.5-1.0 mm from the recording electrode. Excitatory 
postsynaptic currents were evoked by 0.1ms, 3 to 6V cathodal pulses delivered at 15 sec 
intervals. In order to isolate glutamate receptor-mediated EPSCs, all experiments were 
performed in the presence of (-) bicuculline methiodide (BMI, 10µM) in bath solution to 
block GABAA receptor-mediated synaptic currents. BMI was applied 30 min before 
obtaining whole-cell configuration to ensure a complete diffusion in the slice tissue. In all 
experiments the EPSCs were recorded from an online voltage-clamped potential of -70mV. 
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The effects of D-Tyr [11] NT on glutamatergic EPSCs were assessed at a holding 
membrane potential of -70mV.Three concentrations of the peptide (0.01µM, 0.1 µM and 
0.5 µM) were tested, one concentration per cell. Upon agonist application, the change in 
amplitude of the glutamatergic EPSC was measured. Five minutes of baseline EPSC 
activity was recorded before superfusion with the peptide. The EPSC amplitudes were 
recorded during 7 min after the onset of the peptide application and averaged over the last 
5 min. A washout period of 15 min was allowed before the amplitude of the recovered 
EPSC was measured. In some experiments, the control EPSC amplitude was measured for 
4 min before a NT antagonist was added to the superfusion medium. SR142948 nor 
SR48692 produced any change in EPSC amplitude (n=12; data not shown); therefore in 
further experiments where NTS receptor antagonists were used, SR142948 or SR48692 
was added to the superfusing medium for 7 min and a control response was measured in 
the presence of the antagonist.  
 
Drugs and peptides 
 
The following pharmacological agents were applied through the superfusing ACSF: (-) 
bicuculline methiodide obtained from Sigma Aldrich (Oakville, Ontario, Canada); D-Tyr 
[11] NT from Bachem (Sunnyvale, CA, USA); SR-48692 and SR1429482 obtained from 
Tocris Biosciences (Burlington, ON, Canada). All drugs were made up as 10 mM stock 
solutions in distilled water and diluted with ACSF solution to final concentration just 
before addition to the perfusion medium with the exception of SR48692 which was 
dissolved in DMSO (final concentration 0.1%) and distilled water.  
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Data analysis   
 
Data analysis was performed using Signal software (Cambridge Electronic Design, 
Cambridge, England). The magnitude of EPSC recorded after application of the peptide 
was expressed as percent of baseline and group means were calculated for drug condition. 
A one-way ANOVA was performed and Duncan post-hoc test used to determine 
significant differences between concentration or drug and peptide condition when justified; 
level of significance was set at 0.05 (Statistica V5.0, StatSoft). 
 
 
 
Results 
 
Behavioral experiment 
 
From the 86 rats that completed the experiment, 10 were excluded from the analysis 
because the injection sites were dorsal or anterior to the VTA, or because the sites (left and 
right hemisphere) overlapped on the midline; an additional rat was excluded because the 
injection sites could not be located. 
 
Ventral midbrain microinjection of [D-Tyr11]NT induced a  conditioned place preference. 
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Figure 1 illustrates the preference score (top panel) and locomotor activity (middle and 
bottom panels) measured during the conditioning test in different groups of rats that were 
conditioned with the vehicle and one of two doses of [D-Tyr11]NT. As can be seen, animals 
that were conditioned with VTA [D-Tyr11]NT microinjections spent more time in the peptide 
associated compartment than the animal conditioned with VTA microinjections of the 
vehicle. The ANOVA yielded a significant effect of treatment (F2,31 = 13.1, p < 0.001) and 
post-hoc test showed that preference score of each [D-Tyr11]NT group was significantly 
different than vehicle; although the preference score for the group treated with the highest 
dose was superior to that of the lower dose there was no significant difference between the 
two doses (p > 0.05). In order to determine whether the preference for the [D-Tyr11]NT-
paired compartment was in part related to a conditioned aversion to the unpaired 
compartment, we compared the preference score for this compartment and the neutral 
compartment among the three groups. Animals that were injected with [D-Tyr11]NT spent 
less time in the unpaired compartment on the conditioned test day than those injected with 
the vehicle (Figure 2, top panel) but the ANOVA yielded no significant effect of treatment 
(F2,31 = 2.4, p > 0.05). Moreover the animals conditioned with the high dose of [D-Tyr11]NT 
spent slightly less time in the neutral compartment (Figure 2, bottom panel) compared to the 
other groups but the difference was not significant (F2,31 = 2.33, p > 0.05). Altogether, these 
results suggest that the reduction in the time spent in the compartment non-associated with 
VTA [D-Tyr11]NT in the conditioned groups was due to an increase in the amount of time 
spent in the conditioned but not the neutral compartment, hence confirming the occurrence 
of a conditioned preference effect. 
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The overall locomotor activity (in the entire apparatus) measured during the conditioned 
test did not differ between groups suggesting that repeated exposure to VTA [D-Tyr11]NT 
did not induce conditioned locomotor activity (Figure 1, middle and bottom panels). The 
ANOVA performed on each measure of activity, horizontal and stereotypy-like, yielded no 
significant effect of treatment (horizontal activity, F2, 31 = 0.63 p > 0.05; stereotypy-like 
activity, F2, 31 = 0.14, p > 0.05).  
 
 
 
 [D-Tyr11]NT-induced a conditioned place preference: Role of NTS1 receptors. 
 
To determine which NT receptor is involved in the induction of a CPP by VTA [D-
Tyr11]NT, we compared the preference score obtained from animals that were conditioned 
with vehicle and [D-Tyr11]NT alone to that of animals conditioned with either SR142948 
with [D-Tyr11]NT or SR48692 with [D-Tyr11]NT, or each NT antagonist alone. Results 
presented in Figure 3 (top panel) shows that SR48692 blocked the induction of a CPP. The 
ANOVA yielded a significant effect of treatments (F5,61 = 5.74, p < 0.001) and post-hoc test 
showed that the preference score of the group injected with preferred NTS1 antagonist, 
SR48692, with [D-Tyr11]NT is not significantly different than that of the vehicle injected 
animals but is significantly different than that of the [D-Tyr11]NT alone injected animals. 
The NTS1/NTS2 antagonist, SR142948, attenuated the induction of a CPP. When 
administered alone during the conditioning phase, the antagonists induced no conditioned 
effect. Altogether, these results show that the conditioned preference is due to activation of 
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VTA NTS1 receptors. Locomotor activity measured in the entire apparatus during the 
conditioned test did not differ between groups (Figure 3, middle and bottom panels; 
horizontal activity, F5, 61 = 1.14, p > 0.05; stereotypy-like activity, F5, 61 = 0.93. p > 0.05).  
 
Electrophysiological results 
 
Whole-cell voltage-clamp recording was carried out on 96 physiologically identified 
VTA neurons. Neurons were designated as Ih+ (n=54) or Ih- (n=42) based on the presence or 
absence of the hyperpolarisation activated cationic current (Ih). The amplitude of Ih in Ih+ 
positive neurons ranged from 67 pA to 419 pA with an average of 192.3 pA (n = 54; data 
not shown).  
    
    
Effects of D-Tyr [11] NT on glutamatergic EPSCs in Ih+ and Ih- neurons. 
The effects of [D-Tyr11]NT on glutamatergic EPSCs in VTA neurons were measured at 
a holding membrane potential of -70mV upon application at three different concentrations 
(0.01µM, 0.1 µM and 0.5 µM). Desensitization of the response to [D-Tyr11]NT application 
allowed only one concentration of the peptide to be tested per cell. 
 
Representative traces of the evoked EPSCs from a single Ih+ cell obtained before, during 
and after washout of 0.01 µM of [D-Tyr11]NT are shown in Figure 4. It can be seen that [D-
Tyr11]NT attenuated the EPSC and that this effect was completely reversible. As shown in 
Figure 5 [D-Tyr11]NT produced a dose dependent reduction in the amplitude of the 
                                                           
 
102 
 
glutamatergic EPSCs in Ih+ cells. At concentrations of 0.01 µM, 0.1 µM and 0.5 µM, the 
mean decrease in EPSC amplitude was 20±1.5 % (n=6), 29 %±3 % (n=6) and 47%±4% 
(n=7) respectively. A one way ANOVA yielded significant effect (F2,16 = 20.95, p < 0.001) 
and post-hoc test confirmed that the highest concentration produced a decrease that was 
significantly different than that produced by the lower concentration (p < 0.001).  
 
In Ih- cells, [D-Tyr11]NT produced a dose-dependent increase in the amplitude of the 
evoked EPSC. Representative traces obtained from a single Ih- cell illustrated in Figure 6 
show that the enhancement effect of [D-Tyr11]NT was also reversible. The mean increase at 
concentrations of 0.01 µM, 0.1 µM and 0.5 µM was 15±2.5 % (n=6), 28±2 %( n=6) and 
56±3.5 % (n=9) respectively (Figure 5). A one way ANOVA yielded significant results (F2, 
18 = 51.7, p < 0.001); post-hoc test showed that there a significant different between the 
highest concentration and the two others (p < 0.001), and between the medium and the lowest 
concentration (p < 0.01).  
 
 
Effect of NTS antagonists in Ih+ and Ih- neurons 
 
To identify the neurotensin receptor subtype(s) involved in the enhancement and 
attenuation effects of [D-Tyr11]NT on the evoked EPSCs in each cell population, we 
measured the EPSCs in the presence of SR142948 or SR48692. We found that in Ih+ cells, 
SR48692 (0.5µM) and SR142948 (0.5 µM) were both effective at blocking the decrease in 
EPSC amplitude produced by [D-Tyr11]NT (Figure 7, top panel). It can be noted that in the 
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in the presence of this high concentration of the antagonists, [D-Tyr11]NT produced an 
enhancement of the EPSC amplitude. A one way ANOVA yielded a significant effect 
(F2,11, 89.3 = p < 0.001) and post-hoc test confirmed that the EPSCs measured in the 
presence of the antagonist were significantly different than the EPSCs measured in the 
presence of [D-Tyr11]NT  alone; there was also a significant difference between the effect of 
SR142948 and SR48692.  Interestingly, different results were obtained when the 
concentration of the antagonist was reduced to 0.1 µM. At this concentration, SR142948 
blocked the attenuation effect of [D-Tyr11]NT  while SR48692 had no effect (Figure 4 and 
7).  The ANOVA yielded significant effect (F2,11 = 37.7, p <0.001) and post-hoc test 
confirmed that the mean EPSC measured in the presence of SR142948 was significantly 
different than that measured in the presence of [D-Tyr11]NT alone or SR48692 + [D-
Tyr11]NT.   
                                                           
In Ih- cells, at the highest concentration (0.5µM), SR48692 and SR142948 blocked the 
enhancement effect of [D-Tyr11]NT on the EPSC (Figure 7, bottom panel); in the presence 
of SR142948, [D-Tyr11]NT produced a large attenuation of the EPSC. The ANOVA 
yielded significant effect (F2, 14 = 40.6, p < 0.001) and post-hoc test showed that the EPSC 
measured in the presence of SR142948 and SR48692 was significantly different than that 
measured in the presence of [D-Tyr11]NT alone. There was also a significant difference in 
EPSCs measured in the presence of SR142948 and SR48692, confirming that SR142948 
led to a significant attenuation. Similarly to what we observed in Ih+ cells, different results 
were obtained when the concentration of the antagonists was reduced to 0.1 µM. At this 
concentration, SR142948 and SR48692 similarly blocked the enhancement effect of [D-
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Tyr11]NT (Figure 6 and 7). The ANOVA yielded significant effect (F2,13 = 18.5, p <0.001) 
and post-hoc test confirmed that the mean EPSC measured in the presence of SR142948 
and SR48692 were not different but were both different than that measured in the presence 
of [D-Tyr11]NT alone. 
 
Discussion 
 
The main finding of this study is that activation of ventral midbrain NTS1 receptor 
induces a CPP and that this effect can be mediated, at least in part, through an enhancement 
of glutamatergic synaptic input in non-dopamine neurons in the VTA. Our results also show 
that [D-Tyr11]NT activates NTS2 receptors to reduce glutamatergic synaptic input to VTA 
dopamine and non-dopamine neurons. To our knowledge these findings constitute the first 
evidence that NT acts on two different NT receptor sub-types to modulate in an opposite 
manner glutamatergic neurotransmission in different populations of VTA neurons. 
   
Previous studies have shown that ventral midbrain NT microinjection produces a 
rewarding effect as it sustains self-administration (Glimcher et al. 1987), enhances brain 
stimulation reward (Kalivas and Taylor 1985a;Rompre et al. 1992) and induces a CPP 
(Kitabgi et al. 1980a). Consistently, we found that ventral midbrain microinjections of [D-
Tyr11]NT dose-dependently induced a preference for the environment associated with the 
peptide. The fact that the time spent in the other two compartments, the neutral compartment 
and the compartment associated with the vehicle, was not significantly different between 
vehicle and [D-Tyr11]NT microinjected animals confirms that the increase in the amount of 
                                                           
 
105 
 
time spent in the peptide associated compartment was due to its reward inducing effect; it 
also suggests that no aversive effect developed during the day that follows the peptide 
injection. The induction of a CPP by [D-Tyr11]NT is consistent with many other results 
showing that this NT analog mimics several behavioral, physiological and neurochemical 
effects of NT (al-Rodhan et al. 1991;Donoso et al. 1986;Ferraro et al. 2000;Jolicoeur et al. 
1984;Steinberg et al. 1995). According to Glimcher et al. (Glimcher et al. 1984a), however, 
the induction of CPP by repeated ventral midbrain NT is not reproduced by an equimolar 
concentration of NT-(8-13); such a result was unexpected because NT-(8-13) displays a high 
affinity for the NTS1 (Kalivas et al. 1986;Rompre and Gratton 1993b) and has been shown 
to be as effective as NT at inducing locomotor activity (Steinberg et al. 1995), enhancing 
brain stimulation reward (Rompré and Gratton 1993), increasing dopamine cell firing (Seutin 
et al. 1989;Shi and Bunney 1991a) and inducing polydipsia (Hawkins et al. 1989). One 
possible explanation is that Glimcher et al. (1984) compared the effectiveness of bilateral 
VTA microinjections of NT to equimolar unilateral microinjections of NT-(8-13); it could 
be that at the concentration used unilateral microinjections were insufficient to induce a CPP.  
In order to determine which sub-type(s) of NT receptor is involved in the conditioned 
rewarding effect of [D-Tyr11]NT, we studied the effectiveness of SR142948 and SR48692 
at preventing the induction of a CPP. Results show that SR142948 attenuated and SR48692 
blocked the conditioned rewarding effect of [D-Tyr11]NT, hence suggesting that it is 
mediated by NTS1 receptor. A large body of evidence shows that VTA dopamine neurons 
play a key role in reward. For instance, VTA microinjection of drugs that enhance dopamine 
impulse flow sustains self-administration, induces a CPP and enhances brain stimulation 
reward (see Ikemoto and Bonci, 2014; Wise 1996). More convincing are recent optogenetic 
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results showing that selective activation of VTA dopamine neurons induces a CPP and 
sustains operant responding (Tsai et al. 2009; Witten et al 2011). NTS1 receptors are 
expressed on dopamine cell bodies and dendrites and their activation stimulates dopamine 
cell firing and dopamine release in brain regions known to play a key role in reward (Luo et 
al. 2010a;Rompre and Bauco 2006b). Kempadoo et al (2013) also showed that activation of 
VTA NTS1 receptors by local NT release reinforces operant responding. Altogether this 
suggests that the induction of a CPP by [D-Tyr11]NT is due to activation of NTS1 receptors 
expressed on VTA dopamine neurons. 
 
Conditioned place-preference is a learning process that involves neural plasticity. Drugs 
that induce a CPP, such as cocaine and morphine, induce lasting changes in VTA 
glutamatergic neurotransmission (Zweifel et al. 2008) and blockade of VTA glutamatergic 
receptors prevents cocaine- (Harris and Aston-Jones 2003) and morphine-induced CPP 
(Harris et al. 2004). Kempadoo et al (Kempadoo et al. 2013a) have also shown that the 
rewarding effect of VTA NT release is associated with an enhancement of glutamatergic 
input to dopamine neurons. In order to determine whether the induction of a conditioned 
reward by [D-Tyr11]NT was related to a modulation of glutamatergic inputs to VTA neurons, 
we investigated the effect of [D-Tyr11]NT on glutamatergic EPSCs in different population 
of neurons distinguished with the presence or absence of an Ih current. Nearly all 
dopaminergic neurons express an Ih current while Ih+ neurons represent a subset of non-
dopaminergic neurons; some GABA and glutamatergic neurons also express an Ih current 
(Hnasko et al. 2012; Johnson and North, 1992; Lacey et al., 1989; Margolis et al., 2006; 
2012).    
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In the present study, we observed that bath application of varying concentrations of [D-
Tyr11]NT generated a dose-dependent enhancement in the amplitude of glutamatergic EPSCs 
in Ih- neurons (non-dopamine neurons). This enhancement was most likely mediated by 
activation of NTS1 receptors as it was blocked by SR142948 and SR48692. These findings 
are in parallel with the behavioral results and suggest the action of NT on glutamatergic 
inputs to non-dopamine neurons may also play a key role in conditioned reward. Since the 
VTA contains a high density of NT terminals, it is thus possible that the effect of NT is not 
limited to glutamatergic inputs to dopamine neurons in this region (Jennes et al. 1982a;Sarret 
et al. 2003b;Seroogy et al. 1987). Luo et al. (2010), for instance, showed that cocaine still 
induces a CPP in animals that had selective deletion of NMDA receptors onto dopamine 
neuron, and that this conditioned rewarding effect was NMDA-dependent.   
  
In several limbic regions such as in the entorhinal cortex and the dentate gyrus of the 
hippocampus, activation of NTS1 receptors induces an excitatory effect and an increase in 
glutamate release (Antonelli et al. 2007;Antonelli et al. 2008); these effects are dependent 
on coupling to PLC, phosphokinase C (PKC) and Ca2+influx through L-type Ca2+ channels 
and activation of myosin light chain kinases respectively (Xiao et al. 2014;Zhang et al. 2015). 
Additionally, evidence of a facilitatory NTS1-NMDA receptor interaction at cortico-striatal 
glutamate terminals strengthens the role of NT in modulating glutamate release (Antonelli 
et al. 2004). Although within the scope of our study, we were not able to identify the exact 
effector molecules mediating this action, association of NTS1 receptors to such downstream 
excitatory signaling cascades might have come into play.  
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When tested over the same range of concentrations, [D-Tyr11]NT generated a dose-
dependent attenuation in the amplitude of glutamatergic EPSCs in Ih+ neurons. This 
attenuation was most likely mediated by activation of NTS2 receptors as it was blocked by 
a low concentration of SR142948 but not SR48692. As mentioned previously, all VTA 
dopamine neurons are Ih+ and that strongly suggests that [D-Tyr11]NT reduces glutamatergic 
inputs to at least a population of VTA dopamine neurons. In view of the evidence of a role 
for VTA dopamine in reward, and of the enhancement effect of NT on VTA dopamine 
impulse flow, these results were unexpected. They suggest that the action of [D-Tyr11]NT 
on glutamatergic inputs to VTA dopamine neurons through activation of NTS2 receptors is 
unlikely involved in the induction of a  conditioned reward. In fact, the action of [D-Tyr11]NT 
on NTS2 should oppose its action on NTS1 and contribute to reduce its effectiveness at 
inducing a conditioned reward. This may explain why SR142948 which displays a similar 
affinity for NTS1 and NTS2 (Gully et al. 1997) was less effective than SR48692, a preferred 
NTS1 antagonist (Gully et al. 1995), at attenuating the induction of CPP. 
 
There is also a large proportion of VTA GABA neurons that express an Ih current and it 
has been shown that GABA provides an inhibitory drive to dopamine neurons that is under 
the control of glutamate (Grace et al. 2007). An attenuation of glutamatergic input to these 
neurones is likely to enhance dopamine impulse flow resulting in reward and/or reward 
enhancement. If [D-Tyr11]NT is acting on NTS2 receptors to reduce glutamatergic EPSCs 
to these neurons, SR142948 would have been more effective than SR48692 at attenuating 
the induction of CPP; but as mentioned above, we observed the opposite.  
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The attenuation effect of [D-Tyr11]NT on glutamatergic EPSCs in Ih+ neurons contrasts 
with the enhancement effect of NT and NT-(8-13) reported in previous studies (Bose et al. 
2015; Kempadoo et al. 2013). Indeed both NT and NT-(8-13) enhance glutamatergic EPSC 
in Ih+ neurons by activating NTS1 receptors. Kempadoo et al. (Kempadoo et al. 2013a), 
however, observed a biphasic effect with NT-(8-13), an enhancement of NMDA EPSCs at a 
low concentration and an attenuation at a high concentration; the former but not the latter 
was blocked by SR48692 suggesting that the attenuation is not mediated by the NTS1 
receptor. It thus appears that both NTS1 and NTS2 modulate glutamatergic inputs to Ih+ 
neurons and that [D-Tyr11]NT has a predominant effect on the NTS2 receptor subtype. [D-
Tyr11]NT has a higher affinity for NTS2 than NTS1 (Kitabgi et al. 1980; Labbe-Jullie et al. 
1994) and activation of NTS2 receptors do not induce excitatory effects. For instance, 
activation of human NTS2 receptors expressed on CHO cell lines lacks the potential to 
elevate intracellular Ca2+ levels by mobilizing internal calcium reserves or accumulation IP3; 
it was rather associated with activation mitogen activated protein kinases (MAPK) that led 
to inhibition (Sarret et al. 2002). It could be that activation of NTS2 receptors on putative 
dopamine neurons enhances MAPK signaling and produces a reduction in glutamatergic 
signaling.  
 
The 11th position substitution in [D-Tyr11]NT by a D-tyrosine residue makes it more 
resistant to cleavage by endopeptidases (Checler et al. 1983a). In fact, after an 
intracerebroventricular injection of NT, 98% of the NT was cleared and degraded in brain 
tissues during a 30 min period after the injection. Under the same conditions, 33% of  [D-
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Tyr11]NT was retained, suggesting a half-life  1.5 times greater than that of  NT (Checler et 
al. 1983a). Owing to the relatively stable metabolic profile of [D-Tyr11]NT it is possible that 
the reduction in EPSC observed by Kempadoo et al (2013) with higher concentrations of 
NT8-13 reflects that produced by the lower concentrations of [D-Tyr11]NT used in the 
present study.   
 
Interestingly, in the presence of a high concentration (0.5 M) of SR142948, but not 
SR48692, [D-Tyr11]NT produced an opposite, significant inhibition, of glutamatergic EPSCs 
in Ih- neurons. This could possibly arise because at this concentration, SR142948 interacts 
with an NT receptor subtype other than NTS1 and NTS2 (possibly NTS3). The NTS3 protein 
and its mRNA are present in VTA and are mainly expressed on cell bodies and dendrites. 
According to Mazella et al. (1998), the NTS3 receptor is nearly insensitive to SR48692. 
Others, however, reported that SR142948 is effective at blocking the NTS3-mediated growth 
response to NT in cancer cells (Dal Farra et al. 2001); that would rather exclude a role for 
this receptor in the opposite effect of [D-Tyr11]NT on  EPSC in the presence of SR142948. 
In Ih+ neurons, the presence of a high concentration of SR142948 and SR48692 had the same 
impact; [D-Tyr11]NT enhanced the EPSC, an effect opposite to what was observed when it 
was infused alone. As mentioned previously, it remains unclear why the antagonists produce 
such a reverse effect.   
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Figure 1 
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Figure 1. Induction of a CPP by [D-Tyr11]NT. Top panel illustrates the preference score 
measured on the test day for the animals that were injected with 1.5 nmol (NT1.5, n = 6), 3 
nmol (NT3, n = 13) of [D-Tyr11]NT or its vehicle (VEH, n = 15). Preference score 
corresponds to the amount of time (in sec) spent in the paired compartment on the test day 
minus the time spent at baseline in the same compartment. Measures of locomotor activity 
recorded during the preference test for the animals in each treatment group are presented in 
the middle panel (horizontal) and bottom panel (stereotypy-like). Asterisks indicate a 
statistical significant difference with VEH (**p < 0.01; ***p < 0.001). 
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Figure 2 
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Figure 2. Mean preference score measured on the test day in the unpaired (top panel) and 
neutral (bottom panel) compartment for the animals that were injected with 1.5 nmol (NT1.5, 
n = 6), 3 nmol (NT3, n = 13) of [D-Tyr11]NT or its vehicle (VEH, n = 15). Preference score 
corresponds to the amount of time (in sec) spent in the unpaired or neutral compartment on 
the test day minus the time spent at baseline in the same compartment. See text for details. 
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Figure 3  
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Figure 3. Effects of SR142948 and SR48692 on [D-Tyr11]NT-induced CPP. Top panel 
illustrates the preference score measured on the test day for the animals that were injected 
with 3 nmol of [D-Tyr11]NT (NT, n = 13), 1.2 nmol of SR142948 (SR142, n = 10), 1.2 
nmol of SR48692 (SR48, n = 7), SR142948 + [D-Tyr11]NT (SR142+NT, n = 12), SR48292 
+ [D-Tyr11]NT (SR48+NT, n = 10) or the vehicle (VEH, n = 15). Preference score 
corresponds to the amount of time (in sec) spent in the paired compartment on the test day 
minus the time spent at baseline in the same compartment. Measures of locomotor activity 
recorded during the preference test for the animals in each treatment group are presented in 
the middle panel (horizontal) and bottom panel (stereotypy-like). The asterisks and the 
cross indicate a statistical significant difference with VEH (**p < 0.01; ***p < 0.001) and 
NT (+ p <0.05) respectively.  
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Figure 4 
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Figure 4. Effect of [D-Tyr11]NT and antagonists on Ih+ neurons. Panel 1: Current traces of 
glutamatergic EPSC recorded during superfusion of [D-Tyr11]NT ; control(1), with [D-
Tyr11]NT (0.01µM)(2) and following the washout of [D-Tyr11]NT (3) at a holding 
membrane potential of -70mV in Ih+ neurons (n=6). Panel 2: Current traces of 
glutamatergic EPSC recorded during superfusion with SR142948 (0.1 µM) (1), with 
SR142948and [D-Tyr11]NT (0.01µM)  (2) and with SR142948 following the washout of 
(3) at a holding membrane potential of -70mVin Ih+ neurons (n=5). Panel 3: Current traces 
of glutamatergic EPSC recorded during superfusion with SR48692 (0.1 µM) (1), with 
SR48692and [D-Tyr11]NT (0.01µM)  (2) and with SR48692 following the washout of [D-
Tyr11]NT (3) at a holding membrane potential of -70mVin Ih+ neurons (n=4). 
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Figure 5 
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Figure 5. Effects of [D-Tyr11]NT on glutamatergic EPSCs in Ih+ and Ih- neurons. Mean 
percent change in EPSC amplitude recorded in Ih+ (black bar) and Ih- (white bar) following 
application of different concentrations of [D-Tyr11]NT. The number of neurons recorded at 
each concentration is as follow: 0.01µM, n=12 (Ih+ n = 6, Ih- n = 6); 0.1 µM, n = 12 (Ih+ n = 
6, Ih– n = 6); 0.5µM, n = 16 (Ih+ n = 7, Ih– n = 9). All concentrations of D-Tyr[11]NT are 
reported in µM. Asterisks indicate a statistically significant difference with the lowest 
concentration (**p < 0.001; *** p < 0.001). See text for details. 
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Figure 6 
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Figure 6. Effect of [D-Tyr11]NT  and antagonists on Ih- neurons. Panel 1: Current traces of 
glutamatergic EPSC recorded during superfusion of [D-Tyr11]NT; control (1), with [D-
Tyr11]NT(0.01µM)(2) and following the washout of [D-Tyr11]NT(3) at a holding 
membrane potential of -70mV in Ih- neurons (n=6). Panel 2: Current traces of 
glutamatergic EPSC recorded during superfusion with SR142948 (0.1 µM) (1), with 
SR142948 and [D-Tyr11]NT (0.01µM)  (2) and with SR142948 following the washout of 
[D-Tyr11]NT(3) at a holding membrane potential of -70mVin Ih- neurons (n=5). Panel 3: 
Current traces of glutamatergic EPSC recorded during superfusion with SR48692 (0.1 µM) 
(1), with SR48692and [D-Tyr11]NT (0.01µM)  (2) and with SR48692 following the 
washout of [D-Tyr11]NT (3) at a holding membrane potential of -70mVin Ih- neurons 
(n=5). 
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Figure 7 
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Figure 7. Effect of SR142948 and SR48692 on glutamatergic EPSCs in Ih+ and Ih- neurons. 
Mean percent change in EPSC amplitude recorded in Ih+ (panel A) and Ih- neurons (panel 
B) following application of [D-Tyr11]NT alone or in the presence of SR142948 or 
SR48692. The number of neurons recorded under each condition is as follow: Ih+ 
neurons[D-Tyr11]NT (0.01µM, n =6; 0.1µM, n = 6);  SR142948 (0.1µM, n = 5; 0.5µM, n = 
4); SR48692 (0.1µM, n = 4; 0.5µM, n=4); Ih- neurons, [D-Tyr11]NT (0.01µM, n =6; 
0.1µM, n = 6);  SR142948 (0.1µM, n = 5; 0.5µM, n = 5); SR48692 (0.1µM, n = 5; 0.5µM, 
n=4). All concentrations of D-Tyr[11]NT, SR142948 and SR48692 are reported in µM. 
Asterisks and crosses  indicate a statistically significant difference with [D-Tyr11]NT alone 
at 0.01µM and 0.1µM respectively (*** p < 0.001 with 0.01 µM; +++ p < 0.001 with 0.1 
µM). The ### sign indicates a statistical significant difference between SR142948 (0.5µM) 
+D-Tyr[11]NT (0.1µM) and SR48692(0.5µM) +D-Tyr[11]NT(0.1µM). See text for 
details.  
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Abstract:  
 
Neuroadaptation at glutamatergic synapses in the ventral tegmental area (VTA) appears to 
underlie the development of behavioural sensitization to drugs of abuse in animals. The VTA 
is heavily innervated by neurotensin (NT) terminals and receptors and NT antagonists have 
been shown to block the development of behavioural sensitization in rats. It is thus possible 
that NT modulates glutamatergic neurotransmission in VTA neurons and that this 
modulation may explain why NT antagonists block sensitization mechanisms. However, 
how NT modulates glutamatergic neurotransmission in VTA neurons remain largely 
unknown. In the present study, VTA neurons were classified as Ih+ or Ih- based on the 
presence or the  absence of the hyperpolarisation activated cationic current (Ih) respectively. 
Using in vitro whole cell patch-clamp electrophysiology we measured the effect of D-Tyr 
[11] NT on pharmacologically isolated n-methyl-D-aspartate (NMDA) and AMPA 
excitatory post-synaptic currents (EPSCs) in Ih+ and Ih- VTA neurons. We found that in Ih+ 
neurons both NMDA and AMPA receptor mediated EPSCs were attenuated by the 
neurotensinergic analog D-Tyr [11] NT. This attenuation was mediated by both NTS1 and 
NTS2. In contrast, both NMDA and AMPA receptor mediated EPSCs were enhanced by an 
NTS1 dependent mechanism in Ih- neurons. This enhancement in EPSC amplitudes in Ih- 
neurons appeared to be mediated by neurotensinergic receptor located on glutamatergic 
terminals. These results provide additional evidence that NT exerts a bidirectional 
modulation on glutamatergic neurotransmission in VTA neurons and highlights a novel 
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peptidergic modulation of glutamatergic inputs to non-DA neurons that might be implicated 
in drug seeking behaviours.   
Keywords: VTA, Neurotensin, Excitatory post synaptic currents, NMDA receptors, AMPA 
receptors. 
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Introduction  
  The endogenous neuropeptide, neurotensin (NT), found in several limbic regions have 
been implicated in sensitization and reward mechanisms (Dobner et al. 2003;Rompre and 
Perron 2000a). Sensitization is a progressive augmentation of drug elicited responses that 
relates to the rewarding properties of abused drugs or psychostimulants and is a key feature 
of compulsive pattern of drug intake (Glimcher et al. 1984a;Robinson and Berridge 
1993;Wise and Bozarth 1987). The ventral tegmental area (VTA), an anatomical substrate 
involved in the development of sensitization contains a significant number of NT cell 
bodies and receives dense NT innervation from brain regions such as the lateral 
hypothalamus, preoptic area and rostral lateral septum (Binder et al. 2001a;Fallon 
1988;Sarret et al. 2003b;Uhl et al. 1979). It contains a high density of NT receptors which, 
when activated, stimulate dopamine cell firing mediated partly by inactivation of 
somatodendritic autoreceptors and an increase in non-selective cationic conductance 
(Farkas et al. 1997;St-Gelais et al. 2006a). Activation of NT receptors on DA neurons 
elicits a two component excitatory response; an NTS2 mediated fast, short component and 
another NTS1 mediated slow, long component (Binder et al. 2001a;Chien et al. 
1996;Farkas et al. 1996). However, these responses are NT analog specific; only the 
hexapeptide NT analog (NT8-13) induces the fast response by activation of NTS2 whereas 
both the native peptide NT1-13 and NT8-13 elicit the slow response mediated by NTS1 
(Farkas et al. 1996;Nalivaiko et al. 1998a). Another active NT analog, D-Tyr[11]NT has a 
substitution at the 11th  position by a d-tyrosine residue  that renders it more resistant to 
cleavage by endopeptidases, has a higher affinity for NTS2 and a lower affinity for NTS1 
receptor compared to NT1-13 and NT8-13 (Steinberg et al. 1995). However, VTA 
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injections of D-Tyr [11] NT induces dopamine dependent behaviours like NT or NT8-
13(Bauco and Rompre 2003;Blackburn et al. 2004). It has also been shown that repeated 
central injections of NT or D-Tyr [11] NT induces sensitization to psychostimulants (such 
as cocaine and amphetamine) (Rompre 1997a;Rompre and Bauco 2006b). However, VTA 
injections of D-Tyr [11] NT produce different levels of dopamine efflux in the rostral and 
caudal nucleus accumbens (nAcb) and is not effective in the prefrontal cortex (PFC) in 
contrast to NT or NT8-13 (Sotty et al. 2000a).  
Interestingly, a role for glutamate in the initiation of sensitization was suggested as 
blockade of VTA N-methyl D-aspartate receptors (NMDA) disrupted the induction of 
locomotor sensitization to amphetamine (Cador et al. 1999a). This is congruent with 
another study that showed that the long term effects of sensitization to cocaine by NT were 
blocked by an NMDA antagonist (Vezina and Queen 2000b). The involvement of 
glutamate is further supported by a recent optogenetic study in which the selective 
stimulation of hypothalamic neurotensinergic efferents to the VTA DA neurons and 
induced a rewarding effect that is NMDA dependent (Kempadoo et al. 2013a) . Thus 
NMDA receptor activation induced VTA neural plasticity tempts us to hypothesize that 
NT’s role in initiating sensitization involves modulating glutamatergic inputs to VTA 
neurons. However, this modulation is complex and depends on the concentration of the 
neurotensin agonist used as well as the glutamatergic component being studied. For 
instance, Kempadoo et al., (Kempadoo et al. 2013a)suggested a bidirectional effect on the 
NMDA component dependent on the concentration of the NT agonist used and a dose-
dependent decrease of the AMPA component both being NTS1 receptor independent; 
whereas another study reported an NTS1 mediated depression of glutamatergic excitatory 
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post synaptic currents (EPSCs) using a higher concentration of the agonist (Kempadoo et 
al. 2013a;Kortleven et al. 2012a).  
We therefore sought to characterize the NT modulation of VTA glutamatergic 
neurotransmission, by using whole cell patch clamp recordings to measure the effects of D-
Tyr [11] NT on isolated glutamatergic EPSC components measured in putative VTA DA 
and non-DA neurons. Putative VTA DA neurons were characterized by the presence of the 
hyperpolarisation activated cationic current (Ih) and the absence of it categorized the 
neuron as non-DA. The effects of NT antagonists were also evaluated to identify the 
receptors mediating the effects.   
Methods 
Animals and slice preparation   
All experimental procedures were approved by the Institutional Animal Committee in 
accordance with guidelines of the Canadian Council on Animal Care. All efforts were 
made to minimize the suffering and number of animals used. 
 Fourteen to 21-day-old (P14-P21) Long Evans pups of either sex obtained from Charles 
River (St-Constant, QC) were used. Pups were anaesthetized by inhalation of 
methoxyfluran vapour in a closed chamber, decapitated and their brain quickly removed 
and transferred to chilled, oxygenated artificial cerebrospinal fluid (ACSF) in which NaCl 
had been replaced by equivalent osmolarity of sucrose and containing (in mM) sucrose 252 
(NaCl 126 in standard ACSF); KCl, 3; NaH2PO4, 1.25; MgSO4 7 H2O, 1.3; CaCl2, 2.5; 
NaHCO3, 26; and glucose, 10, and saturated with a gas mixture of 95% O2 and 5% CO2. 
                                                           
 
143 
 
Two hundred and fifty micrometer thick horizontal slices preserving the VTA afferents 
(Margolis et al. 2006b) were cut using a vibrating microtome(DSK Microslicer). Slices 
were transferred to a submerged recording chamber maintained between 32 to 34°C and 
superfused with standard ACSF at a rate of 2 ml/min; slices were incubated for at least one 
hour before the commencement of  recording.   
Drugs and peptides 
The following pharmacological agents were applied through the superfusing ACSF:  (-) 
bicuculline methiodide (BMI), 6 cyano-7-nitroquinoxaline-2,3-dione (CNQX), (+)-2-
amino-5-phosphonopentanoic acid (APV) obtained from Sigma Aldrich(Oakville, Ontario, 
Canada) ; D-Tyr[11]NT was obtained from Bachem (Sunnyvale, CA,USA); SR-48692 [2-
(1-[7-chloro-4-quinolinyl]-5-[2, 6-dimethoxyphenyl]-1H-pyrazol-3-)carbonylamino-
adamantane-2-carboxyl acid] ,SR142948A2-[[[5-(2,6-Dimethoxyphenyl)-1-[4-[[[3-
(dimethylamino)propyl]methylamino]carbonyl]-2-(1-methylethyl)phenyl]-1H-pyrazol-3-
yl]carbonyl]amino]-tricyclo[3.3.1.13,7]decane-2-carboxylic acid (Tocris Biosciences). All 
drugs were made up as 10 mM stock solutions in distilled water and diluted with ACSF 
solution to final concentration just before addition to the perfusion medium with the 
exception of SR48692 and CNQX which were dissolved in DMSO (final concentration 
0.1%) and distilled water.  
Electrophysiological recordings  
Whole-cell configuration was achieved using the ‘blind’ patch-clamp technique(Blanton et 
al. 1989a). Pipettes were pulled from thin wall borosilicate capillary glass on a P-87 
micropipette puller (Sutter Instrument, Novato, CA, USA). Recording pipettes had a 
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resistance of 3-5MΩ when filled with a solution containing (in mM) potassium gluconate, 
140; MgCl2, 2; CaCl2, 0.1; EGTA, 1.1; HEPES, 10; K2-adenosine triphosphate (ATP), 2; 
guanosine triphosphate (GTP), 0.5 ,biocytin (5%) and QX314 ,2. The pH was adjusted to 
7.3 with KOH solution, and final osmolarity was 280 ±5 mosmol/kg. All recorded neurons 
were labelled to confirm their location in the medial VTA. 
Whole-cell recordings were made with an Axoclamp 2B amplifier (Molecular Devices, 
Sunnyvale, CA, USA) in continuous single-electrode voltage-clamp mode. The output of 
the amplifier was fed into a LPF 200A DC amplifier/filter (Warner Instruments Corp., 
Hamden, CT, USA) and digitized at 5 to 10 kHz with a real-time acquisition system (CED 
1401 Power). Data acquisition was achieved using the Signal 4.0 software (Cambridge 
Electronic Design, Cambridge, England). Recording pipette’s capacitance was optimally 
adjusted before whole-cell configuration was achieved. The resting membrane potential 
was measured just after rupturing the cell membrane and the offset potential, measured 
upon withdrawal of the electrode from the cell, was accounted for assuming that it drifted 
in a linear fashion with time from the start of the recording session. We did not correct for 
liquid junction potential, which for a pipette containing 140 mM potassium gluconate 
amounts for an additional potential shift of around -10mV(Spigelman et al. 1992). 
Synaptic activation and drug application 
The presence of Ih was first determined by voltage clamping cells at -60mV and stepping  
to −40, −50, −70, −80, −90, −100, −110 and −120 mV. Input resistance was monitored 
with hyperpolarizing pulses in current clamp mode. A monopolar tungsten stimulating 
microelectrode was placed rostral to the recording site in the medial VTA, on the slice 
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superficial layer, 0.5-1.0 mm from the recording electrode. Excitatory postsynaptic 
currents were evoked by 0.1ms, 3 to 6V cathodal pulses delivered at 15 sec intervals. In 
order to isolate glutamate receptor-mediated EPSCs, all experiments were performed in the 
presence of (-) bicuculline methiodide (BMI, 10µM) in bath solution to block GABAA 
receptor-mediated synaptic currents. BMI was applied 30 min before obtaining whole-cell 
configuration to ensure a complete diffusion in the slice tissue. In experiments that studied 
AMPA or NMDA EPSCs, APV or CNQX (respectively) was added to the superfusion 
medium 30min before the commencement of recording. The composite glutamatergic 
EPSCs were recorded from an online voltage-clamped potential of -70mV, while the 
NMDA EPSCs were voltage clamped at-20mV in the presence of CNQX (20µM) and the  
AMPA EPSCs were voltage clamped at -70mV in the presence of APV (50µM). The 
effects of D-Tyr[11]NT(0.01µM) on glutamatergic EPSCs were assessed at a holding 
membrane potential of -70mV in case of AMPA EPSCs and -20MV in the case of NMDA 
EPSCs. D-Tyr [11] NT (0.01µM) was tested only once per cell. Upon agonist application, 
the change in amplitude of the glutamatergic EPSC was measured. Five minutes of 
baseline EPSC activity was recorded before superfusion with the peptide. The EPSC 
amplitudes were recorded during 7 min after the onset of the peptide application and 
averaged over the last 5 min. A washout period of 15 min was allowed before the 
amplitude of the recovered EPSC was measured. In some experiments, the control EPSC 
amplitude was measured for 4 min before a NT antagonist was added to the superfusion 
medium. However, SR142948A or SR48692 produced no effect on the control EPSC 
amplitude (n=9; data not shown). Therefore in further experiments where NTS receptor 
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antagonists were used, SR142948 or SR48692 was added to the superfusing medium for 7 
min and control response was measured in the presence of the antagonist.  
Data analysis   
Data analysis was performed using Signal software (Cambridge Electronic Design, 
Cambridge, England). Statistical analysis was performed using Sigmaplot 12 software 
(Systat, San Jose, CA, USA). The magnitude of EPSC recorded after application of the 
peptide was expressed as % of baseline and group means were calculated for drug 
condition. Student’s t test was performed to compare between groups of cells (NMDA vs 
non-NMDA). A one-way ANOVA was performed in comparing the effects of the 
antagonists and the agonist for a cell group and post hoc Bonferroni’s test was used to 
determine significant differences between concentration and peptide condition when 
justified; level of significance was set at 0.05 (Statistica V5.0, StatSoft). 
  
 
RESULTS  
 Whole-cell voltage-clamp recording was obtained from 102 VTA neurons in slices 
from rats between P14 and P21. Based on the presence or the absence of the 
hyperpolarisation activated cationic current (Ih), neurons were categorized as Ih+ (n=49) or 
Ih-(n=53). The amplitude of Ih in Ih+ neurons ranged between 92 pA and 437 pA with an 
average of 206.72 pA (±10.87) (data not shown). All neurons filled with biocytin (5%) were 
examined under light microscopy and were confirmed to be located in the VTA. 
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 Characteristics of glutamatergic EPSCs 
 Typically, postsynaptic currents evoked by electrical stimulation in the presence of 
the GABAA receptor antagonist BMI consisted of a compound glutamatergic EPSC 
comprising an early and a late component mediated, respectively, by the activation of 
AMPA/KA and NMDA receptors respectively (Fig. 1). We characterized composite 
postsynaptic glutamatergic EPSCs in 11 neurons; the late component of the EPSC was 
isolated and recorded in 35 neurons and the early component was isolated and recorded in 
33 neurons. The remaining 23 neurons were tested for paired pulse protocols for early (n=12) 
and late components (n=11). 
 The early EPSC peaked between 3.4 and 20 msec. after stimulus onset at a holding 
membrane potential of –70 mV, had a linear relationship with the membrane potential and 
reversed around 0 mV (n=44). In contrast, the maximal amplitude of the late EPSC occurred 
much later, was usually observed at holding membrane potentials of  –20 or –40 mV, 
displayed a non-linear relationship with voltage and also reversed around 0 mV (n=36). 
 Figure 1 shows a representative example of an EPSC recorded in an Ih+ VTA neuron 
from a P20 animal on which specific glutamatergic antagonists were tested. During the 
control period (Fig. 1A panel 1), the early EPSC peaked 9 msec. after the stimulus onset at 
a holding membrane potential of –70 mV and the response decayed to baseline within 25 
msec. The current voltage relationship (IR-Vm) of the early EPSC was almost linear at 
membrane potentials between –120 mV and 20 mV (Fig. 1B panel 1). Bath application of 
the AMPA/KA receptor antagonist CNQX completely abolished the early component of the 
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EPSC and there was virtually no residual postsynaptic current at all membrane potentials at 
the latency the early response was measured (Fig. 1A panel 2 and Fig. 1B panel one).  
 The late component, measured after the early component had decayed, increased at 
membrane potentials between –100 and –40 mV and reached its maximum usually at–20 
mV. At more depolarized membrane potentials, it decreased and reversed polarity around 0 
mV (Fig. 1A and Fig. 1B panel 2), a current-voltage relationship typical of NMDA receptor-
mediated current. The further addition of the NMDA receptor antagonist APV to the 
superfusing medium completely abolished the late EPSC (Fig. 1A panel 3), demonstrating 
that it was mediated by NMDA-type receptors. In the presence of CNQX alone, the NMDA 
receptor-mediated EPSC was recorded in isolation showing that measurements of the late 
component of the EPSC made on the compound EPSC were close to the peak of the NMDA-
mediated EPSC and represented mostly NMDA receptor-mediated current (Fig. 1A panel 
2). Also, note there was no residual postsynaptic current in the presence of CNQX and APV, 
showing that glutamatergic EPSCs were effectively isolated by the addition of BMI to the 
superfusing medium. CNQX and APV were tested together in 11(Ih+ n=5; Ih- n=6) other 
neurons producing similar results. There were no differences in the characteristics of 
glutamatergic EPSCs in Ih+ or Ih- neurons (data not shown). In addition, CNQX and APV 
were tested individually in 35 and 33 neurons respectively. 
[Figure 1] 
 In most neurons, the effects of neurotensinergic agonist and antagonists were 
assessed at holding membrane potentials usually between -100 and 20 mV in steps of 20 
mV. The AMPA/KA-mediated EPSC was measured at the peak of the early component of 
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the EPSC at a holding membrane potential of –70 mV, when the amplitude of the late 
component was minimal (left vertical dotted lines in Fig. 1A) whereas the effects on NMDA 
receptor-mediated currents were measured at a latency at which the early component 
recorded at a holding membrane potential of –70 mV had decayed (see right vertical dotted 
lines in Fig. 1A).  
Effects of D-Tyr [11] NT on NMDA EPSCs.  
 The addition of the neurotensin agonist, D-Tyr [11] NT to the superfusing medium 
in the presence of BMI and CNQX typically produced a decrease of the late NMDA 
component of the EPSC in Ih+ neurons. The average decrease in the amplitude of the 
pharmacologically isolated NMDA EPSC produced was found to be 30±3.0% (n=6; see 
Figure2 E). A representative example is shown in Figure 2A. In this case, the amplitude of 
the NMDA component of the EPSC recorded at–20 mV, was reduced by 33% during the 
application of D-Tyr [11] NT.  
To identify the type of receptors mediating the inhibitory action of D-Tyr [11] NT, it was 
administered in the presence of the broad spectrum NT antagonist SR142948 or NTS1 
antagonist, SR48692. When administered alone, SR142948A (0.1µM) produced no change 
in the amplitude of the NMDA EPSC (data not shown), however when of D-Tyr [11] NT is 
administered in the presence of SR142948A (n=7), the inhibition of the NMDA EPSC was 
successfully blocked (see Figure 2E). A representative example of this effect is shown in 
Figure 2B. However, in the presence of D-Tyr [11] NT, SR48692 (0.1µM) (n=5) 
significantly attenuated the NMDA EPSC inhibition by 15±1.5%, suggesting the 
involvement of NTS1 and NTS2 in mediating the effect. A one way ANOVA yielded a 
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significant effect (F2,11=57.95,p<0.001) and post-hoc test confirmed that the mean change in 
EPSC measured in the presence of SR142948 was significantly different than that measured 
in the presence of [D-Tyr11]NT alone or SR48692 + [D-Tyr11]NT (p<0.001).    
In contrast the addition of D-Tyr [11] NT in in Ih- neurons produced an increase in the 
amplitude of the pharmacologically isolated NMDA EPSCs. The average change in the 
amplitude of excitation produced was found to be 35±5.5% (n=7; see figure 2E). A 
representative example of this effect is shown in Figure 2C. In this case, the amplitude of the 
late component recorded at -20mV was enhanced by 31% during the application of D-Tyr 
[11] NT.  
We next sought to characterize the neurotensin receptors responsible for mediating the 
excitatory effect of D-Tyr [11] NT in Ih- neurons. SR142948A when applied alone produced 
no effect on the late component of the EPSC (data not shown). In the presence of SR142948A 
(0.1µM), D-Tyr [11] NT failed to produce the enhancement in the NMDA EPSC amplitude 
(n=6; see figure 2E). A representative example of this effect is shown in Figure 2D. 
SR48692, the NTS1 receptor antagonist also blocked the enhancement effect, thus 
confirming the role of NTS1 in mediating this effect (n=5). A one way ANOVA yielded a 
significant effect (F2,12=36.22,p<0.001) and post-hoc test confirmed that the mean change in 
EPSC measured in the presence of SR142948 was significantly different than that measured 
in the presence of [D-Tyr11]NT alone or SR48692 + [D-Tyr11]NT (p<0.001). 
[Figure 2] 
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Effects of D-Tyr [11] NT on non-NMDA EPSCs. 
Similar to the observation in NMDA EPSCs, the addition of D-Tyr [11] NT to the 
superfusing medium in the presence of BMI and APV also resulted in a decrease of the early 
AMPA component of the EPSC in Ih+ neurons. The average inhibitory effect was found to 
be 10±1.0% (n=7; see Figure 3E). Figure 3 A shows a representative example of this effect. 
In this case the, pharmacologically isolated AMPA EPSC recorded at -70mV and it was 
inhibited by 10%. When compared to the inhibition produced in the amplitude of NMDA 
component, the decrease in the amplitude of the AMPA EPSC was significantly lower 
(student’s t test p<0.001).  
To characterize the receptor subtypes responsible in mediating this effect, when D-Tyr [11] 
NT was added to the superfusing medium in the presence of SR142948A (0.1µM), the 
inhibitory effect in AMPA EPSCs was completely abolished (n=6; see figure 3E). A 
representative example of this effect is shown in Figure 3 B. However, when SR48692 
(0.1µM) was tested (n=6; see Figure3E) the inhibitory effect of D-Tyr [11] NT persisted, 
thus ruling out the possibility of a role for NTS1 receptor. A one way ANOVA yielded a 
significant effect (F2,12=34.85,p<0.001) and post-hoc test confirmed that the mean change in 
EPSC measured in the presence of SR142948 was significantly different than that measured 
in the presence of [D-Tyr11]NT alone or SR48692 + [D-Tyr11]NT (p<0.001). 
In Ih- neurons, addition of D-Tyr [11] NT to the superfusing medium produced an increase 
in the AMPA component of the EPSC. The average enhancement of the EPSC was found to 
be 13±1.5 %( n=7; see figure3E). Figure 3C shows a representative example of this effect in 
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the AMPA EPSC in the presence of APV and recorded at-70mV in an Ih-neuron. The 
enhancement effect in this case was 12.65%. 
In comparison to the enhancement of the NMDA component in Ih- neurons (13±1.5 %) 
produced by D-Tyr [11] NT, the AMPA EPSC was significantly less enhanced (6±0.5 %) 
(Student’s t test p<0.001). 
To identify the receptor subtype mediating the increase in the AMPA EPSC amplitude, D-
Tyr [11] NT was tested in the presence of SR142948A (0.1µM). SR142948A failed to 
completely block the enhancement effect; instead it significantly attenuated to about 50% of 
the increase produced. The average decrease in the enhancement of the AMPA EPSCs was 
found to be 6±0.5 %( n=6; see figure3E). However, when SR48692 (0.1µM) was tested, the 
excitation effect was significantly blocked (n=5). A representative example of this effect is 
shown in Figure 3D. A one way ANOVA yielded a significant effect (F2,13=25.89,p<0.001) 
and post-hoc test confirmed that the mean change in EPSC measured in the presence of 
SR142948 was significantly different than that measured in the presence of [D-Tyr11]NT 
alone or SR48692 + [D-Tyr11]NT (p<0.001). 
            [Figure 3] 
Locus of neurotensinergic modulation of evoked EPSCs. 
Our evidence suggests that D-Tyr[11]NT modulates AMPA glutamatergic responses in Ih- 
neurons exclusively by presynaptic mechanisms. The rationale behind using a paired pulse 
protocol in discerning pre-synaptic mechanisms resides in the fact that synaptic facilitation 
is associated with augmentation in presynaptic Ca2+ levels and neurotransmitter release i.e 
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the residual calcium hypothesis. The use of two consecutive stimuli with a 50msec interval 
generates a larger 2nd EPSC than the 1st, reflecting an enhanced neurotransmitter release 
from the residual calcium [23, 28, 29]. In our experiments, we found that the ratio (PPR; 2nd 
EPSC amplitude/1st EPSC amplitude) significantly changed during the application of D-
Tyr[11]NT in Ih
- neurons, thus suggesting presynaptic mechanisms. In the presence of D-
Tyr[11]NT (n=7), the amplitude of both the first and second evoked EPSCs increased, 
but the second response increased to a larger extent, resulting in an increase in the PPR 
(Fig. 4A). In contrast, no significant changes in PPR was observed in Ih+ neurons (Fig.4A, 
panel 3). 
 
To identify the locus (pre- or postsynaptic) of action of neurotensin agonist D-
Tyr[11]NT, we compared two features of our recordings in the presence and absence 
of the neurotensinergic agonist. Since NMDA receptors are voltage dependent and 
activated at greater positive potentials (-20mV) than AMPA receptors, the depolarized 
membrane potentials are more susceptible to generate population spikes and consequently 
affecting paired pulse ratios. Therefore we next investigated the locus of modulation of 
AMPA responses by D-Tyr[11]NT. 
 
This suggests that under the present experimental conditions neurotensin receptors agonists 
produced no detectable postsynaptic effects in VTA Ih- neurons and that the present results 
reflect an action on presynaptic receptors.  
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Second, we found that under the present experimental conditions D-Tyr [11] NT produced a 
direct effect on the membrane and/or firing properties of Ih- neurons when   QX314 was 
omitted from the pipette solution. Figure 4B shows an example of the effects produced by 
D-Tyr [11] NT (0.01µM) under these conditions. In this case, D-Tyr [11] NT, produced a 
membrane depolarization of 13 mV. Intracellular depolarizing current pulse that was 
subthreshold during control readily increased spiking when D-Tyr [11] NT was added to the 
superfusing medium and the number of action potentials increased in response to 
suprathreshold current injection. These results suggest that the presence of   QX314 into the 
recording pipette occluded the postsynaptic effects mediated by neurotensinergic receptors. 
 
 
 
      [Figure4] 
Discussion 
We found that D-Tyr[11]NT, an active analog of NT, reduced and enhanced glutamatergic 
neurotransmission respectively in VTA Ih+ and Ih- neurons respectively and this modulation 
was mediated by  activation of different NT receptor subtypes. While the decrease in 
glutamatergic neurotransmission was mediated by NTS2 in Ih+ neurons, the enhancement 
in Ih- neurons involved NTS1 seemingly located on glutamatergic terminals. To our 
knowledge this is the first study that highlights a neurotensinergic modulation of 
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glutamatergic neurotransmission in non-DA neurons (Ih-) in the VTA that might be 
relevant to sensitization and reward mechanisms. 
 The substitution of a d-tyrosine residue at the 11th position in the native NT peptide (NT1-
13), renders D-Tyr[11]NT  more resistant to cleavage by endopeptidases when compared 
to NT1-13 itself or to the carboxy terminal hexapeptide, NT8-13 (Checler et al. 1983a). 
Both NT1-13 and NT8-13 have a higher binding affinity for NTS1 than NTS2(Binder et al. 
2001a). On the contrary, D-Tyr [11] NT has a higher binding affinity for NTS2 than NTS1 
(Sotty et al. 2000a). However, despite differences in binding affinities for NT receptor 
subtypes in comparison to either NT1-13 or NT8-13, D-Tyr [11] NT injections in the VTA 
induced DA release both in vitro and in vivo and produced dopamine dependent behaviours 
like NT1-13or NT8-13 (Rompre 1997a;Steinberg et al. 1995). Nonetheless, in comparison 
to NT, it has greater potency in inducing these effects. This can be accounted for by the 
stability of D-Tyr [11] NT. It was found that in the presence of thiorphan, a peptidase 
inhibitor, it induced larger locomotor effects caused by increased levels of DA 
concentrations (Steinberg et al. 1995). Since D-Tyr [11] NT has differential binding 
affinities for NT receptor subtypes we used D-Tyr [11] NT to delineate the role of NT 
receptors in modulating glutamatergic neurotransmission in VTA neurons (Binder et al. 
2001a;Gully et al. 1997a;Steinberg et al. 1995).   
 
 
Effect of D-Tyr [11] NT on Ih+ neurons 
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The disruption in the development of cocaine sensitization could be induced by blockade 
of NMDA receptors in the VTA(Rompre and Bauco 2006b). Concomitantly, sensitization 
to amphetamine could also be blocked by administration of NT antagonists(Panayi et al. 
2005b). This is suggestive of an interaction between NMDA receptors and NT, which 
could contribute to the disruption of the development of sensitization. We have previously 
shown that both NT1-13 and NT8-13 enhance glutamatergic neurotransmission in Ih+ and 
Ih- neurons by recruiting NTS1 and 2 receptors respectively(Bose et al. 2015) . However, 
we obtained different results when D-Tyr [11] NT was tested in VTA neurons. D-Tyr [11] 
NT induced a reduction in glutamatergic neurotransmission in Ih+ neurons and that this 
involved NTS2 (unpublished data). The present results show that D-Tyr [11] NT reduces 
the amplitude of isolated NMDA EPSCs by activating NTS2receptors. An NTS1 
independent form of reduction in NMDA EPSCs induced by NT8-13 in VTA DA neurons 
has been reported by Kemapdoo et al., (Kempadoo et al. 2013a). However, the authors also 
reported a bidirectional modulation rather than a dose-dependent effect. At lower 
concentrations of 0.01µM, NT8-13 induced an enhancement effect which was NTS1 
receptor dependent, whereas higher concentrations of NT8-13 attenuated the EPSC 
amplitude, an effect which was not NTS1 dependent. This is partly consistent with our 
results as we observed that D-Tyr [11] NT attenuated NMDA receptor mediated EPSCs in 
Ih+ neurons dose-dependently. Moreover, we found that the selective NTS1 antagonist, 
SR48692 attenuated the inhibitory effect whereas SR142948A the non-selective antagonist 
blocks the inhibitory effect in Ih+ neurons thereby suggesting an NTS2 receptor 
involvement. Additionally, activation of NTS2 is associated with the lack of mobilization 
of intracellular calcium reserves and increase in Ca2+ levels. Also accumulation of inositol-
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3-phosphate (IP3) or inhibition of IP3 production is associated with the induction of 
inhibitory effects to depolarise the cell (Sarret et al. 2002). Kortleven et al. (Kortleven et al. 
2012a) suggested a reduction in glutamatergic EPSCs through an NTS1 dependent 
mechanism. Thus in Ih+ neurons, D-Tyr [11] NT induces a reduction in glutamatergic 
neurotransmission. Within the population of Ih+ neurons in our studies it is possible that 
there might be some glutamatergic neurons in addition to the majority of them being DA 
neurons. Additionally, glutamatergic neurons with Ih current have been mostly found in the 
medial VTA, the site of recording in our studies (Hnasko et al. 2012). It is important to 
note that Margolis et al., (Margolis et al. 2012a) reported that GABA VTA neurons are 
also characterized by the presence of Ih current and are almost equal in number compared 
to Ih+ DA neurons. However many other studies have considered Ih to be a reliable marker 
for putative DA neurons (Binder et al. 2001a;Kempadoo et al. 2013a;Mao et al. 
2011;Margolis et al. 2006c;Ungless and Grace 2012;Zweifel et al. 2008). The distribution 
of GABA Ih+ neurons have been reported to be rather uniform throughout the VTA 
according to the study by Margolis and are reconciled to as being Ih+ TH- neurons. 
However, in a previous study by the same group (Margolis et al. 2006c) these neurons 
were noticeably less found  in the medial VTA. Considering the reported heterogeneity of 
Ih+ neurons, a more heterogeneous pattern of response to an NT agonist is logically 
expected. However, we observe a uniform response in all Ih+ neurons tested with NT 
agonists. Moreover, categorizing VTA neurons as Ih+ or Ih- allowed us to demonstrate 
profound physiological and pharmacological differences in synaptic properties that are 
modulated by D-Tyr[11]NT. 
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Previous studies have reported a reduction in glutamatergic EPSCs recorded at -70mV in 
DA cells of the VTA through endocannabinoid release. Additionally this depression also 
involved NTS1 (Kortleven et al. 2012a). However, Kempadoo et al., reports a similar 
decrease in pharmacologically isolated AMPA EPSCs that was not mediated by NTS1 
(Kempadoo et al. 2013a). Our results are congruent with this latter study as we observe a 
reduction in isolated AMPA EPSC amplitude in Ih+ neurons in the presence of D-
Tyr[11]NT and this decrease was not mediated by NTS1 as SR49692 failed to block the 
depression. Additionally, the broad spectrum NT antagonist SR142948A significantly 
blocked the depression of the EPSCs thus suggesting a role for NTS2. Since D-Tyr [11] 
NT has a higher affinity for NTS2, it is possible that this NT agonist preferentially binds to 
NTS2 and causes a reduction in AMPA receptors mediated glutamatergic 
neurotransmission. An NTS1 mediated glutamate induced excitotoxic effect is reported in 
the mPFC which lacks NTS2 (Antonelli et al. 2008). This suggests that NTS2 receptor 
activation likely produce an inhibitory effect. Indeed, when expressed in CHO cell lines, 
NTS2 receptor activation was not associated with excitatory effects (Sarret et al. 2002). 
Given the fact that D-Tyr[11]NT  has a higher binding affinity at NTS2 than NTS1 and the 
metabolically stable profile of D-Tyr[11]NT, we suggest that NTS2 are activated on 
putative DA cells in the presence of relatively higher concentrations of NT. However, 
whether the site of action is presynaptic or postsynaptic in Ih+ neurons is still unclear as we 
obtained non-significant results with paired pulse experiments. It should be noted that the 
inclusion of QX314 in the recording pipette could have blocked the post synaptic effects, 
and in such a situation we should have observed a presynaptic effect if there was one. 
                                                           
 
159 
 
Additionally Kempadoo et al., (Kempadoo et al. 2013a) also failed to observe a significant 
effect in paired pulse experiments with NT8-13.  
  
Effect of D-Tyr [11] NT on Ih- neurons 
 The possible role of VTA non-DA neurons in reward and sensitization mechanisms have 
received less attention compared to VTA DA neurons. In a study by Luo et al., (Luo et al. 
2010a)selective ablation of NMDA receptors on VTA DA neurons did not disrupt the 
development of sensitization to cocaine. The sensitization was only blocked upon 
administration of an NMDA antagonist, suggesting that NMDA receptors on non-DA 
neurons might play a role in sensitization mechanisms. However, NTergic modulation of 
glutamatergic neurotransmission on VTA non-DA neurons has not received much attention 
compared to its DA counterpart. In other brain areas for instance the cortex, activation of 
NTS1 are reported to enhance NMDA receptor functions thereby augmenting the 
glutamatergic neurotransmission, an effect that is blocked by SR48692 (Ferraro et al. 
2011). This suggests an NT induced excitatory effect. We observe a similar augmentation 
in the NMDA EPSC in Ih- neurons, by D-Tyr [11] NT at equimolar concentrations at which 
it reduces NMDA glutamatergic transmission in Ih+ neurons. This augmentation in Ih- is 
NTS1 dependent and reflective of an NTS1 mediated excitatory effect of neurotensin at 
lower concentrations. Both SR142948A and SR48692 blocked the excitatory effect of D-
Tyr [11] NT in Ih- neurons thereby asserting the role for NTS1. Although D-Tyr [11] NT 
has a greater affinity for NTS2 than NTS1 the difference in the binding affinities do not 
vary greatly, suggesting the possibility of NTS1 binding (Kitabgi et al. 1980a;Labbe-Jullie 
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et al. 1994). An alternative explanation for this observation can be that NTS1 on Ih- 
neurons are differently sensitive than in Ih+ neurons and are activated at lower 
concentrations. The possibility of  existence of a single NT receptor in multiple active 
states in which each agonist is able to select its own receptor state has been suggested. 
These receptor states can be coupled to different G proteins and transduce varied effects 
(Sotty et al. 2000a).  
Similar to the augmentation of NMDA receptor mediated EPSC amplitudes; we found an 
augmentation of AMPA mediated EPSCs in Ih- neurons in our studies. Albeit, the AMPA 
mediated enhancement effect is lower compared to the NMDA mediated enhancement 
given that glutamate has a greater binding affinity for NMDA receptors than AMPA 
receptors (Isaacson 1999;Kullmann and Asztely 1998). When tested with a paired pulse 
protocol, the NTS1 mediated enhancement of the AMPA component was found to be 
presynaptic. We examined the changes in paired pulse ratio (PPR) produced during D-Tyr 
[11] NT application as pre- and or post synaptic mechanisms. We found that bath 
application of D-Tyr [11] NT enhanced the EPCSs but the enhancement resulted in an 
increase of PPR, suggesting that NT acted presynaptically to increase the probability of 
glutamate release from presynaptic terminals. A similar presynaptic mode of glutamate 
release is suggested in a study that characterized the effect of NT8-13 on glutamatergic 
EPSCs in medium spiny neurons of the nucleus accumbens (Yin et al. 2008). As we 
routinely added QX314 to the recording pipette solution to block action potential 
generation, we found that by omitting QX314 from the recording pipette solution, D-
Tyr[11]NT modulated the membrane and firing properties of non-DA neurons. In addition 
to blocking voltage gated Na+ channels, QX314 is also known to block G-protein gated K+ 
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conductances (Gabel and Nisenbaum 1999;Galarraga et al. 1999). The reduction of such 
conductance produces membrane depolarisation, an effect that is observed on postsynaptic 
NT receptor activation (Binder et al. 2001a;Farkas et al. 1996). These observations further 
strengthens the notion that activation of NTS1 on terminals close to non-DA cells, leads to 
increased glutamate release which then activates non-DA cells. 
Conclusions 
Glutamatergic neurotransmission in the VTA has been ascribed to be crucial for the 
development of sensitization and reward mechanisms (Britt and Bonci 2013;Nestler 2013). 
However blockade of AMPA receptors induced a time dependent increase in reward 
threshold whereas injection of NMDA antagonists in the same VTA sites resulted in a time 
dependent decrease in reward threshold. This suggests  opposite modulatory roles for 
NMDA and AMPA receptors in brain stimulation reward mechanisms involving the 
VTA(Ducrot et al. 2013). Therefore it is tempting to hypothesize that these opposite 
modulation of glutamate receptors can be ascribed to two different populations of cells in 
the VTA –the putatively dopaminergic (Ih+) and non-dopaminergic (Ih-). The rationale for 
such a hypothesis lies in the observation that while in putative dopaminergic neurons D-
Tyr [11] NT depress both NMDA and AMPA components of glutamatergic EPSCs, it 
produced an enhancement in putative non-dopaminergic neurons(Khalil Rouibi K. 2015) 
(In press).  
 D-Tyr[11] NT possess differential binding affinities for  NTS1 and 2 receptors(Sotty et al. 
2000a) and that activation of either receptor subtype  respectively generates a depression or 
augmentation in Ih+ or Ih- neurons. This suggests that the observed effects might be 
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concentration dependent. The likelihood of the idea, that NT activates two separate 
populations of cells at high and low concentrations, is supported by the already reported 
concentration dependent actions of NT on NMDA and AMPA mediated neurotransmission 
in VTA DA neurons (Kempadoo et al. 2013a). This leads us to propose that when NT 
concentrations are high, NT activates NTS2 on glutamatergic terminals or putative DA 
neurons and decrease glutamatergic neurotransmission. On the contrary when endogenous 
NT concentrations are low, NT activates presynaptic NTS1 that increase glutamatergic 
neurotransmission mediated by AMPA receptors. At these concentrations, NT can also 
bind to pre or post synaptic NTS1 that increase glutamatergic neurotransmission through 
NMDA receptors. Depending on the neurotransmitter content of the non-dopaminergic 
neuron, two possibilities arise. If the non-dopaminergic neuron is GABAergic, then 
enhanced excitatory input to GABA neurons, may increase the brake like effect that 
GABA neurons are known to exert on DA neurons and prevent them from firing (Clark et 
al. 1992). Recent studies that selectively activated GABA neurons using optogenetic 
techniques suggest that activation of GABA neurons inhibited the spontaneous firing rate 
of DA neurons (Tan et al. 2012). In contrast, inhibiting GABA neurons resulted in 
disinhibition of DA neurons (Bocklisch et al. 2013). Activity of GABA neurons is high in 
the presence of an aversive stimulus and is relevant in reward prediction error and reward 
consumption (Ungless 2004;van et al. 2012). However, if the non-DA neuron is 
glutamatergic, then enhanced glutamatergic input to DA neurons may promote enhanced 
firing and DA release in terminal fields of projection leading to dopamine dependent 
behaviours similar to those that are observed upon administration of psychostimulants 
(Sotty et al. 2000a). Although we can only speculate on the outcomes of increased 
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glutamatergic neurotransmission by NT on non-DA neurons at this point, further 
behavioural insights are required to characterise the implications of enhanced glutamate 
signalling in eliciting neuroadaptive changes associated with sensitization and reward 
mechanisms involving VTA non-DA neurons.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           
 
164 
 
Reference List 
 
 1.  Dobner PR, Deutch AY, Fadel J (2003) Neurotensin: dual roles in psychostimulant 
and antipsychotic drug responses. Life Sci 73: 801-811. S0024320503004119 
[pii]. 
 2.  Rompre P, Perron S (2000) Evidence for a role of endogenous neurotensin in the 
initiation of amphetamine sensitization. Neuropharmacology 39: 1880-1892. 
S0028390899002695 [pii]. 
 3.  Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-
sensitization theory of addiction. Brain Res Brain Res Rev 18: 247-291. 
 4.  Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol 
Rev 94: 469-492. 
 5.  Glimcher PW, Margolin DH, Giovino AA, Hoebel BG (1984) Neurotensin: a new 
'reward peptide'. Brain Res 291: 119-124. 0006-8993(84)90657-7 [pii]. 
 6.  Binder EB, Kinkead B, Owens MJ, Nemeroff CB (2001) Neurotensin and dopamine 
interactions. Pharmacol Rev 53: 453-486. 
 7.  Uhl GR, Goodman RR, Snyder SH (1979) Neurotensin-containing cell bodies, fibers 
and nerve terminals in the brain stem of the rat: immunohistochemical 
mapping. Brain Res 167: 77-91. 0006-8993(79)90264-6 [pii]. 
                                                           
 
165 
 
 8.  Fallon JH (1988) Topographic organization of ascending dopaminergic projections. 
Ann N Y Acad Sci 537: 1-9. 
 9.  Sarret P, Perron A, Stroh T, Beaudet A (2003) Immunohistochemical distribution of 
NTS2 neurotensin receptors in the rat central nervous system. J Comp Neurol 
461: 520-538. 10.1002/cne.10718 [doi]. 
 10.  St-Gelais F, Jomphe C, Trudeau LE (2006) The role of neurotensin in central nervous 
system pathophysiology: what is the evidence? J Psychiatry Neurosci 31: 229-
245. 
 11.  Farkas RH, Chien PY, Nakajima S, Nakajima Y (1997) Neurotensin and dopamine 
D2 activation oppositely regulate the same K+ conductance in rat midbrain 
dopaminergic neurons. Neurosci Lett 231: 21-24. S0304-3940(97)00530-2 
[pii]. 
 12.  Farkas RH, Chien PY, Nakajima S, Nakajima Y (1996) Properties of a slow 
nonselective cation conductance modulated by neurotensin and other 
neurotransmitters in midbrain dopaminergic neurons. J Neurophysiol 76: 
1968-1981. 
 13.  Chien PY, Farkas RH, Nakajima S, Nakajima Y (1996) Single-channel properties of 
the nonselective cation conductance induced by neurotensin in dopaminergic 
neurons. Proc Natl Acad Sci U S A 93: 14917-14921. 
 14.  Nalivaiko E, Michaud JC, Soubrie P, Le FG (1998) Electrophysiological evidence for 
putative subtypes of neurotensin receptors in guinea-pig mesencephalic 
                                                           
 
166 
 
dopaminergic neurons. Neuroscience 86: 799-811. S0306-4522(98)00084-0 
[pii]. 
 15.  Steinberg R, Brun P, Souilhac J, Bougault I, Leyris R, Le FG, Soubrie P (1995) 
Neurochemical and behavioural effects of neurotensin vs [D-
Tyr11]neurotensin on mesolimbic dopaminergic function. Neuropeptides 28: 
43-50. 
 16.  Blackburn A, Dewar K, Bauco P, Rompre PP (2004) Excitotoxic lesions of the 
prefrontal cortex attenuate the potentiation of amphetamine-induced 
locomotion by repeated neurotensin receptor activation. Brain Res 998: 184-
193. S0006899303040605 [pii]. 
 17.  Bauco P, Rompre PP (2003) Central neurotensin receptor activation produces 
differential behavioral responses in Fischer and Lewis rats. 
Psychopharmacology (Berl) 168: 253-261. 10.1007/s00213-003-1436-8 [doi]. 
 18.  Rompre PP (1997) Repeated activation of neurotensin receptors sensitizes to the 
stimulant effect of amphetamine. Eur J Pharmacol 328: 131-134. S0014-
2999(97)00159-3 [pii]. 
 19.  Rompre PP, Bauco P (2006) Neurotensin receptor activation sensitizes to the 
locomotor stimulant effect of cocaine: a role for NMDA receptors. Brain Res 
1085: 77-86. S0006-8993(06)00423-9 [pii];10.1016/j.brainres.2006.02.011 
[doi]. 
                                                           
 
167 
 
 20.  Sotty F, Brun P, Leonetti M, Steinberg R, Soubrie P, Renaud B, Suaud-Chagny MF 
(2000) Comparative effects of neurotensin, neurotensin(8-13) and [D-
Tyr(11)]neurotensin applied into the ventral tegmental area on extracellular 
dopamine in the rat prefrontal cortex and nucleus accumbens. Neuroscience 
98: 485-492. S0306-4522(00)90023-X [pii]. 
 21.  Cador M, Bjijou Y, Cailhol S, Stinus L (1999) D-amphetamine-induced behavioral 
sensitization: implication of a glutamatergic medial prefrontal cortex-ventral 
tegmental area innervation. Neuroscience 94: 705-721. S0306-
4522(99)00361-9 [pii]. 
 22.  Vezina P, Queen AL (2000) Induction of locomotor sensitization by amphetamine 
requires the activation of NMDA receptors in the rat ventral tegmental area. 
Psychopharmacology (Berl) 151: 184-191. 
 23.  Kempadoo KA, Tourino C, Cho SL, Magnani F, Leinninger GM, Stuber GD, Zhang 
F, Myers MG, Deisseroth K, de LL, Bonci A (2013) Hypothalamic 
neurotensin projections promote reward by enhancing glutamate transmission 
in the VTA. J Neurosci 33: 7618-7626. 33/18/7618 
[pii];10.1523/JNEUROSCI.2588-12.2013 [doi]. 
 24.  Kortleven C, Bruneau LC, Trudeau LE (2012) Neurotensin inhibits glutamate-
mediated synaptic inputs onto ventral tegmental area dopamine neurons 
through the release of the endocannabinoid 2-AG. Neuropharmacology 63: 
                                                           
 
168 
 
983-991. S0028-3908(12)00386-3 [pii];10.1016/j.neuropharm.2012.07.037 
[doi]. 
 25.  Margolis EB, Lock H, Hjelmstad GO, Fields HL (2006) The ventral tegmental area 
revisited: is there an electrophysiological marker for dopaminergic neurons? J 
Physiol 577: 907-924. jphysiol.2006.117069 
[pii];10.1113/jphysiol.2006.117069 [doi]. 
 26.  Blanton MG, Lo Turco JJ, Kriegstein AR (1989) Whole cell recording from neurons 
in slices of reptilian and mammalian cerebral cortex. J Neurosci Methods 30: 
203-210. 
 27.  Spigelman I, Zhang L, Carlen PL (1992) Patch-clamp study of postnatal development 
of CA1 neurons in rat hippocampal slices: membrane excitability and K+ 
currents. J Neurophysiol 68: 55-69. 
 28.  Hoffman AF, Lupica CR (2001) Direct actions of cannabinoids on synaptic 
transmission in the nucleus accumbens: a comparison with opioids. J 
Neurophysiol 85: 72-83. 
 29.  Jimenez-Rivera CA, Figueroa J, Vazquez-Torres R, Velez-Hernandez ME, Schwarz 
D, Velasquez-Martinez MC, Arencibia-Albite F (2012) Presynaptic inhibition 
of glutamate transmission by alpha2 receptors in the VTA. Eur J Neurosci 35: 
1406-1415. 10.1111/j.1460-9568.2012.08029.x [doi]. 
                                                           
 
169 
 
 30.  Checler F, Vincent JP, Kitabgi P (1983) Neurotensin analogs [D-TYR11] and [D-
PHE11]neurotensin resist degradation by brain peptidases in vitro and in vivo. 
J Pharmacol Exp Ther 227: 743-748. 
 31.  Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, Steinberg 
R, Suaud-Chagny MF, Santucci V, Vita N, Pecceu F, Labbe-Jullie C, Kitabgi 
P, Soubrie P, Le FG, Maffrand JP (1997) Biochemical and pharmacological 
activities of SR 142948A, a new potent neurotensin receptor antagonist. J 
Pharmacol Exp Ther 280: 802-812. 
 32.  Panayi F, Colussi-Mas J, Lambas-Senas L, Renaud B, Scarna H, Berod A (2005) 
Endogenous neurotensin in the ventral tegmental area contributes to 
amphetamine behavioral sensitization. Neuropsychopharmacology 30: 871-
879. 1300638 [pii];10.1038/sj.npp.1300638 [doi]. 
 33.  Bose P, Rompre P, Warren RA (2015) Neurotensin enhances glutamatergic EPSCs in 
VTA neurons by acting on different neurotensin receptors. Peptides. 
 34.  Sarret P, Gendron L, Kilian P, Nguyen HM, Gallo-Payet N, Payet MD, Beaudet A 
(2002) Pharmacology and functional properties of NTS2 neurotensin 
receptors in cerebellar granule cells. J Biol Chem 277: 36233-36243. 
10.1074/jbc.M202586200 [doi];M202586200 [pii]. 
 35.  Hnasko TS, Hjelmstad GO, Fields HL, Edwards RH (2012) Ventral tegmental area 
glutamate neurons: electrophysiological properties and projections. J Neurosci 
                                                           
 
170 
 
32: 15076-15085. 32/43/15076 [pii];10.1523/JNEUROSCI.3128-12.2012 
[doi]. 
 36.  Margolis EB, Toy B, Himmels P, Morales M, Fields HL (2012) Identification of rat 
ventral tegmental area GABAergic neurons. PLoS One 7: e42365. 
10.1371/journal.pone.0042365 [doi];PONE-D-12-06480 [pii]. 
 37.  Margolis EB, Lock H, Hjelmstad GO, Fields HL (2006) The ventral tegmental area 
revisited: is there an electrophysiological marker for dopaminergic neurons? J 
Physiol 577: 907-924. jphysiol.2006.117069 
[pii];10.1113/jphysiol.2006.117069 [doi]. 
 38.  Mao D, Gallagher K, McGehee DS (2011) Nicotine potentiation of excitatory inputs 
to ventral tegmental area dopamine neurons. J Neurosci 31: 6710-6720. 
31/18/6710 [pii];10.1523/JNEUROSCI.5671-10.2011 [doi]. 
 39.  Zweifel LS, Argilli E, Bonci A, Palmiter RD (2008) Role of NMDA receptors in 
dopamine neurons for plasticity and addictive behaviors. Neuron 59: 486-496. 
S0896-6273(08)00464-9 [pii];10.1016/j.neuron.2008.05.028 [doi]. 
 40.  Ungless MA, Grace AA (2012) Are you or aren't you? Challenges associated with 
physiologically identifying dopamine neurons. Trends Neurosci 35: 422-430. 
S0166-2236(12)00030-6 [pii];10.1016/j.tins.2012.02.003 [doi]. 
 41.  Antonelli T, Tomasini MC, Fournier J, Mazza R, Tanganelli S, Pirondi S, Fuxe K, 
Ferraro L (2008) Neurotensin receptor involvement in the rise of extracellular 
glutamate levels and apoptotic nerve cell death in primary cortical cultures 
                                                           
 
171 
 
after oxygen and glucose deprivation. Cereb Cortex 18: 1748-1757. bhm217 
[pii];10.1093/cercor/bhm217 [doi]. 
 42.  Luo Y, Good CH, Diaz-Ruiz O, Zhang Y, Hoffman AF, Shan L, Kuang SY, Malik N, 
Chefer VI, Tomac AC, Lupica CR, Backman CM (2010) NMDA receptors on 
non-dopaminergic neurons in the VTA support cocaine sensitization. PLoS 
One 5: e12141. 10.1371/journal.pone.0012141 [doi]. 
 43.  Ferraro L, Beggiato S, Tomasini MC, Fuxe K, Tanganelli S, Antonelli T (2011) 
Neurotensin regulates cortical glutamate transmission by modulating N-
methyl-D-aspartate receptor functional activity: an in vivo microdialysis 
study. J Neurosci Res 89: 1618-1626. 10.1002/jnr.22686 [doi]. 
 44.  Kitabgi P, Poustis C, Granier C, Van RJ, Rivier J, Morgat JL, Freychet P (1980) 
Neurotensin binding to extraneural and neural receptors: comparison with 
biological activity and structure--activity relationships. Mol Pharmacol 18: 
11-19. 
 45.  Labbe-Jullie C, Dubuc I, Brouard A, Doulut S, Bourdel E, Pelaprat D, Mazella J, 
Martinez J, Rostene W, Costentin J, . (1994) In vivo and in vitro structure-
activity studies with peptide and pseudopeptide neurotensin analogs suggest 
the existence of distinct central neurotensin receptor subtypes. J Pharmacol 
Exp Ther 268: 328-336. 
                                                           
 
172 
 
 46.  Kullmann DM, Asztely F (1998) Extrasynaptic glutamate spillover in the 
hippocampus: evidence and implications. Trends Neurosci 21: 8-14. S0166-
2236(97)01150-8 [pii]. 
 47.  Isaacson JS (1999) Glutamate spillover mediates excitatory transmission in the rat 
olfactory bulb. Neuron 23: 377-384. S0896-6273(00)80787-4 [pii]. 
 48.  Yin HH, Adermark L, Lovinger DM (2008) Neurotensin reduces glutamatergic 
transmission in the dorsolateral striatum via retrograde endocannabinoid 
signaling. Neuropharmacology 54: 79-86. S0028-3908(07)00167-0 
[pii];10.1016/j.neuropharm.2007.06.004 [doi]. 
 49.  Gabel LA, Nisenbaum ES (1999) Muscarinic receptors differentially modulate the 
persistent potassium current in striatal spiny projection neurons. J 
Neurophysiol 81: 1418-1423. 
 50.  Galarraga E, Hernandez-Lopez S, Reyes A, Miranda I, Bermudez-Rattoni F, Vilchis 
C, Bargas J (1999) Cholinergic modulation of neostriatal output: a functional 
antagonism between different types of muscarinic receptors. J Neurosci 19: 
3629-3638. 
 51.  Nestler EJ (2013) Cellular basis of memory for addiction. Dialogues Clin Neurosci 
15: 431-443. 
 52.  Britt JP, Bonci A (2013) Optogenetic interrogations of the neural circuits underlying 
addiction. Curr Opin Neurobiol 23: 539-545. S0959-4388(13)00026-3 
[pii];10.1016/j.conb.2013.01.010 [doi]. 
                                                           
 
173 
 
 53.  Ducrot C, Fortier E, Bouchard C, Rompre PP (2013) Opposite modulation of brain 
stimulation reward by NMDA and AMPA receptors in the ventral tegmental 
area. Front Syst Neurosci 7: 57. 10.3389/fnsys.2013.00057 [doi]. 
 54.  Clark JA, Deutch AY, Gallipoli PZ, Amara SG (1992) Functional expression and 
CNS distribution of a beta-alanine-sensitive neuronal GABA transporter. 
Neuron 9: 337-348. 0896-6273(92)90172-A [pii]. 
 55.  Tan KR, Yvon C, Turiault M, Mirzabekov JJ, Doehner J, Labouebe G, Deisseroth K, 
Tye KM, Luscher C (2012) GABA neurons of the VTA drive conditioned 
place aversion. Neuron 73: 1173-1183. S0896-6273(12)00176-6 
[pii];10.1016/j.neuron.2012.02.015 [doi]. 
 56.  Bocklisch C, Pascoli V, Wong JC, House DR, Yvon C, de RM, Tan KR, Luscher C 
(2013) Cocaine disinhibits dopamine neurons by potentiation of GABA 
transmission in the ventral tegmental area. Science 341: 1521-1525. 
341/6153/1521 [pii];10.1126/science.1237059 [doi]. 
 57.  Ungless MA (2004) Dopamine: the salient issue. Trends Neurosci 27: 702-706. 
S0166-2236(04)00329-7 [pii];10.1016/j.tins.2004.10.001 [doi]. 
 58.  van ZR, Phillips JL, Budygin EA, Stuber GD (2012) Activation of VTA GABA 
neurons disrupts reward consumption. Neuron 73: 1184-1194. S0896-
6273(12)00177-8 [pii];10.1016/j.neuron.2012.02.016 [doi]. 
 
 
                                                           
 
174 
 
Figure 1 
 
                                                           
 
175 
 
Figure 1.Characteristics of the glutamatergic EPSCs. 
 Nature of the EPSC evoked by local electrical stimulus in the presence of BMI (10µM). 
A:Current traces of the response evoked by single electrical stimulus and recorded at holding 
membrane potentials of –20 and –70 mV before glutamatergic antagonists application 
(1.Control) and during superfusion with CNQX (20µM; 2.CNQX) and CNQX and APV 
(50µM; 3.CNQX+APV). Recordings were obtained in an Ih+ neuron from a P20 animal. 
Current traces represent the average of 6 sweeps. B: Current-voltage relationship of the 
response (IR-Vm) between –120 and 20 mV. The early component was measured 9 ms, after 
the stimulus as indicated by the left vertical dotted line in A. The late component was 
measured 43 msec. after the stimulus as indicated by the right vertical dotted line in A. 
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Figure 2: Effects of D-Tyr [11] NT on NMDA EPSCs. A: Current traces of NMDA EPSC 
recorded before (1), during (2) and after (3) superfusion with D-Tyr [11] NT (0.01µM) at a 
holding membrane potential of -20mV in Ih+ neurons (n=6). B: Current traces of NMDA 
EPSC recorded during superfusion with SR142948A (1), with SR142948A and D-Tyr [11] 
NT (0.01µM) (2) and with SR142948A following the washout of D-Tyr [11] NT (3) at a 
holding membrane potential of -20mV in Ih+ neurons (n=7). C: Current traces of NMDA 
EPSC recorded before (1), during (2) and after (3) superfusion with D-Tyr [11] NT (0.01µM) 
at a holding membrane potential of -20mV in Ih- neurons (n=5)  D: Current traces of NMDA 
EPSC recorded during superfusion with SR48692 (1), with SR48692and D-Tyr [11] NT (2) 
and with SR48692 following the washout of D-Tyr [11] NT (3) at a holding membrane 
potential of -20mVin Ih- neurons (n=6). E: Summary of the effect of D-Tyr [11] NT 
(0.01µM), SR142948A (0.1µM) and SR48692 (0.1µM) on Ih+ and Ih- neurons at a holding 
membrane potential of -20mV. One way ANOVA in Ih+ neurons; p<0.001. * indicates 
statistical significance (p<0.05). ** indicates statistical significance (p<0.001). 
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Figure 3: Effects of D-Tyr [11] NT on non-NMDA EPSCs. A: Current traces of AMPA 
EPSC recorded before (1), during (2) and after (3) superfusion with D-Tyr [11] NT (0.01µM) 
at a holding membrane potential of -70mV in Ih+ neurons (n=7).B: Current traces of AMPA 
EPSC recorded during superfusion with SR142948A (1), with SR142948A and D-Tyr [11] 
NT (0.01µM) (2) and with SR142948A following the washout of D-Tyr [11] NT (3) at a 
holding membrane potential of -70mV in Ih+ neurons (n=7). C: Current traces of AMPA 
EPSC recorded before (1), during (2) and after (3) superfusion with D-Tyr [11] NT (0.01µM) 
at a holding membrane potential of -70mV in Ih- neurons (n=6)  D: Current traces of AMPA 
EPSC recorded during superfusion with SR48692 (1), with SR48692and D-Tyr [11] NT (2) 
and with SR48692 following the washout of D-Tyr [11] NT (3) at a holding membrane 
potential of -70mVin Ih- neurons (n=6). E: Summary of the effect of D-Tyr [11] NT 
(0.01µM), SR142948A (0.1µM) and SR48692 (0.1µM) on Ih+ and Ih- neurons at a holding 
membrane potential of -70mV.One way ANOVA in Ih+ neurons; p<0.001.* indicates 
statistical significance (p<0.05). ** indicates statistical significance (p<0.001). 
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Figure 4: Locus of neurotensinergic modulation of evoked AMPA EPSCs in Ih-neurons. 
A:  Current  traces of the responses evoked by a pair of single local electrical stimuli 50 ms 
apart at a holding membrane potential of -100 mV before (1) and during (2) superfusion 
with D-Tyr [11] NT1-13  (0.01µM).3 : the average amplitude of  PPR from 6 neurons 
before and during superfusion with D-Tyr [11] NT 1-13. PPR was statistically larger in the 
presence of D-Tyr [11] NT 1-13 than during control conditions (student’s t test; p<0.001) 
in Ih- neurons (n=6). No significant effect was found in Ih+ neurons (student’s t test; p> 
0.05; n=7). B: Effect of D-Tyr [11] NT 1-13 on the membrane and firing properties of Ih- 
neurons. Voltage responses evoked with intracellular current pulses of 10pA from resting 
membrane potential before (1) , during (2) and after (3) addition of D-Tyr [11] NT 1-
13(0.01µM) to the superfusing medium. In this case the addition of the neurotensin agonist 
produced a depolarisation of 13mV of the membrane potential. Recordings were obtained 
under the same experimental conditions with the exception that QX314 was omitted from 
the internal recording solution in the pipette 
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4. Discussion  
 
This section of the thesis aims to provide a short summary of the results obtained in the 
studies followed by a global discussion and interpretation of the results obtained in the three 
articles. Lastly I would like to draw the attention of the readers to some technical 
considerations encountered while performing the experiments and conclude my thesis with 
the implications of the results in understanding behavioural disorders like addiction.  
4.1 Summary of the results 
 
In the work undertaken in this thesis, we sought to characterise the neurotensinergic 
modulation of glutamatergic neurotransmission in VTA neurons. To this end we first tested 
the effects of NT1-13 and its analogs on glutamatergic EPSCs in VTA DA and non-DA 
neurons and identify the receptors involved in mediating the effects. The first study is aimed 
at comparing the effects of NT-(1-13), to that of the active C terminal fragment NT-(8-13) 
and test the ability of the NT antagonists at blocking the effects of these NT peptides. The 
results of the experiments conducted to characterize these effects are presented in the first 
article. We found that both NT-(1-13) and NT-(8-13) dose dependently excite both Ih+ 
(putative DA neurons) and Ih- neurons (non-DA neurons) in the VTA. While the 
enhancement of glutamatergic EPSCs in putative DA neurons involves activation of NTS1 
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receptors, the enhancement of glutamatergic EPSCs in non-DA neurons is mediated by 
NTS2 receptors. 
   Since NT8-13 activated two different NT receptor subtypes in different population of VTA 
neurons despite having a higher binding affinity for NTS1 than NTS2 receptors, we sought 
to test the effects of another NT analog, D-Tyr[11]NT  which  has a higher binding affinity 
at NTS2 receptors than NTS1 on glutamatergic EPSCs of VTA neurons. In the second 
article, we describe the work undertaken to characterise the effects of D-Tyr[11]NT on 
glutamatergic neurotransmission in VTA neurons. D-Tyr[11]NT was found to decrease 
glutamatergic neurotransmission in putative DA neurons in a dose dependent manner, 
whereas in non-DA neurons it was found to enhance glutamatergic neurotransmission dose 
dependently. The reduction in glutamatergic EPSCs in putative DA neurons was mediated 
by the activation of NTS2 receptors whereas in non-DA neurons, the enhancement involved 
activation of NTS1 receptors. CPP was found to be dose-dependently enhanced by D-Tyr 
[11] NT and at the highest concentration, the effect was blocked by SR48692 suggesting the 
involvement of NTS1. Since both behavioural and electrophysiological paradigms suggested 
the involvement of NTS1, it is likely that the development of sensitization induced by D-Tyr 
[11] NT involves the activation of NTS1 on non-DA neurons. 
The existence of NT receptors on both cell bodies and axon terminals (Rostene et al., 1992), 
suggests that in addition to exerting its effect on VTA neurons, NT could also modulate 
glutamate release from terminals. Bath application of NT may directly modulate glutamate 
release through the activation of NT receptors on terminals or indirectly activate DA 
neurons, stimulate DA release that acts on D1/ D2 receptors on terminals to modulate 
glutamatergic neurotransmission. Since D-Tyr[11]NT is known to act on different receptors 
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and we found bidirectional effects on putative DA and non-DA neurons, we sought to 
characterize the effects of D-Tyr[11]NT on isolated NMDA and AMPA components of the 
glutamatergic EPSCs and identify the locus of the receptors involved in mediating these 
effects. In the third article, we describe the work undertaken to characterize the effects of D-
Tyr[11]NT on isolated NMDA and AMPA EPSCs and the locus of receptors involved in 
mediating these effects. D-Tyr[11]NT reduced the amplitude of both NMDA and AMPA 
EPSCs dose dependently in Ih + neurons by an NTS2 dependent mechanism. In Ih- neurons, 
D-Tyr[11]NT produced an NTS1 dependent enhancement of glutamatergic EPSCs. Paired 
pulse experiments on Ih- neurons suggest that the enhancement effect involves activation of 
presynaptic NTS1 receptors. A summary of all the results obtained (categorized by type of 
neuronal population has been presented in Table 2. 
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Table 2 
Ih+ neurons Ih- neurons 
NT1-13 and NT8-13 increase 
glutamatergic neurotransmission. 
Receptor involved : NTS1 
NT1-13 and NT8-13 increase 
glutamatergic neurotransmission. 
Receptor involved : NTS2 
D-Tyr [11] NT1-13 decreases 
glutamatergic neurotransmission. 
Receptor involved : NTS2 
D-Tyr [11] NT increases glutamatergic 
neurotransmission. 
Receptor involved: NTS1. 
 
D-Tyr [11] NT increases CPP. 
Receptor involved : NTS1 
 
D-Tyr [11] NT1-13 decreases both 
AMPA and NMDA EPSC 
components. 
Receptor involved: NTS2. 
Locus of receptor modulation: post 
synaptic. 
D-Tyr [11] NT increases both AMPA 
and NMDA EPSC components. 
Receptor involved: NTS1. 
Locus of receptor modulation: 
presynaptic. 
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4.2 NT exerts a complex effect on glutamatergic 
neurotransmission in VTA neurons 
 
 4.2.1 Bidirectional effects of NT analogs on 
glutamatergic EPSCs in Ih+ neurons  
 
The present study entails the use of three NT analogs: NT1-13, NT 8-13 and D-Tyr[11]NT. 
These analogs have been previously shown to elicit different cellular and behavioural 
responses in the same anatomical substrate. NT1-13 is the 13 amino acid, native 
neurotensin peptide which is endogenous in the brain, mostly found in the dopamine rich 
regions (for example the VTA) and most effects mediated by this peptide are through its C 
terminal region fragment, NT8-13. At the rat NTS1 receptor, NT1-13 has a Kd of 1.97nM 
while NT8-13 has a Kd of 1.607nM. NT 1-13 has a lower binding affinity than NT8-13 at 
NTS1 receptors whereas at the NTS2 receptors, NT 1-13 has a similar binding affinity as 
that of NT 8-13(Kitabgi et al. 1980a;Labbe-Jullie et al. 1994). Local application of NT1-13 
increased dopamine cell firing in the VTA (Seutin et al. 1989;Shi and Bunney 1991b), and 
consequentially resulted in dopamine release in the terminal fields of DAergic projections 
(Cador et al. 1995;Kalivas and Taylor 1985a) and that these effects were similarly 
mimicked by NT 8-13. NT8-13 produces most of the known effects of NT and therefore 
most peptide agonists for NT receptors are analogs of this hexapeptide. For example, a 
study by Rompre et al., (Rompre and Boye 1993) suggests, both NT1-13 and NT8-13 are 
equally effective in operant responding for brain stimulation reward paradigms. The 
similarity of both these peptides in terms of binding affinities and receptor activation 
explains the mimicking of the effects (Kitabgi et al. 1980a). 
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In our studies, we find an enhancement in glutamatergic neurotransmission in both Ih+ and 
Ih- neurons that is induces by either NT1-13 or NT8-13. Several previous studies have 
shown a similar NT induced increase in glutamate release in the striatum (Ferraro et al. 
1995;Ferraro et al. 1998), the SN (Ferraro et al. 2001) and the cerebral cortex (Ferraro et 
al. 2000). This increase in glutamatergic release is suggested to involve the interference of 
NT in inhibitory D2 autoreceptor signalling by formation of an NTS1-D2autoreceptor 
complex (Antonelli et al. 2007). Such complexes might exist on the terminals and cell 
bodies/dendrites of VTA DA neurons. Activation of such complexes on DA cell bodies by 
NT could antagonize the inhibitory D2 receptor mediated signalling, lead to an increased 
firing of DA cells and consequentially release dopamine. The released dopamine could 
then activate post junctional D2 receptors on glutamate terminals and increase glutamate 
release which activate glutamatergic receptors on DA neurons and increase glutamatergic 
neurotransmission. Alternatively, NT could directly increase glutamate release from the 
terminals by the antagonizing effect of NT on D2 receptors located on glutamatergic 
terminals. The NTS1-D2 interaction in DA neurons also involves calcium dependent and 
protein kinase C mechanisms (Antonelli et al. 2004).  
Prior activation of D2 receptors inhibit NTS1 signalling indicating the possibility of the 
NTS1-D2 interactions being oppositely regulated (Jomphe et al. 2006). Nevertheless, 
evidences of facilitatory NTS1-NMDA receptor interactions at cortico-striatal glutamate 
terminals strengthen the role of NT in inducing glutamate release (Antonelli et al. 2004). 
Since our population of Ih+ neurons could also include a subset of glutamatergic neurons 
(about 10 %) (Yamaguchi et al. 2007;Yamaguchi et al. 2013) , we think that the observed 
increase in glutamatergic neurotransmission is mediated not only by mechanisms involving 
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reduced D2 receptor autoinhibition through putative DA neurons but also direct activation 
of glutamate receptors on glutamatergic neurons.  
Interestingly, there are studies that report an NT induced reduction in glutamatergic 
neurotransmission in VTA DA neurons (Kempadoo et al. 2013a;Kortleven et al. 2012a). 
However, while Kortleven et al., reported an attenuation of glutamatergic 
neurotransmission involving NTS1 receptors and endocannabinoid mediated long term 
depression (LTD), Kempadoo et al, suggested an NTS1 independent form of reduction. 
Although a small biphasic concentration dependent effect on NMDA EPSCs has been 
suggested by Kempadoo et al., we did not observe an inhibition of the glutamatergic 
EPSCs with NT1-13 or NT8-13 ay any of the concentrations used (0.01 µM, 0.1µM or 
1µM). This is possibly due to the technique used in recording from the cells or other 
factors for example interspecies difference, age of the animals or the slicing procedure 
itself might be a source of the difference (Ungless and Grace 2012). Since we used the 
blind patch technique to record from VTA neurons, it is possible that the effective 
concentration of NT8-13 reaching the receptors on the cell bodies and the terminals in the 
deeper layers of the slice are less than what they receive on the surface of the slice (as in 
the other two studies cited). Therefore, we think that had we used an even higher 
concentration of the NT peptides, we would have observed a decrease in the glutamatergic 
neurotransmission. This hypothesis is supported by the decrease in glutamatergic EPSC 
amplitudes in Ih+ neurons by D-Tyr[11]NT. We have found a dose dependent decrease in 
glutamatergic EPSCs by this NT analog in Ih+ neurons and this reduction is mediated by 
the activation of NTS2 receptors as SR142948A blocks the inhibition which SR48692 fails 
to. D-Tyr[11]NT is reported to have a half -life 1.5 times greater than that of NT8-13 
                                                           
 
189 
 
(Checler et al. 1983a). Therefore we suspect that NT8-13 at the highest concentrations used 
in our studies resemble the effects of D-Tyr[11]NT at lower concentrations. Since NT8-13 
has a greater affinity for NTS1 than NTS2 receptors and NTS1 receptors have a lower 
binding affinity than NTS2, we propose that at the concentrations used NTS1 receptors are 
activated. NTS1 receptors have been associated with inducing excitatory effects as it is 
coupled to an increase in IP3 , PLC and elevation in intracellular levels of Ca2+  (Binder et 
al. 2001a;St-Gelais et al. 2004). On the contrary, D-Tyr[11]NT has  a higher affinity for 
NTS2 receptors than NTS1 and activation of these receptors  do not induce excitatory 
effects. For example, activation of human NTS2 receptors expressed on CHO cell lines 
lacked the potential to elevate intracellular Ca2+ levels by mobilizing internal calcium 
reserves or accumulate IP3 but were associated with MAPKs to induce inhibitory effects 
(Sarret et al. 2002). This suggests, that when NT is present in higher concentrations, NTS2 
receptors may be preferentially activated thereby inducing inhibitory effects.  
On evaluating the effects of D-Tyr[11]NT on isolated NMDA and AMPA components, we 
observed reduction in both components mediated by activation of NTS2 receptors; albeit 
the reduction being larger in NMDA components than AMPA owing to the higher affinity 
of glutamate for NMDA than AMPA receptors. A similar NTS1 independent reduction in 
both AMPA and NMDA components of glutamatergic EPSCs by higher concentrations of 
NT8-13 (0.1µM, 0.3µM and 0.5µM) further supports our hypothesis. Surprisingly 
Kortleven et al., reports a decrease in glutamatergic EPSCs in VTA DA neurons by NT8-
13 (0.05µM) that is mediated by NTS1 receptors (Kortleven et al. 2012a). 
 This leads us to suggest that NT modulates glutamatergic neurotransmission is 
concentration specific and that higher concentrations of this peptide, by activation of NTS2 
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receptors decrease glutamatergic neurotransmission in Ih+ neurons. Our studies highlight a 
novel mechanism for synaptic glutamatergic neurotransmission modulation in DA neurons 
of the VTA in response to a neuropeptide, which is capable of modulating DA neurons and 
subsequently DA release.  
 
4.2.2 NT analogs increase glutamatergic 
neurotransmission in Ih- neurons 
 
  Most studies till now have focussed on the modulation of glutamatergic 
neurotransmission on DA neurons of the VTA and characterize plasticity mechanisms that 
are relevant to sensitization and addiction (Britt and Bonci 2013;Kauer and Malenka 
2007;Nestler 2013). However, the VTA is home to non-DA neurons which may be 
glutamatergic or GABAergic and these establish local synapses on DA cells (Dobi et al. 
2010). The inhibitory control exerted by GABA neurons on the VTA shape the DA neuron 
activity (Britt and Bonci 2013;Nestler 2013).  
Although, the perisomatic GABAergic innervation to DA and non-DA cells are not 
significantly different, there exists a higher degree of dendritic innervation on GABA 
neurons than DA neurons. This is indicative of a possible indirect modulatory effect that 
involves disinhibition of the GABAergic inputs to GABA neurons, thereby releasing the 
DA neurons from the tonic inhibition (Ciccarelli et al. 2012). Alternatively, enhanced 
glutamatergic neurotransmission at these GABA neurons could also result in the same 
effect. Since NT terminals densely innervate the VTA, it is possible that NTergic 
modulation could enhance or attenuate glutamatergic neurotransmission on non-DA cells. 
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In the present studies, we found that NT1-13 and NT8-13 dose dependently enhance 
glutamatergic neurotransmission in Ih- cells. The similarity in the effects of both the 
peptides suggests that these peptides share similarities in their binding affinities for NTS 
receptors. Surprisingly, we observe that the increase in glutamatergic neurotransmission in 
Ih- neurons is mediated by NTS2 receptors as SR142948A blocks the increase in the EPSC 
amplitudes produced by NT1-13or NT8-13 whereas SR48692 did not block it. Given the 
fact that NTS2 receptors are activated in the presence of high concentrations of NT, it 
would be logical to suggest that increased NT levels activate NTS2 receptors to mediate 
the increase in glutamatergic neurotransmission. However, NTS2 receptors are associated 
with inhibitory actions. This leads to two hypotheses. One, the formation of NTS1-NTS2 
heterodimers that leave the NT induced internalization of NTS1 receptors intact but 
modulates the trafficking of these receptors by making it more similar to NTS2 receptors 
and decrease the NTS1 receptor density on the surface (Perron et al. 2007). Two, NTS2 
receptors on non-DA neurons are differently sensitive to NT agonists and may be activated 
at a lower concentration of the agonist than that required to activate them on DA neurons. 
The possibility of the existence of a single receptor in multiple activation states has been 
suggested before (Sotty et al. 2000a). Moreover, there is evidence that NT may act as a 
partial or weak agonist or a neutral antagonist at NTS2 receptors (Richard et al. 2001). It is 
possible that at the concentration of NT used in the study cited above, NT acts as a neutral 
antagonist and blocks NTS2 receptors and activate NTS1 receptors which mediate the 
increase in glutamatergic neurotransmission. In fact, we observe an NTS1 mediated dose 
dependent increase in the amplitude of glutamatergic EPSCs in non-DA neurons by D-
Tyr[11]NT. Additionally, both the isolated AMPA and NMDA components of the 
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glutamatergic EPSCs were also enhanced by D-Tyr[11]NT and that NTS1 receptors 
mediated this enhancement. The increase in AMPA EPSCs is mediated by presynaptic 
NTS1 receptors suggesting that D-Tyr[11]NT acts on NTS1 receptors on glutamatergic 
terminals and triggers intracellular signalling cascades that result in enhanced glutamate 
release. A similar mode of presynaptic glutamate release at the synapse between the 
perforant path and the granule cells of the hippocampus has been reported (Zhang et al. 
2015). The authors suggest that NT induced an increase in the release probability of readily 
releasable vesicles at the presynaptic terminals that required influx of Ca2+ ions through L 
–type calcium channels and functional calmodulin and myosin light chain kinase. A 
previous study in cortical neurons has also implicated a Ca2+ dependent mechanism that is 
associated with the functional coupling of NTS1 receptors with the IP3 signalling cascade 
to mediate glutamate release (Pigozzi et al., 2004; Antonelli et al., 2004). Although we 
have not been able to identify the precise intracellular effector molecules involved in this 
effect, we suggest a similar mechanism of NT induced glutamate release.   
There are evidences for NTS1-NMDA interactions that enhance glutamate release and 
often lead to excitotoxic glutamate effects (Ferraro et al., 2007). In our studies we found an 
enhancement of NMDA EPSCs in non-DA neurons mediated by NTS1 receptors. It is thus 
possible that presynaptic activation of NTS1 receptors that lead to enhanced glutamate 
release acts on postsynaptic NMDA receptors on non-DA cells and increase glutamatergic 
neurotransmission. Additionally, NTS1 receptor induced PKC activation is known to cause 
a sixfold increase in NMDA receptor surface expression involving phosphorylation of the 
NMDA receptor subunit itself or a protein associated with the receptor (Lan et al. 2001). 
Alternatively, direct facilitatory NTS1-NMDA interactions have been reported in rat 
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cortical cells as application of NMDA resulted in increase of endogenous extracellular 
glutamate levels  that was blocked by the NTS1 antagonist SR48692 (Antonelli et al. 
2004). From these evidences we hypothesize that NT acts on presynaptic and /or 
postsynaptic NTS1 receptors and increase glutamatergic signalling in non-DA neurons. 
This potentiation of glutamatergic signal in the VTA may trigger neuroadaptive changes 
that are pertinent in addiction mechanisms. 
 
4.3 Conclusion  
 
 Taken altogether, within the scope of our studies, we could not identify the 
neurotransmitter content of the non-DA neuron and thus these population of neurons may 
be either glutamatergic or GABAergic. Since we found that NT increases glutamatergic 
neurotransmission in non-DA neurons, two possibilities arise. One, if the non-DA neuron 
is GABAergic, then enhanced excitatory input to these neurons might release GABA and 
exert a brake like effect on DA neurons and prevent them from firing. Synaptic GABA 
inputs to the VTA DA neurons alter reward related behaviours. Recent studies show that 
optogenetic activation of GABA neurons that directly synapse on DA neurons suppress the 
activity and excitability of neighbouring DA neurons and decrease the release of DA in the 
nAcb (van et al. 2012).  
 The second possibility is that if excitatory input to glutamatergic neurons are increased by 
NT, it could result in more glutamate release to DA neurons and thus increase DA cell 
firing and consequentially DA release and DA dependent behaviours. In parallel to the 
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electrophysiological studies, behavioural studies show an increased conditioned place 
preference in animals that receive an intra-VTA injection of D-Tyr[11]NT. This effect was 
blocked by the NTS1 antagonist suggesting that D-Tyr[11]NT acted on NTS1 receptors to 
induce this effect. Since we found a role for NTS1 receptors in increasing glutamatergic 
neurotransmission in non-DA neurons, we think that we think that this second possibility is 
more likely as increased activation of glutamatergic neurons result in a larger glutamate 
signal that induce neuroadaptive changes that lead to a sensitized state in the animal. In 
fact, selective inactivation of NMDA receptors on DA neurons leaves behavioural 
measures of cocaine sensitization like locomotor activity and conditioned place preference 
intact highlighting the role of glutamatergic neurotransmission on non-DA neurons in 
sensitization mechanisms (Luo et al. 2010a). The possibility of regulating non-DA neuron 
activity in the VTA through modification of its excitatory inputs by NT thus represents a 
potential area of investigation in addiction mechanisms. 
4.4. Technical considerations: 
 
4.4.1 Identification of DA neurons in the VTA 
 
In the present studies, VTA neurons have been categorized as DA or non-DA neurons 
based on the presence or the absence of the hyperpolarisation activated cationic current (Ih) 
respectively. Around 80-90% of DA neurons of the VTA possess this characteristic current 
and  has therefore been used routinely in many studies as  the identification criteria (Bonci 
and Malenka 1999;Grace and Onn 1989;Johnson and North 1992a;Kempadoo et al. 
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2013a;Korotkova et al. 2002;Korotkova et al. 2004;Mao et al. 2011). The remaining 10-
20% of DA neurons that are without Ih, have undergone considerations and 
reconsiderations owing to the heterogeneity of  VTA DA neurons and the variety of criteria 
that have been used, to classify these neurons over the course of VTA DA neuron 
literature(Ungless and Grace 2012). For example, although Margolis et al., (Margolis et al. 
2006c)reports a subset of DA neurons that are characterized as Ih+TH-, neurons that are Ih- 
have been reported to be non-DAergic, suggesting that DA neurons might be Ih+ but TH-. 
The absence of Ih reliably predicts the non-DAergic entity of a VTA neuron and therefore 
the identification criteria used in the present studies can be considered reliable. Moreover, 
classifying cells with this approach enabled us to demonstrate profound physiological and 
pharmacological differences in synaptic properties that are modulated by NT and thus 
validates our approach. It is important to note that we have routinely processed the 
recorded slices for biocytin labelling and consistently confirmed their location in the 
medial VTA. This region is reported to contain some glutamatergic neurons with the Ih 
current (Hnasko et al. 2010;Li et al. 2013). Therefore within our population of Ih+ neurons, 
it is possible that some cells are glutamatergic. The medial VTA sends projections to the 
mPFC and nACb (Margolis et al. 2008). Interestingly, the efferent projections from PFC 
that synapse on DA neurons of this area project back to the PFC and release DA when  
neuronal activity of these DA neurons are stimulated (Carr and Sesack 2000;Dobi et al. 
2010;Ungless and Grace 2012). These two regions are known to undergo neuroadaptive 
changes that are crucial for sensitization mechanisms. Nevertheless, the absence of Ih 
identifies a non-dopaminergic cell type and we have used this criteria to define our 
population of non-DA neurons (Margolis et al. 2006a). However, it is important to note 
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that the identification criteria for classifying DA neurons have undergone controversies 
owing to the heterogeneity of this neuronal population. 
 The classical identification criteria proposed by Johnson and North(Johnson and North 
1992a) using in vitro patch clamp recording in slices, discerned on a convention for 
classifying VTA neurons as principal (mostly DAergic) that stained positive for TH ,were 
hyperpolarised by dopamine and fired spontaneously (1-3Hz). Later, the presence of Ih 
(hyperpolarisation activated cationic current), dopamine transporter (DAT), D2 
autoreceptors and G protein regulated inward rectifier potassium channel subtype 2 
(GIRK2) was added to the list and these have since, been considered a conventional criteria 
for identifying a DA neuron (Bellone and Luscher 2006;Saal et al. 2003;Wanat et al. 
2008a). Nonetheless, different studies have used combinations of different parameters from 
the list of conventional criteria. Recent studies question these criteria and suggest that 
although the phenotype of the cell may be DAergic as evidenced from positive TH staining 
or DAT expression, it might not have Ih(Margolis et al. 2006a;Zhang et al. 2010). 
Additionally not all DA neurons may be sensitive to DA induced  hyperpolarisation 
(Lammel et al. 2008) and differ from non-DA neurons in their action potential width(which 
in case of a putative DA neuron is broader than that of a non-DA neuron) (Ungless and 
Grace 2012). It was also reported that prolonged duration of intracellular recordings (more 
than 10 mins) can lead to TH washout leading to false negatives (Zhang et al. 2010). 
However, since the present studies do not entail the use of TH immunohistochemistry for 
identifying DA neurons, the possibility that longer recording duration might have 
incorporated false negatives in the scientific data can be negated. 
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Use of alternative techniques, such as optogenetic techniques, to selectively activate or 
inhibit DA neurons in TH Cre rats could be useful. Virus mediated expression of channel 
rhodopsin on DA neurons followed by selectively activating or inhibiting them could 
enable achieving precision on the identification criteria (Witten et al. 2011). Alternatively, 
singe cell RT-PCR of the contents of the recorded cell would enable neurotransmitter 
content identification of the recorded cells. 
 
4.4.2 Recording technique:  
 
The use of blind patch technique (Blanton et al. 1989b), although uncommon has allowed 
us to record from neurons that are located in the deeper layers of the slice and generate 
stable recordings of up to 1 hr. or more. The blind patch technique is uncommon as it does 
not allow the visualization of the cell being recorded, before or immediately after the 
recording. However, this technique is useful for obtaining stable recordings of long 
duration. Post hoc labelling with biocytin enabled us to visualize the cells within the deeper 
layers of the slice and confirm the neuron’s location in the medial VTA. While this 
technique is excellent for recording the electrophysiological activity of the cells within the 
scope of our studies, post hoc immunochemical labelling results for TH to identify DA 
neurons was not consistent. This may be due to the inefficiency of the antibodies to 
permeabilize into the cells of the deeper layers of the slice and thus did not always generate 
double labelled cells (TH and biocytin) on the same focal plane. However, we could 
always visualize the biocytin filled cell as biocytin was added in the patch pipette. 
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4.5 Implications in behavioural disorders and future 
directions 
 
A peculiar aspect of the neurotensin literature is that both NT agonists and antagonists 
have been showed to be effective in animal models of addiction. For example the NT 
agonist, NT69L is effective in blocking nicotine induced hyperactivity (Boules et al. 2013), 
initiation and expression of sensitization to nicotine, nicotine self-administration in animal 
models of addiction (Fredrickson et al. 2003). NT69L when given intraperitoneally , also 
blocks the acute locomotor effects of cocaine and d-amphetamine (Boules et al. 2001). 
This is one line of evidence suggesting the potential efficacy of NT agonists in treatment of 
nicotine, cocaine and amphetamine addiction. In fact, Acamprosate, which is one of the 
FDA approved drugs for treating alcohol use disorder acts by modulating extracellular 
concentrations of dopamine and glutamate in the striatum. Interestingly, NT69L also 
induces similar modulations in dopamine and glutamate concentrations in the striatum 
(Dahchour and De 2000;Prus et al. 2007). The efficacy of NT69L in attenuating alcohol 
preference and consumption in mice and nicotine self-administration in alcohol dependent 
rats, indicate that there are common substrates of cross-sensitization that are modulated by 
this NT agonist (Boules et al. 2011;Li et al. 2011). 
In contrast, the non-specific NT antagonist, SR142948A was found to block initiation of 
amphetamine induced sensitization to NT (Panayi et al. 2005b). In another study, 
locomotor sensitization and conditioned place preference to cocaine was attenuated by 
NTS1 antagonist. SR48692 (Felszeghy et al. 2007). 
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The intriguing question that surfaces is, how then can NT agonists and antagonists induce 
similar effects in animal models of addiction? Or, do NT agonists have abuse potential?  
It should be noted that in the studies cited above, NT69L was shown to be effective in 
nicotine and d-amphetamine sensitization mechanisms whereas SR48692 was shown to be 
effective in cocaine and d-amphetamine induced sensitization. This would predict that 
mice null for NTS1 receptors would not sensitize to psychostimulants. Strikingly, an acute 
injection of d-amphetamine had an enhanced response to the sensitizing effects in null 
mice than wild type mice (Boules et al. 2006;Boules et al. 2007). This observation argues 
in favour of using NT agonists for treating psychostimulant induced drug abuse.  
 Although, intra-VTA NT injections in animals, elicit effects that mimic those induced by 
psychostimulants, NT injections in the nAcb block psychostimulant induced effects 
(Caceda et al. 2006). Additionally, extracranial administration of NT analogs attenuate 
nicotine self-administration in rats (Boules et al., 2006). Another evidence that argues 
against an abuse potential of NT agonists comes from a study in rhesus monkeys, in which 
animals failed to self-administer NT69L (Fantegrossi et al. 2005). Therefore the prevalence 
of evidences argues against NT agonists possessing an abuse potential. 
Nonetheless, the development of highly selective NT antagonists and agonists are required 
to ameliorate further investigations involving the deciphering of common substrates of 
addiction that NT exerts an effect upon. Although no NT antagonists or agonists have 
reached the stage of clinical trials, the potential of NT in modulating glutamatergic 
processes that are crucial for addiction mechanisms hold a promise for development of 
future therapeutics. 
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In part the glutamate homeostasis in nAcb and VTA is maintained by proteins localized to 
astrocytes such as GLT1 and xCT (Hazell et al. 2001;Kalivas et al. 2009). Psychostimulant 
drug exposure lead to downregulation of these proteins that result in enhanced glutamate 
signalling and spillover. Such glutamatergic events have been implicated in cue-induced 
drug seeking and relapse to drug seeking behaviour. Recent pharmacotherapies target to 
induce mGluR2/3 agonism in the nACb and enhancing xCT and GLT1 expression to 
modulate the glutamate tone (Scofield and Kalivas 2014). Although there has been no 
compelling evidence of a drug that rescues the increased glutamate tone in drug exposed 
animals, Ceftriaxone, a third-generation cephalosporin β-lactam antibiotic, has been 
evaluated in attenuating glutamate induced excitotoxicity and neuronal damage by 
enhancing GLT1 and xCT levels in drug seeking animals (Fischer et al. 2013).  
 Given, that NT modulates glutamatergic neurotransmission in VTA neurons that project to 
the nAcb and a subset of glutamatergic neurons in the VTA project to the accumbens 
where DA and glutamate might be co released (Hnasko et al. 2012), the findings from our 
studies open up the question of whether these astrocytic proteins in addition to 
glutamatergic neurotransmission in VTA neurons might be regulated by NT.   
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